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Abstract 
Malaria /HIV co-infection is a major challenge to public health in developing countries and yet 
potential drug-drug interactions between antimalarial and antiviral regimens have not been 
adequately investigated in people with both HIV and Plasmodium falciparum infections. Earlier 
studies on the use of artemether-lumefantrine (AL) in Nigeria have neither addressed its use in 
HIV-positive subjects nor in asymptomatic-malaria infection. 
The present study investigated associations between drug resistant P. falciparum and the use 
of medication for HIV management, drug-drug interactions between artemether-lumefantrine 
and antiretroviral drugs (ARV) and the molecular markers of artemether-lumefantrine and 
other antimalarial drugs. 
Results of the study revealed an elevated day 7 lumefantrine concentrations in HIV subjects on 
nevirapine treatment compared to their HIV-negative counterparts. Associations between 
elevated day 7 levels of lumefantrine and the persistent parasitaemia could not be evaluated 
due to inadequate power. Genetic analysis by DNA sequence of P. falciparum isolates revealed 
strong selection for the pfmdr1codon86N allele among all treated individuals. This 
polymorphism is a strong indicator of AL treatment failure or slow clearance in vivo. There was 
a 72.6% prevalence of the pfcrt76T mutations in the population and this was observed to be 
higher in the HIV-positive subjects. Three new mutations F73S, S97L and G165R were detected 
on the pfmdr1 gene and the first case S436F mutation on the pfdhps gene to be reported in 
Nigeria. The dhpsK540E and dhfrI164L mutations, associated with high-level resistance to 
sulfadoxine-pyrimethamine (SP) were not observed in our small sample size.  
The study also revealed that HIV-positive subjects were more likely to harbour parasites, at a 
higher density, before and after treatment. Improvement of the immune status of HIV-infected 
patients was suggested by the increase of CD4 cell count level in about 68% of the HIV-positive 
patients.  
This is a preliminary study and first of its kind to investigate drug-drug interactions between 
ARVs and the antimalarial drug AL in HIV-positive patients co-infected with P. falciparum in 
relation to parasite clearance. The findings of the study are very important but more work is 
urgently needed with a larger sample size to confirm these findings. 
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1.0   Introduction 
Malaria and HIV are two of the most common and important health problems facing 
developing countries and the most common infections in sub-Saharan Africa (UNAIDS, 2005). 
They constitute the major public health threats responsible for morbidity and mortality in these 
areas. 
Half of the world population is at risk of malaria and an estimated 243 million cases occurred in 
2008. Of these, there was an estimated 863,000 malaria deaths, 767,000 (89%) of which 
occurred in Africa where malaria is the leading cause of mortality in children under 5 years. 
(WHO 2004a; WHO 2009a). However the World Malaria Report, 2011 indicates that over a 
period of two years, the malaria cases have reduced from 243 million cases in 2008 to 216 
million in 2010 and the number of deaths have reduced to 655, 000 (WHO, 2011). Despite this 
reduction, the global burden of malaria has remained very high especially in the tropics. A 
recent report (UNAIDS, 2011) shows that by 2010, about 34million people were living with 
HIV/AIDS of which 2.7million are new infections and the greatest burden is in sub-Saharan 
Africa where an estimated population of 22.9million (68%) of HIV-infected people live. The 
report further states that the total number of new HIV infections in this area dropped by more 
than 26% since 1997 when HIV infection epidemic was at the peak.  
Malaria and HIV/AIDS are both diseases of poverty, they cause poverty and are commonly 
found among the poor. Together, the two diseases cause over 4 million deaths a year. Both 
diseases are highly endemic, and there is a wide geographic overlap in sub-Saharan Africa 
(WHO, 2005). HIV co-infection is thought to contribute to 3 million additional malaria cases, 
higher malaria parasite densities in immunosuppressed children and a 5% greater mortality.  
(UNAIDS, 2005; (Korenromp et al., 2005).   
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1.1 Malaria  
Malaria is a protozoan infection in humans caused by the parasite Plasmodium which until 
recently was thought to be classified into four species P. falciparum, P. ovale, P. malariae and 
P. vivax. However current study (Sutherland et al., 2010) has shown that there are two non-
recombining species of ovale (ovale curtisi and ovale wallikeri) which are non-sympatric in 
nature (Oguike et al., 2011). Of all these, Plasmodium falciparum is the agent of the most 
malignant form of malaria, usually presenting with severity mostly in children in sub-Saharan 
Africa (Urdaneta et al., 2001). It is the most dangerous form of malaria with the highest rates of 
complications. It is also the commonest species in virtually all parts of Africa accounting for up 
to 98% of the confirmed cases in Nigeria and is associated with significant morbidity and 
mortality. Plasmodium falciparum is responsible for virtually all the features of severe malaria. 
P. malariae usually occurs as a mixed infection with P. falciparum. (NPC & NMCP, 2012). The 
main vector of malaria in Nigeria is Anopheles. gambiae but A. funestus and A. arabiensis are 
also commonly encountered. A. melas is found in the coastal areas. (NPC & NMCP, 2012). 
1.2 Malaria biology 
1.2.1 Life cycle of the malaria parasite-P. falciparum  
The life cycle of Plasmodium falciparum begins with the bite of an infected female mosquito. 
The mosquito while taking a blood meal, releases sporozoites into the blood stream which 
invade the liver cells within 30 minutes of the release. Inside the hepatic cells of the liver, the 
parasites rapidly differentiate and undergo asexual multiplication resulting in the release of 
merozoites which invade other liver cells. These merozoites from the hepatocytes burst into 
the host’s blood stream where they invade the erythrocytes. Further multiplication takes place 
inside the erythrocytes enlarging into ring trophozoites which divide asexually producing 
schizonts. The schizonts divide further causing a release of merozoites when the erythrocytes 
are ruptured. The released merozoites in the blood stream are responsible for the clinical 
manifestation in malaria illness such as fever, joint and muscle pains and chills. This stage called 
the erythrocytic stage is the asexual life cycle of the parasite and usually lasts for 48hours. 
Some of the schizonts divide into sexual forms resulting in male and female gametocytes. The 
gametocytes are taken up by the female anopheles mosquito during another blood meal from 
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a host. The male gametocytes undergo a rapid nuclear division inside the midgut of the 
mosquito resulting to microgametes which fertilise the female microgametes producing 
ookinete. The ookinete later crosses the gut wall as oocyst which subsequently ruptures 
releasing merozoites into the body cavity of the mosquito from where they eventually migrate 
to the salivary gland of the mosquito. With another blood meal the mosquito transmits the 
merozoites into another victim and continues the life cycle.  
(Adapted from http://www.cdc.gov/malaria/about/biology/). 
 
 
Figure 1.1 Plasmodium life cycle 
Source: http://www.parasitaesinhumans.org/plasmodium-falciparum-malaria.html 
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1.3 Endemicity of malaria. 
Malaria is essentially a disease of the tropics and subtropics particularly the sub-Saharan 
African region although it can be found in some people in temperate areas due to migration 
from the tropics. Malaria tends to affect mainly children and pregnant women. 
The level of malaria endemicity in Africa varies between different countries and sometimes 
from one part to another within the same country. Some of the factors responsible for the 
variations in endemicity include: rainfall pattern, altitude and temperature. High rainfall 
pattern is associated with high malaria transmission while places with high altitudes and low 
temperatures tend to be associated with lower rates of transmission (WHO, 2004a). In areas of 
stable transmission, there is often an increased incidence coinciding with increased mosquito 
breeding during rainy season. 
1.4 The burden of malaria in Nigeria.  
Nigeria bears up to 25% of the malarial disease burden in Africa, hence contributing 
significantly to the one million lives lost per year in the region (PMI, 2011). 
Malaria has proven to be a colossal and very difficult human disease amongst the health 
problems confronting countries in sub-Saharan Africa thereby hampering their development 
with a high proportion of its wealth being drained by the disease which accounts for over 60% 
of outpatients visit in Nigeria. It is the commonest cause of hospital attendance in all age 
groups in all parts of Nigeria. It is also one of the four commonest causes of childhood mortality 
in the country.  It is estimated that 50% of the population has at least one episode of malaria 
each year while children under five have on the average of 2-4 attacks in a year (FMOH, 2005a). 
Treatment of malaria illnesses accounted for 40% of the curative health care cost incurred by 
households.   
  National Malaria Control Programme (NPC & NMC), 2012, reports that the disease is 
responsible for 30% childhood mortality, 25% of infant mortality and 11% maternal death and 
300,000 Nigerians die yearly from malaria related deaths. The direct financial loss due to 
malaria according to the report is estimated to be about 132 billion Naira (about 8.8million US 
dollars) in the form of treatment costs, prevention and loss of person-hours annually. 
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Treatment of malaria illnesses accounted for 40% of the curative health care cost incurred by 
households (FMOH, 2005a). The indirect cost of malaria cannot be quantified, but malaria has 
been shown to have a long term effect on the cognitive function and educational attainment in 
children (Jukes et al., 2006, Clarke et al., 2008).  However this observation has not been 
reported in Nigeria. Malaria is the commonest cause of fever and death especially in young 
children (WHO, 2000). This is made worse by the situation of multi-drug resistance as a result 
of self- medication, sub-optimal doses of antimalarial drug, improper diagnosis and improper 
treatment due to resource limitations as is the case in Nigeria.  
Malaria is holoendemic in Nigeria with transmission all the year round. Nigeria has two main 
seasons in the year, the dry season which is from October to about March and the rainy season 
which is from April to September with peak of the rains between May and July when malaria 
transmission is very intense. Rainfall pattern in Nigeria varies with the South having more rains 
than the North. Annual rainfall decreases northward; rainfall ranges from about 2,000 
millimeters in the coastal zone (averaging more than 3,550 millimeters in the Niger Delta) to 
500–750 millimeters in the north. The far south is defined by its tropical rainforest climate, 
where annual rainfall is 60 to 80 inches (1,524 to 2,032 mm) a year.   
With an estimated population of 162 million and being the most populous African country and 
the eighth most populous country in the world (PRB, 2009; UN, 2013), the burden of malaria in 
Nigeria is conversely a world burden especially with the level of migration of Nigerians 
particularly to the western world. The UK Health Protection Agency (HPA, 2011), states that 
about 1,614 malaria cases were reported in the UK yearly between 2005 and 2010, and 22% of 
these cases in 2010 were from Nigeria. 
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Figure 1.2: Nigeria Distribution of Endemic Malaria  
Source: (http://www.mara.org.za) July 2005 
Red Colour= >75% malaria endemic 
 
1.5 Malaria and Immunity 
The immune system of man plays a very important role of defense against the infections that 
attack the body and malarial infection is not exempt in this. The human immune system is 
comprised of innate or natural and adaptive immunity. As the name implies, innate immunity is 
that which the individual is born with; it is non-specific and does not depend on any previous 
infection. It is usually genetic hence it is passed down to the offspring. It is the first line of 
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defense which recruits the second line of defense into action in the face of pathogenic invasion 
of the body. This second line of defense is the adaptive or the acquired immune system. 
Adaptive/acquired immunity is antigen-specific developing after an infection and provides long 
lasting protection depending on the host, the type and number of infections. Its role is 
essentially to destroy invading pathogens and any toxic molecules they produce. Adaptive 
immune responses are carried out by white blood cells (WBCs) which are made up of the 
lymphocytes, monocytes, granulocytes, basophils, neutrophils and eosinophils. The T-
lymphocytes are the most important of the lymphocytes involved in malaria infection and are 
activated by antigens that are presented to it by the dendritic cells.  
Upon activation, the T-lymphocytes proliferate and mature into effector cells which can be 
either T-helper cells or cytotoxic cells. T-helper cells play a very important role in the 
acquisition and regulation of malaria immunity. The predominant T cells are the CD4 cells and 
are the major cells that control blood stage malaria infection (Perlmann and Troye-Blomberg, 
2000) while on the other hand cytotoxic T- cells kill infected cells. The activation of CD4 T-
helper cells leads to the stimulation of certain responses which manifest in the release of 
macrophages and cytokines (IL-10) through the secretion of IFN-γ to prevent the pathology of 
the disease. IFN-γ which is also secreted by CD8 T cells is known to be associated with 
protective immune responses (Schofield et al., 1987,  Moreno et al., 1991, Seguin et al., 1994, 
Doolan and Hoffman, 2000). Studies (Lyke et al., 2004) have illustrated that elevated levels of 
cytokines such as interleukins IL-6, IL-12, IL-1 and IL-10 influence the severity of the malaria 
disease while TNF and INF-γ stimulate neutrophils which increase parasite destruction 
(Kumaratilake et al., 1992, Lyke et al., 2004). Although the TNF is protective against parasite by 
increasing the parasite destruction, in very high serum concentrations it is associated with 
greater severity and death (Kwiatkowski, 1990).   
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Figure 1.3: Role of CD4 cells in malaria infection.  
Sketch based on studies: (Schofield et al., 1987, Moreno et al., 1991, Seguin et al., 1994, Doolan 
and Hoffman, 2000, Kumaratilake et al., 1992, Lyke et al., 2004). 
 
CD8 T cell responses are suppressed during blood stage malaria and this maybe the explanation 
for the increased or higher viral load in HIV-positive individuals with Plasmodium falciparum 
infection (Hoffman et al., 1999). The CD4 cells are therefore seen as the bedrock of the body 
immune system because upon exposure to malaria infection, they are primed for protection by 
initiating the recruitment and release of the other cells and chemicals that prevent the 
pathology of the disease. The severity of the malaria disease is dependent on the speed of the 
response of the immune system.  
Individuals without pre-existing malaria immunity are at risk of malaria infection whereas in 
malaria endemic areas where there is moderate or intense transmission, immunity that is 
acquired by virtue of several exposures plays a very important role in protecting the individuals 
from developing the clinical  and severe form of the disease.  (Bates et al., 2004, Cohen et al., 
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2005). Therefore over time, individuals infected with malaria acquire partial protection and 
therefore have reduced risk of severe malaria hence many adults are not at risk of malaria-
caused deaths. In immunosuppression such as is obtained in HIV-positive persons, the situation 
is not the same. Studies have shown that vulnerability and frequency of malaria infections 
appear to be increased in HIV-positive adults particularly those with low CD4 cell counts 
(French et al., 2001,  Whitworth et al., 2000; Ladner et  al., 2002). 
1.6 Clinical features of malaria. 
The first symptoms of malaria are non-specific and similar to the symptoms of minor systemic 
viral illness. The characteristic presentation of uncomplicated malaria includes fever, headache, 
joint pains, weakness, muscle pains, chills and rigors. Nausea, vomiting, orthostatic 
hypotension and abdominal pain may occur and in children there may be loss of appetite. In 
addition to the above, there is also general malaise and fatigue 
(http://www.cdc.gov/malaria/about/disease.html, last reviewed 2010). 
The severity of clinical malaria depends very much on the acquired immunity and intensity of 
malaria transmission in the area of residence. In areas of stable transmission which prevail in 
much of sub-Saharan Africa, partial immunity to clinical malaria has been acquired in early 
childhood therefore clinical diseases is almost always confined to young children who suffer 
high parasite densities and acute clinical disease (WHO. 2006a). 
1.7 Control of malaria 
Malaria control is multifaceted and consists of vector control, chemotherapy or the treatment 
of malaria with drugs and chemoprophylaxis which includes seasonal malaria chemoprevention 
(SMC). Malaria vector control is the reduction of transmission of malaria through the 
eradication and control of vectors involved in transmission. The various methods include 
indoor residual spraying (IRS), insecticide treated nets (ITNs) and long-lasting insecticidal nets 
(LLINs), larviciding and integrated vector management (IVM). In sub-Saharan Africa, the 
primary interventions for preventing malaria are the ITNs and the LLINs (Lengeler, 2004, Hill et 
al., 2006). Recent studies have suggested that the combination of LLIN and IRS provides 
additive protective benefit by preventing mosquito blood feeding (Okumu et al., 2013).  
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Chemoprophylaxis on the other hand is the prevention of the development of malaria through 
the regular use of anti-malarial drugs. SMC is the intermittent administration of full treatment 
courses of an antimalarial medicine during the malarial season with the objective of 
therapeutic antimalarial drug concentrations in the blood throughout the period of greatest 
malarial risk (WHO, 2012a) and was previously referred as Intermittent preventive treatment of 
malaria in children (IPTc). Study of SMC in Senegal showed a lower prevalence of molecular 
markers of resistance associated with SP or AQ in SMC areas than in control areas, reflecting 
the lower prevalence of parasitaemia in areas where SMC was delivered (Lo et al., 2013). 
Malaria prophylaxis is generally not necessary in persons living in malaria endemic regions. It is 
however needed in non-immune people, persons with sickle cell anaemia, children and infants 
and in pregnant women because of the risk of severe disease.  
Intermittent preventive treatment in infants (IPTi) which is closely related to SMC is the 
administration of a full course of an effective anti-malarial treatment at specified time points to 
infants at risk of malaria, regardless of whether or not they are infected with malaria, with the 
objective of reducing the infant malaria burden (WHO, 2009a). The administration of this 
prophylaxis is usually included during the course of the immunization of the child and reduces 
the incidence of clinical malaria in under-ones by about 30% (Aponte et al., 2009). This 
intermittent preventive prophylaxis is similar to the treatment of asymptomatic-malaria 
infection which has been proposed as a method to reduce malaria–associated morbidity 
(O'Meara et al., 2006).  
Intermittent preventive treatment in pregnancy (IPTp) is the administration of full treatment of 
an antimalarial drug to pregnant women at specific intervals. In Africa, Sulfadoxine 
/Pyrimethamine (SP) has been in use for several years and has been shown to be effective. 
Trimethoprim-Sulphamethoxazole (TS) has also been reported to be more effective than SP-
IPTp in reducing malarial infections and anemia and a combination of both drugs provided 
further reduction in malaria parasitaemia. However the toxicity of combining the two was not 
assessed in the study (Kapito-Tembo et al., 2011). However pregnant women who are HIV 
positive and are on Trimethoprim-Sulphamethoxazole (TS) chemoprophylaxis are not to be 
placed on IPTp with SP because of the possible increased risk of adverse effects of 
sulphonamides (Peters et al,2007). The efficacy of antimalarial drugs for use in prophylaxis and 
treatment is greatly affected by antimalarial drug resistance. This is particularly of importance 
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in situations of immunosuppression as in HIV-positive patients who are regularly placed on TS 
and in pregnant women who are placed on SP for prophylaxis against malaria. The focus of this 
study is on chemotherapy or treatment of malaria. 
1.7.1 Treatment of malaria. 
Treatment of malaria with drugs is the most common and one of the most important measures 
for the control of malaria. The goals of treatment of uncomplicated malaria are: to provide 
rapid and long lasting cure, to reduce morbidity including malaria-related anaemia, to prevent 
the progression of uncomplicated malaria to severe and potentially fatal diseases and to 
minimize the likelihood and rate of development of drug resistance in addition to reducing 
transmission (Sutherland et al., 2005, Sawa et al., 2013).  
Antimalarial drugs can be classified into related groups based on the chemical structure of the 
compounds as follows  
 8-Amino quinolines (Mefloquine, primaquine) 
 4-Amino quinolines (Chloroquine, amodiaquine, piperaquine) 
 Antifolates (Sulfonamides, sulfones) 
 Aryl amino alcohols (Quinine, Lumefantrine, Halofantrine) 
 Artemisinis (Artemisinin,  Dihydroartemisinin, artesunate, artemether, arteether)  
 Biguanides (proguanil and chlorproguanil) 
 Unclassified quinolones (Pyronaridine)  
 Antibiotics (tetracyclines, azithromycine) 
 Naphthoquinones (Atovaquone) 
They can also be classified based on their mode of action (Warhust, 2001a) as blood 
schizonticides, antifolates and antimitochondrials.   
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1.7.2 Blood Schizonticides: The blood schizonticides are the drugs that are used for clinical and 
suppressive cure of malaria. They act only on the haemoglobin-digesting cycle in the RBC (the 
asexual erythrocytic stage of the parasite). These include the 4-aminoquinolines such as 
chloroquine and amodiaquine, the aryl aminoalcohols which include quinine (a natural aryl 
aminoalcohol),  lumefantrine, halofantrine and mefloquine (synthetic aryl aminoalcohols),  
quinine and their related derivatives such as mefloquine and also artemisinin and its derivatives 
like artemether, arteether, artesunate and dihydroartemisinin and other antimalarial 
endoperoxides.  
Artemisinin and its derivatives possess an endoperoxide bridge in their structure which is 
crucial to its antimalarial activity (Brossi et al., 1988). The endoperoxide bridge is very unstable 
in the presence of heme iron and malaria parasites are rich in heme. This bridge is broken 
down upon interaction with intraparasitic heme in the digestive vacuole leading to a release of 
free radicals. These free radicals are toxic to the parasite and damage specific intracellular 
targets possibly via alkylation (Meshnick, 2002). Another suggested mode of action of 
artemisinins is the inhibition of sarcoplasmic-endoplasmic reticulum Ca2+-ATPase ortholog 
SERCA known as PfATP6 (Eckstein-Ludwig et al., 2003, Valderramos et al., 2010).  
Due to the mortality and morbidity rate of malaria especially in children, the choice of 
antimalarial drug to use is of utmost importance particularly in the immunocompromised. The 
choice of antimalarial drug is dependent on a number of factors such as efficacy and safety, the 
cost and dose regimen of the drug. The World Health Organization (WHO) has established an 
antimalarial treatment policy which is a set of recommendations and regulations concerning 
the availability and rational use of antimalarial drugs in a country. The primary purpose of 
antimalarial treatment policy is to select and make accessible to the population at risk of 
malaria safe, effective, good quality and affordable antimalarial drugs so that malaria disease 
can be promptly, effectively and safely treated. 
For several decades, the gold standard for the treatment of malaria was chloroquine, a 4-
aminoquioline that was previously characterized by its efficacy, low toxicity and affordability 
(Fidock et al., 2004). However the efficacy of the drug has deteriorated worldwide due to 
chloroquine-resistant strains of P. falciparum. The resistant foci of chloroquine were first 
detected at the Thailand-Cambodia border in the late 1950s (Payne, 1987) and has spread to 
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many malaria-endemic areas thereby making the drug increasingly ineffective. The spread of 
these resistant strains extended from South America, Southeast Asia and India in the 1960s and 
1970s and to Africa in the late 1970s when resistance was detected in Kenya and Tanzania 
(Wellems and Plowe, 2001). However, chloroquine resistance was not reported in West Africa 
until early 1980s in Burkina Faso, Gabon and Senegal (Nuwaha, 2001, Trape et al., 1989) and by 
the 1990s, there was increased mortality rate in children due to chloroquine resistance in West 
Africa (Trape et al., 1998). 
Another equally cheap drug in use in sub-Saharan Africa which has also come under serious 
resistance is sulphadoxine-pyrimethamine (SP). These two drugs were the first and second line 
drugs for use in treatment of uncomplicated malaria in Nigeria. However in the six geopolitical 
zones of the country, resistance to these drugs has been reported to occur in 23-96% of cases 
hence the need for a change in policy (FMOH, 2005a). 
1.7.3 Treatment failure 
One of the challenges in the chemotherapy of malaria is treatment failure which is the inability 
of a drug to produce the desired therapeutic effect. Treatment failure is caused by various 
factors which include drug resistance, poor bioavailability, fake or substandard drug quality, 
poor patient compliance, suboptimal dose, wrong diagnosis, antagonistic interactions with 
other medications and the immune status of patient (Bloland, 2001). On the other hand, the 
ability of a drug to produce the desired therapeutic effect is described as the efficacy of the 
drug. Of paramount importance to the efficacy of the drug is the host immunity and this may 
be ineffectual in HIV-infected subjects who are immunosuppressed (Kamya et al, 2001; Birku et 
al, 2002). Where the administration of the drug has met the appropriate standards of quality, 
patient compliance, optimal dose, the other factor exacting immense influence on efficacy is 
the bioavailability of orally administered drugs, i.e. the concentration of therapeutically active 
drug or drug metabolite that reaches the blood and is available at the site of action. Day 7 
blood/plasma concentration has been established as a simple measure of assessment of the 
bioavailability of  antimalarial drugs (Ezzet et al., 2000).  
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1.7.4 Combination therapy 
 Antimalarial combination treatment is the simultaneous use of two or more blood 
schizonticidal drugs with independent modes of action and different biochemical targets in the 
parasites (WHO, 2001).Combination therapy is based on the synergistic or additive potential of 
two or more drugs to improve treatment efficacy and retard the development of resistance to 
individual components of the combination. Therefore combination therapy offers better 
advantages over monotherapies. The combination therapy particularly advocated is the 
artemisinin based combination (ACT) because artemisinin produces rapid and sustained 
reduction of the parasite biomass and rapid resolution of clinical symptoms (White, 1997, 
White et al., 1999a).  
1.7.5 Artemisinin and its derivatives 
Artemisinin and its derivatives is currently the mainstay for the treatment of malaria. 
Artemisinin is the active component developed from the leaves of the old Chinese herbal 
medicine Artemisia annua-sweet wormwood or qinghao which has been used for many 
centuries by the Chinese for the treatment of fever. The commonly used derivatives of 
artemisinin are artesunate, artemether and dihydroartemisinin. Other derivatives which are 
less often used include the oil-based lipid soluble arteether (artemotil) and artenilic acid. Every 
form of artemisinin is converted to the active metabolite dihydroartemisinin (DHA).  
The artemisinins and their derivatives are the most rapid acting and efficacious antimalarial 
drugs currently available (Chavchich et al., 2010). Artemisinins are very effective and rapid in 
clearing parasites by killing young, circulating ring-stage parasites and preventing further 
maturation and sequestration of these parasites (ter Kuile et al., 1993, White, 2008). However, 
this is short-lived when used as a monotherapy because of its very short half life. Consequently, 
this results in high rate of recrudescence; therefore for effective treatment of malaria, 
artemisinin is combined with a long acting blood schizonticide which will clear remaining 
parasites, thereby reducing the risk of developing resistance. 
 Among the drugs used in combination with artemisinin (AS) or its derivatives are lumefantrine 
(L), mefloquine (MFQ), piperaquine (PQ), sulfadoxine-pyrimethamine (SP) and amodiaquine 
(AQ), pyronaridine (PYR). ACTs come in various combinations: AL; AS+AQ; AS+SP; AS+MFQ, 
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DHA+PQ and each of the combinations have been proved to be effective in the management of 
uncomplicated malaria (Yeka and Harris, 2010, Croft et al., 2012).  
 
 
 
Figure 1.4 Chemical structures of the artemisinins and partner drugs 
Source: http://www.chemicalbook.com 
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Figure 1.5 Chemical structures of sulphadoxine and pyrimethamine 
Source: http://www.drugbank.ca/drugs/DB00205 
 
1.7.6 Artemether-lumefantrine 
Artemether-lumefantrine was introduced in Nigeria in 2005 as the first line antimalarial drug 
for the treatment of uncomplicated malaria. The drug artemether-lumefantrine is a fixed 
combination of artemether-lumefantrine in the ratio 1(20mg, artemether): 6(120mg, 
lumefantrine). It is indicated for the treatment of acute, uncomplicated infections due to 
Plasmodium falciparum or mixed infection including P. falciparum and strains from multi-drug 
resistant areas for infants, children and adults. Artemether is a sesquiterpene lactone derived 
from the naturally occurring compound artemisinin. It is the methyl ether of dihydroartemisinin 
while lumefantrine is a racemic mixture of a synthetic flourene derivative of the aryl amino-
alcohol family. Lumefantrine has a similar mechanism of action to halofantrine probably due to 
similarities in structure and pharmacokinetic properties, but unlike halofantrine, lumefantrine 
is very safe as it does not prolong the electrocardiographic QT interval (van Vugt et al., 1999). 
Lumefantrine was first synthesized and registered in China and is now commercially available 
only in co-formulated product with artemether as coartemether (Annerberg et al., 2005) Both 
drugs act as blood schizonticides (Lefevre et al., 2001).  
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1.7.6.1 Pharmacology: The site of antiparasitic action of artemether and lumefantrine is the 
digestive food vacuole of the malaria parasite, where they are thought to interfere with the 
conversion of heme, a toxic intermediate produced during haemoglobin breakdown to the non-
toxic haemozoin malaria pigment (del Pilar Crespo et al., 2008). 
Artemether being a derivative of artemisinin is metabolized to DHA and posesses an 
endoperoxide bridge which is very crucial to its antimalarial activity (Brossi et al., 1988). The 
endoperoxide bridge which is very unstable in the presence of heme iron and upon interaction 
between the two is broken down to antiparasitic free radicals in blood stage malarial parasites. 
These free radicals are toxic to the parasite and damage specific intracellular targets possibly 
via alkylation as previously noted above. Lumefantrine interferes with the polymerization 
process. Both artemether and lumefantrine have a secondary action involving inhibition of 
nucleic acid and protein synthesis within the malaria parasite.  
Pharmacodynamics reports (van Vugt et al., 2000, Lefevre et al., 2001) of artemether-
lumefantrine indicate high parasitological cure rates (>95%) in three Thailand studies. It 
eliminates parasites and symptoms significantly faster than most current antimalarials (van 
Agtmael et al., 1999, Kshirsagar et al., 2000) and is rapidly gametocytocidal helping to reduce 
transmission (Sutherland et al., 2005, Sawa et al., 2013). It is also effective in multi-drug 
resistant areas.  
 The two drugs complement each other in their pharmacokinetic activities. They are both 
metabolised by hepatic cytochrome P450 enzyme, CYP3A4 and CYP2B6. Artemether is 
metabolised to its more active metabolite dihydrartemisinin (DHA). Both artemether and DHA 
offer potent antimalarial properties causing significant reduction in asexual parasite mass of 
approximately 10,000-fold per reproductive cycle with prompt resolution of symptoms (Djimde 
and Lefevre, 2009). Lumefantrine is metabolized by N-debutylation to desbutyl-lumefantrine 
which has a 5-8-fold higher antiparasitic effect (White et al., 1999b, Khoo et al., 2005).  
 Peak plasma concentrations of artemether occur around 0.5-2 hours after oral administration 
(Ezzet et al., 1998) and elimination half-life is approximately 2 hours. Lumefantrine on the 
other hand reaches peak plasma levels approximately 10 hours after oral administration (WHO, 
2006a) but is cleared more slowly, showing a terminal half-life of 4-6 days with P. falciparum 
malaria (Lefevre and Thomson, 1999). Oral bioavailabilty is variable and is highly dependent on 
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administration with fatty foods (Ezzet et al., 1998, White et al., 1999b). A meal with only a 
small amount of fat (1.6g) is considered sufficient to achieve adequate exposure to 
lumefantrine (Djimdé and Lefèvre, 2009). 
The manufacturer recommends that Coartem be instituted at the onset of symptoms as a six-
dose regimen with 1-4 tablets per dose depending on body weight and should be administered 
over the course of 3 days. The six-dose regimen was first tested in sub-Saharan Africa in 2002 
and showed both high efficacy and transmission reduction (Sutherland et al., 2005). 
1.7.7 Antimalarial Drug Resistance 
Antimalarial drug resistance is defined as the ability of a parasite strain to survive and multiply 
despite the proper administration and absorption of an antimalarial drug in the dose normally 
recommended (WHO, 2006). It is a shift to the right of the dose-response curve, thus requiring 
higher drug concentrations to achieve the same parasite clearance (White, 2004). In many 
cases even the higher concentration results in treatment failure. However not every treatment 
failure is as result of drug resistance. Assessment of antimalarial drug resistance can be done 
through many ways and this includes: in vivo assays which is usually regarded as the gold 
standard, in vitro tests which involves drug assays and assessment of molecular markers of 
resistance present in the study area of interest. 
Many factors influence antimalarial drug resistance and this includes the nature of the parasite, 
pharmacological properties of the drug, host factors of which the primary one is human 
immune responses, (Travassos and Laufer, 2009), and the ability  to clear a resistant infection is 
closely related to age (Djimde et al., 2003).  
Individuals with lower immunity such as HIV-positive patients, children and pregnant women 
are more vulnerable to antimalarial drug resistance. Reduced immunity allows the survival of a 
residuum of parasites thereby potentially intensifying the development, intensification and 
spread of resistance (Byakika-Kibwika et al., 2010). Additionally, delayed cure rate and higher 
rate of recrudescence which occur in HIV-positive individuals accelerate the spread of resistant 
parasites and increase the parasite biomass in both symptomatic and asymptomatic carriers 
(Birku et al., 2002, Shah et al., 2006, Van Geertruyden et al., 2006).  
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Resistance to antimalarial drugs by Plasmodium falciparum parasite has become a major health 
problem since the first resistance to Chloroquine was recorded in Thailand and Cambodia in the 
late 1950s (WHO, 2006). This has spread to other malaria endemic regions and against other 
antimalarial drugs like sulphadoxine-pyrimethamine (SP) and mefloquine. Studies (Noedl et al., 
2008) reporting artesunate-resistant malaria in western Cambodia and reduced in vivo 
susceptibility of artesunate (Dondorp et al., 2009) and in vitro resistance to its derivative 
artemether (Jambou et al., 2005) indicate a great threat to the management of malaria since 
artemisinin and its derivatives are currently the mainstay for the treatment of uncomplicated 
malaria. Dokomajilar et al., (2006) also reported parasite tolerance to AL in some parts of Africa 
shortly after its introduction. 
1.7.7.1 Mechanisms of drug resistance  
Antimalarial drug resistance can result either from changes in drug accumulation or efflux or 
reduced affinity of the drug target resulting from point mutations in the respective genes 
encoding the target (White et al., 1999b). The efflux of the drug from the DV of the malaria 
parasite via the transporters involved in the carriage of the antimalarial drug have been 
associated with drug resistance such as that obtained in transporters of chloroquine or the 
artemisinins (Sanchez et al, 2005., Duraisingh and Cowman, 2005). Genetic polymorphisms in 
one or more genes that do not actually encode the drug target itself but affect drug efflux can 
lead to reduced drug concentrations within the parasites such as in chloroquine, amodiaquine, 
quinine, mefloquine and halofantrine thereby resulting in drug resistance (Valderramos and 
Fidock, 2006). Another mechanism of resistance is through altered affinity for the drug target 
caused by single or multiple point mutations in genes that encode the drug target as in 
pyrimethamine, cycloguanil, sulphonamide and atovaquone  (Wang et al., 1997). Resistance 
can also be due to expression of higher levels of the gene through amplification thereby 
resulting in increased copy number. This has been reported in the treatment with AL in Sudan 
where increased copy number of pfmdr1 gene was associated with clinical failure (Gadalla et 
al., 2011) and decreased parasite susceptibility to artelinic acid and artemisinin in vitro was 
linked to increased copy number of pfmdr1 gene (Chavchich et al., 2010). Antimalarial drug 
resistance can also occur where there has been no prior resistance in the parent drug because 
of inadequately treated biomass infections (White and Pongtavornpinyo, 2003) or reduced 
sensitivity to a given drug or class of drugs which occurs as a result of spontaneous mutations 
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(Bloland, 2001) and subsequent spread as a result of survival and multiplication. Where a large 
population of parasites are exposed to drug pressure, resistance is reported to develop more 
quickly (Farooq & Mahajan, 2004). Some malaria parasites, especially in West Africa exhibit an 
innate resistance to new drugs of diverse chemical classes such as mefloquine, halofantrine or 
even artemisinin (Oduola et al., 1987, Oduola et al., 1992).   
1.7.8 Molecular markers of resistance  
Molecular markers of drug resistant malaria are based on genetic changes that confer parasite 
clearance to drugs used to treat and prevent malaria (Plowe et al., 2007). Molecular markers 
have been proven to be tools for surveillance of resistance (Djimde et al., 2001a, Djimde et al., 
2001b), provide additional data that compliment clinical observations of the in vivo efficacy of a 
drug and has been instrumental to policy making with regards to control of malaria epidemic 
(Mugittu et al., 2004). They have also served as monitoring tools in parasite drug susceptibility 
following change in treatment policy (Kublin et al., 2003, Laufer et al., 2010). Since resistance 
results from mutations in genes or changes in the copy number of the genes relating to the 
drug’s target of the parasite gene, investigating molecular markers of resistance is therefore a 
very important way of assessing resistance to a drug. Certain molecular markers have been 
associated with certain group of drugs as evidence of resistance. Table 1.1 lists molecular 
markers related to this study. 
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Table 1.1 Molecular markers related to this study (Genes of interest)  
GENE GENE ID CODONS OF  INTEREST DRUGS REFERENCES 
Pfcrt PF3D7_0709000 72-76 CQ, AQ Fidock et al, 2000, Sidhu et 
al, 2002, Warhust, 2003; 
Folarin et al, 2008; Beshir et, 
al 2010 
 
Pfmdr1 
PF3D7_0523000 86,184,1034, 
1042,1246 
CQ,AQ,
AL 
Sutherland et al, 2002; 
Dokomajilar et al, 2006; 
Humphreys et al, 2007; 
Holmgren et al, 2007; Happi 
et al, 2009; Malmberg et al, 
2013. 
Pfdhps PF3D7_0810800 431,436,437,540,581,
613 
SP, TS Pearce et al, 2003; Roper et 
al, 2003; Happi et al, 2005; 
Sutherland et al, 2009; 
Naidoo et al, 2010 
pfdhfr PF3D7_0417200 50,51,59,108,164 SP,TS Pearce et al, 2005; Happi et 
al, 2005; McCollum et al, 
2007; Malamba et al, 2010. 
 
1.7.8.1 Plasmodium falciparum multidrug resistance gene1 (Pfmdr1) 
A similarity in decreased drug accumulation found in the antitumour drugs and antimalarial 
drug resistance led to the discovery of the Plasmodium falciparum multi drug resistance 
(pfmdr1) gene (Krogstad et al., 1988). Pfmdr1 is a 4251 base pair gene on chromosome 5 that 
encodes a protein PfMDR1 majorly localised on the digestive vacuole (DV) of the erythrocyte 
stage of the parasite, very little is present at the parasite plasma membrane (Cowman et al., 
1991). Changes in the transmembrane protein pfmdr1 which encodes the P-glycoprotein 
homologue 1 (PGH-1), results in resistance to the artemisinins. PfMDR1 has been 
demonstrated to be a transporter of various chemicals such as chloroquine, quinine, 
halofantrine into the DV of the parasites and the polymorphisms on this protein define the 
substrate specificity of the antimalarial drug (Sanchez et al., 2010). This has been evidenced by 
its regulation in the in vitro and in vivo response to mefloquine, halofantrine and quinine (Price 
et al., 1999b, Price et al., 2004, Nelson et al., 2005, Duraisingh and Cowman, 2005).    
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Point mutations in the pfmdr1 gene and increased copy number result in decreased 
accumulation of the drugs because of the increased efflux from the DV with subsequent 
resistance or decreased sensitivity (Duraisingh et al., 2000b). Five major mutations (N86Y, 
Y184F, S1034C, N1042D and D1246Y) on the pfmdr1 gene have been implicated in multidrug 
resistance of antimalarial drugs. Studies by (Dokomajilar et al., 2006, Sisowath et al., 2007), 
have indicated that polymorphisms at 86N, 184F and 1246D are involved in the AL resistance 
while a selection of 86Y, 184Y and 1246Y leads to AQ resistance (Humphreys et al., 2007). 
Mutations on points N86Y and D1246Y have also been associated with contributors to 
chloroquine resistance (Plowe, 2003). Happi et al, (2009) in a study of AL for the treatment of 
Nigerian children with uncomplicated falciparum malaria observed that the NFD haplotype of 
the pfmdr1 gene was significantly associated with treatment failure. Additionally, (Gadalla et 
al., 2011) established that amplification of pfmdr1 locus increased copy number may contribute 
to recurrent parasitaemia following AL therapy just as decreasing the copy number was 
demonstrated to heighten susceptibility to lumefantrine, halofantrine, mefloquine, quinine and 
artemisinin (Sidhu et al., 2006). 
1.7.8.2 Plasmodium falciparum dihyropterate synthetase (Pfdhps) and Plasmodium 
falciparum dihydrofolate reductase (pfdhfr) 
Resistance to the antifolate and sulpha drugs Sulphadoxine-pyrimethamine (SP) and 
Trimethoprim-sulphamethoxazole (TS) is mediated by mutations on the Pfdhps and the pfdhfr 
genes. SP is used for both treatment and intermittent prevention of malaria (IPT) while the 
closely related drug TS which is primarily used for prophylaxis of opportunistic infections in 
HIV-infected persons has also been confirmed to have antimalarial activity (Walker et al., 2010, 
Manyando et al., 2013). 
The Plasmodium parasite decreases the affinity of binding of the antifolates pyrimethamine, 
trimethoprim, cycloguanil, proguanil to the enzyme target dihydrofolate reductase (dhfr) 
thereby leading to resistance to the drug.  Sulpha drugs are inhibitors of the enzyme 
dihdropteroate synthetase (dhps) the target enzyme in the folate biosynthesis of the 
plasmodium parasite. A combination of the two classes usually given as sulphadoxine-
pyrimethamine (SP) therefore provides sequential inhibition of folate biosynthesis and show a 
marked synergy in antimalarial activity (White et al., 1999b).    
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Mutations in the genes of these enzymes lead to altered drug binding and the resultant effect 
is resistance. Polymorphisms at certain loci on the genes encoding these enzymes are 
responsible for resistance to these drugs (Kublin et al., 2002, Karema et al., 2010). On the dhfr 
gene, point mutations at positions 51, 59, 108 and 164 have long been associated with 
pyrimethamine resistance (Cowman et al., 1988) while on the dhps gene mutations at positions 
437G and 540E are linked to SP resistance (Kublin et al., 2002, Bwijo et al., 2003). 
The presence of a combination of the five mutations (dhfr N51I, C59R, S108N and the dhps 
A437G and K540E on both genes which is generally referred to as the ‘quintuple mutant’ have 
been statistically associated with SP treatment failure in vivo (Nzila et al., 2000, Kublin et al., 
2002). A Nigerian study, (Happi et al., 2005) established an independent association of SP 
treatment failure with the dhfr triple mutant N51I, C59R, S108N and the double mutant dhps 
A437G and K540E in children less than 5years. The study further stated that the genotype 
strongly associated with the failure is the quintuple mutant.  
Another locus of interest in the dhps gene is substitution of valine for isoleucine at codon I431V 
(Sutherland et al., 2009). The significance of this novel dhps to antifolate resistance has not yet 
been established however it is has been detected in occurrence together with mutations at 581 
and 613 and was first reported in samples of UK infections from Nigerian isolates. Preliminary 
data analysis from the study shows 431V was in occurrence with 437G, 581G and 613S. 
Mutations at codons 581 and 613 have long been associated with SP resistance (Plowe et al., 
1997).  
1.7.8.3 Plasmodium falciparum chloroquine resistance transporter gene (Pfcrt)  
The emergence of Chloroquine resistant (CQR) P. falciparum parasites in the late 1950s (Payne, 
1987) in South-east Asia and South America many years after the first use of CQ as the 
mainstay for treatment and prophylaxis of malaria and its subsequent spread to Africa in the 
late 70s (Wootton et al., 2002) has resulted in a great challenge in malaria control. The 
mechanisms of this resistance are not completely understood however many studies have 
established the role and implication of the gene Plasmodium falciparum chloroquine resistance 
transporter gene (pfcrt) in CQR.  Pfcrt is a gene on chromosome 7 and encodes a putative 
transporter PfCRT which is a 48kDa protein containing 424 amino acids and is localized in the 
digestive vacuole (DV) of the parasite during the eryhthrocytic stage (Fidock et al., 2000).  
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PfCRT has been shown to function as a transporter that directly mediates the efflux of CQ from 
the DV of the parasite (Warhurst, 2003, Bray et al., 2005). Polymorphisms with multiple 
mutations in this protein resulting in changes in pH on the DV have been closely correlated with 
CQR and this is evidenced by the differences observed in the accumulation of chloroquine in 
the DV of CQR and CQS parasites. Furthermore, the reduced accumulation can be reversed in 
the presence of verapamil and thereby increase the sensitivity (Wellems et al., 1990, Bray et al., 
2005, Fidock et al., 2000, Sidhu et al., 2002). Point mutations on this gene particularly change in 
the amino acid at position 76 from lysine K to threonine T (K76T) has been shown to confer 
resistance to CQ by reducing accumulation of the drug in the DV.  
Although there are many point mutations on this gene resulting in different alleles, the most 
critical is the change at codon 76 from lysine K to threonine T (K76T) and has been shown to 
confer resistance to CQ in every geographical setting just like the CQS strains in every 
geographic setting maintain the wild type K76. This was emphasized in the report (Warhurst, 
2003) stating that in the context of other mutations, CQR results from the change of the 
positively-charged lysine-76 to neutral threonine which could facilitate drug efflux.  
The Plasmodium parasite digests haemoglobin from the host red cell which is degraded to 
heme and amino acids in the DV. Being a weak base, CQ accumulates inside the acidic DV, of 
the Plasmodium parasite. CQ-sensitive parasites accumulate high levels of CQ partly because of 
the weak base trapping and binding to haem (Yayon et al., 1985) producing a complex which is 
toxic to the parasite (Orjih et al., 1994, Warhurst, 2003). In the CQS form of PfCRT the positively 
charged side chain of lysine 76 may repel the positively charged CQ molecule reducing its efflux 
through the channel (Warhurst, 2003).  In CQ-resistant strains however, there is less 
accumulation of the drug due to the drug efflux (Sanchez et al., 2003). The pH of the DV may 
also have an influence in the reduction of the accumulation of CQ (Ginsburg and Stein, 1991).  
Various mutations of CQR on the PfCRT present in different haplotypes depending on the 
location however all the alleles maintain the 76T mutation. In Africa and Southeast Asia the 
common haplotype seen is the CVIET (change at positions 72-76), while in South America the 
common allele found is SVMNT (Fidock et al, 2000). Additionally SVMNT was also reported in 
South-East Asia (Dittrich et al., 2005), in Tanzania (Alifrangis et al., 2006)  and a high prevalence 
of >50% in Angola (Sa and Twu, 2010). Another less common haplotype is the CVMNT as 
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reported in Ecuador and Brazil (Vieira et al., 2004) and South-Western Nigeria (Gbotosho et al., 
2012).   
Transfection studies have also proven the role of PfCRT not just on CQR but also on resistance 
to quinoline antimalarial drugs (Bray et al., 2005). This has been evidenced by its involvement 
in AQ failure presenting as SVMNT haplotype (Beshir et al., 2010a, Sa and Twu, 2010). Its 
expanded role in influencing parasite susceptibility to other structurally diverse antimalarials 
was established in its role in conferring hypersensitivity to MFQ and Halofantrine (Johnson et 
al., 2004).  
The implications of antimalarial drug resistance are such that there is continued transmission of 
drug-resistant parasites thereby limiting the efforts to control malaria. This is because drug 
resistance can also lead to increased gametocyte carriage, thereby facilitating the spread of 
resistance through the population (Price et al., 1999a). The continued use of a drug with 
prevalence of resistance in a locality confers a selective advantage to parasites carrying 
resistant genes and leads to higher rates of transmission of drug resistant parasites 
(Handunnetti et al., 1996, Sutherland et al., 2002).  
Antimalarial drug resistance is the predominant factor maintaining the global burden of malaria 
particularly in sub-Saharan Africa (Barnes and White, 2005). This has therefore made the 
management of malaria very difficult and warranted the recommendation of combination of 
antimalarial drugs for the treatment of malaria by the World Health Organisation (WHO). 
 1.8 HIV/AIDS. 
The acquired immune deficiency syndrome (AIDS) is defined as the state of profound 
immunosuppression produced by chronic infection with human immunodeficiency virus (HIV). 
Many theories have been projected as the origin of HIV. It has however been accepted as a 
descendant of the African Green monkey virus, the  Simian immunodeficiency virus (SIV) virus 
because of the similarities between the two viruses (Cohen, 1999).   
 HIV is a retrovirus that belongs to the family of Lentiviruses from the retroviridae. The 
retroviruses possess the enzyme reverse transcriptase which they use to transcribe their RNA 
genome into DNA. After transcription to DNA, the viral DNA then gains access to the DNA of the 
47 
 
cell of the host and there replicates itself.  There are two types of HIV -types 1 and 2. Both HIV-
1 and HIV-2 replicate in CD4 T cells and have been documented as causative agents of AIDS. 
HIV-1 is more virulent than HIV-2, more easily transmitted and is the cause of the vast majority 
of infections globally (Reeves and Doms, 2002). 
1.8.1 Epidemiology of HIV/AIDS 
The first case of AIDS was reported in the USA amongst homosexual men (Gottlieb et al., 1981). 
It later became apparent that other population groups were affected including males who have 
sex with men and intravenous drug users (CDC, 1991). Later reports based on retrospective 
studies have suggested that the oldest HIV infection was that found in a sailor from 
Manchester who died from AIDS-like illness in 1959 and also from African plasma sample that 
was previously found to be seropositive thereby predating the infection before the 1981 case 
(Zhu et al., 1998). The African sample is believed to be the first known case of AIDS and was 
collected from a man who died in the Democratic Republic of Congo in 1959 (Pickrell, 2006). 
An estimated 34-47 million people were infected with HIV/AIDS in 2006, with approximately 
4.3 million of these being newly diagnosed infections (UNAIDS/WHO, 2006). Over 40million 
people are HIV-positive and over half of this number are in Africa (WHO, 2004a). HIV/AIDS 
accounted for the deaths of 2 million people in 2007 and 2.7 million were new infections of 
which 1.9 million occurred in sub-Saharan Africa(Quinn, 2008).  
In Africa, reports in 2003 show that AIDS claimed the lives of an estimated 2.4million people 
and over 600,000 children were newly affected with the virus (WHO, 2004a). HIV/AIDS 
increasingly accounts for a large proportion of mortality among children below five years in the 
heavily affected countries and also affect mainly adults in their most productive years of life 
(15-49years) (UNAIDS /WHO, 2001). A more recent report (UNAIDS, 2011) shows that by 2010, 
about 34million people were living with HIV/AIDS of which 2.7million are new infections and 
the greatest burden is in sub-Saharan Africa with an estimated population of 22.9million (68%) 
of infected people.   
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1.8.1.2 HIV/AIDS in Nigeria 
Nigeria is ranked second in the number of people living with HIV/AIDS after South Africa and 
accounts for about 9% of the global HIV burden (UNGASS, 2010).  AIDS was first reported in 
Nigeria in 1986. The first two cases of HIV and AIDS in Nigeria were identified in 1985 and were 
reported at an international AIDS conference in 1986. (FMOH, 2005b, Nasdi and Harry et al, 
2006). Consequently the number of people living with HIV/AIDS steadily increased and the 
epidemic became established with an increase of HIV-seroprevalence from 1.8% in 1991 to 
5.8% in 2001 and 5.0% in 2003. This meant that Nigeria had 3.5million infected persons, the 
third highest in the world (FMOH, 2005b). Currently an estimated 3.1 million people are living 
with HIV/AIDS and national prevalence is 4.1% (NACA, 2011). Nigeria has the second highest 
number of new infections yearly (UNGASS, 2010). 
In Nigeria, about 80% of HIV transmission is through the heterosexual route (UNGASS, 2010) 
while blood transfusion with a 10% rate accounts for the second largest source of HIV infection 
(FMOH, 2009). In a study of transfusion-transmissible infections among blood donors in Port 
Harcourt, Nigeria,  Ejele et al, (2005a) observed that out of the 146 donors positive for HIV, 138 
(95.5%) had HIV-1 and 8 (5.5%) had HIV-2 with sub-type A and G of HIV-1 being the 
predominant one in circulation (Peeters et al, 2004).  
Another report established an overall prevalence of 1% among blood donors in Niger Delta 
region of Nigeria with the highest occurring among the age group 20-29 years (Ejele et al, 
2005b). Another major route of transmission is the mother to child accounting for about 
360,000 children with HIV. Mode of transmission model studies show that high risk groups men 
that have sex with men (MSM 1%) and female sex workers (FSW 23%) significantly contribute 
to new HIV infection (Nwauche et al, 2006b; UNGASS, 2010).  
Prevalence of HIV/AIDS is highest in the age group 25-29years (5.6%) and lowest in 40-44years 
(2.9%) from the 2008 ANC survey (UNGASS, 2010). In settings as obtained in Nigeria, where 
heterosexual transmission is common, women are more likely to be affected in the epidemic 
thereby increasing the burden of mother to child transmission. The high prevalence of HIV in 
women of reproductive age has led to a growing population of HIV–infected and affected 
children. It is estimated that one HIV- positive child is born every five minutes, in Nigeria (Eneh, 
2007). In 2010, the HIV prevalence was highest in urban areas and among the 30-34 years age 
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group. The prevalence of HIV in the 36 states of Nigeria shows Benue state to be on top of the 
ladder while Kebbi was on the lowest pedals. River state which was our study area is on the 
10th position (Figure 1.6). 
The impact of HIV/AIDS in Nigeria is profound and multifaceted ranging from healthcare, 
political and social instability but the greatest impact is on the economy because HIV/AIDS 
attacks people mostly in their productive years and in resource-limited countries it is usually 
fatal. HIV fosters and promotes poverty, destabilizes the family structure and takes a great toll 
on the nation’s economy. The major effects on the economy are seen on the increased costs 
and reduction in labour supply. This is particularly evident in agriculture which is the primary 
source of activity of the Nigerian population occupying about 45% of the employed labour 
force (Bolinger, et al, 1999). The indirect costs of HIV/AIDS include lost time due to illness, 
recruitment and training and cost to replace workers and care of orphans. Approximately 54% 
of annual income of an affected household is estimated to be spent on HIV and this involves 
income losses due to sickness and out–of-pocket expenses on healthcare (Mahal et al, 2008). 
Personal cost is estimated to be over 200% of household expenditure and include expenses on 
antiretroviral drugs (ARVs), other drugs (e.g for opportunistic infections), laboratory tests and 
investigations (Onwujekwe et al., 2009).           
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Figure 1.6 HIV prevalence by States, 2012 
Source :  Federal Republic of Nigeria Global AIDS Response Progress Report, 2012 (GARPR)  
1.8.1.3 Pathogenesis of HIV/AIDS. 
HIV possesses the enzyme reverse transcriptase which enables it to transcribe its genetic 
material from ribonucleic acid (RNA) to deoxyribonucleic acid (DNA). Docking glycoprotein gp 
120 and transmembrane glycoprotein gp41 found on the HIV virion wall have a strong affinity 
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for the CD4 receptor protein found predominantly on the T helper/inducer lymphocytes. It 
makes use of CD4 molecules to gain entry into the T helper cells of the host since CD4 is its 
primary receptor. It makes use of CD4 molecules to gain entry into the T helper cells of the host 
since CD4 is its primary receptor. Reports have shown that even though CD4 is the primary 
receptor for viral entry into the host cell, there are additional co-receptors required for HIV to 
gain entry into the lymphcyte. The HIV glycoprotein 120 has been found to interact with both 
CD4 as well as CXCR4, a receptor expressed on many T-cells for adherence to the cell in order 
to effect the required conformational changes in the gp120/gp41 complex which then allows its 
fusion to the host cell membrane (Feng et al, 1996). Another co-receptor involved in HIV-
membrane infusion to the host cell is the CCR5 expressed on the macrophages and on some 
populations of T-cells (Deng et al, 1996; Idemyor, 2005). However, the binding of the HIV gp120 
to CCR5 is CD4-dependant. This is evidenced by reports that individuals with certain mutations 
on the CCR5 are resistant to HIV infection (Liu et al, 1996; Samson et al, 1996). The fusion of 
the HIV cell to the host surface and subsequent entry into the host cell results in the formation 
of DNA through the use of its reverse transcriptase enzyme.  
The newly formed DNA is integrated into the host cell and begins to replicate into several 
billion cells daily. The multiplicity of the virus leads to the destruction and depletion of the CD4 
cells ultimately overwhelming the immune system therefore the individual becomes 
immunocompromised and susceptible to other opportunistic infections and tumours. When 
the CD4 cell count of an individual infected with HIV gets depleted to a very low level (less than 
200 cells/mm3, the person is diagnosed with AIDS. HIV also invades other cells such as 
macrophages, monocytes and glial cells of the brain (NIH. 2012). Due to their role in the 
immune system, the T-cells are therefore used as prognostic markers for monitoring the 
progress of immunosuppression such as HIV infection (Abdulazeez, 2012).  
1.8.1.4 Prophylaxis of HIV/AIDS 
Despite the decline in global incidence of new HIV infections from 3.1 million in 2001 to 2.7 
million in 2010 (UNAIDS, 2011), HIV still claims many lives in sub-Saharan Africa where about 
68% of people leaving with HIV reside. Awareness campaigns, HIV testing, prevention of 
mother to child transmission (PMTCT), lifestyle changes etc. have contributed to a great extent 
to the decline in new infections of HIV (Coates et al., 2008), however there is still need for more 
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efforts to further prevent new infections and reduce the incidence. Like the old adage goes 
‘prevention is better than cure’ there is need to devise means of reducing HIV epidemic or 
preventing new infections. Prophylaxis has proven to be effective in the control of many 
diseases, such as malaria and opportunistic infections in HIV/AIDS patients. This approach is 
currently being advocated as an additional tool for the control of HIV. HIV prophylaxis can be 
administered either before (pre-exposure) or after (post exposure) to the infection.  
Post exposure prophylaxis (PEP) is short-term antiretroviral treatment to reduce the likelihood 
of HIV infection after potential exposure, either occupationally or through sexual intercourse 
(WHO, 2007a). The administration of antiretroviral medications 72 hours after exposure of the 
percutaneous and mucous membrane to HIV either through needle-stick injury or 
unanticipated sexual intercourse has been shown to prevent infection (Olshen & Samples, 
2003, Smith et al, 2005). Post exposure prophylaxis is not suitable for individuals with repeated 
high-risk of infection who are unwilling to adhere to risk reduction practices (Omrani and 
Freedman, 2005). 
Pre-exposure prophylaxis (PrEP) on the other hand is the administration of antiretroviral drugs 
to uninfected HIV individuals who are at high risk of infection. It works on the principle of 
supplying a therapeutic level of ARV drugs in the blood stream before exposure to the virus so 
it is crucial that adequate level of drug are present in the system (Morin, 2012).  This therefore 
calls for long-term adherence among uninfected persons considered to be at high risk of HIV 
infection who are placed on prophylaxis.  
There have been trials on the use of microbicides and topical applications of antiretroviorals 
(Cohen et al, 2007; Abdool Qarim et al, 2010) for use in PrEP. The US Food and Drug 
Administration (FDA) approved the use of combination of two medications, tenofovir disoproxil 
fumarate and emtricitabine (TDF-FTC), for daily use as PrEP for people at high risk of HIV 
infection through sexual exposure. Studies have reported a 44% reduction in HIV acquisition 
when PrEP is administered to HIV-negative men or trans-gender women who have sex with 
men (among adherent users) (Grant et al, 2010). Many more trials are being carried on the 
target audience which include people who inject drugs, serodiscordant couples, heterosexual 
men and women, women at high risk of HIV exposure and men and transgender women who 
have sex with men (WHO, 2012b). 
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1.8.1.5 Treatment pattern for HIV infection.  
In order to improve the quality and duration of life of HIV-positive subjects, the goals of 
therapy are 
1. Reduce viral load    
               2. Prevent deterioration of immune function and/or restore immune status 
               3.  Treat and prevent opportunistic infections 
               4. Relieve symptoms. 
The time for initiating antiretroviral treatment is determined by the clinical stage of the HIV 
infection as indicated by symptoms, and where available the CD4 cell count. The optimum time 
for initiation of treatment depends primarily on the CD4 cell count, the plasma viral load and 
the clinical symptoms of the patient.  In the United States of America it is strongly advocated 
that treatment be initiated when the CD4 cell counts fall below 350 cells/mm3 (AIDSINFO, 
2012) while in low income countries, treatment is initiated in patients with CD4 cell counts  
between 200-350 cells/mm3 (Stover et al, 2010). Studies in Nigeria have shown that there is no 
short-term immunological advantage in starting HAART at a baseline CD4 count of > 350 
cells/ul rather than at 200-350 or < 200 cells/ul (Ejele et al, 2005c). However in conditions of 
pregnancy, co-infection with hepatitis B virus, HIV-associated nephropathy and history of an 
AIDS-defining illness, initiation of treatment is advocated in HIV-positive individuals regardless 
of CD4 cell count (AIDSINFO, 2012). 
The drug treatment for HIV disease is tripartite comprising antiretroviral therapy, management 
of opportunistic infections or malignancies and symptom control. The aim of the first of these, 
antiretroviral therapy is reducing the HIV viral load as much as possible, for as long as possible 
and restoring immune function. Opportunistic infections in HIV infections are managed by the 
administration of trimethoprim/sulphamethoxazole (TS). The introduction of antiretroviral 
drugs changed the whole course of HIV/AIDS disease and management so that many infected 
people now live for extended period.  
1.8.2 Classes of antiretroviral drugs. 
Following the deployment of Azidothymidine (AZT) as the first drug (Fischl et al., 1987) for 
treatment of HIV/AIDS, the whole course of the disease prognosis and management has 
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changed such that with the administration of ARVs, there is decreased morbidity and mortality 
(Mahungu et al., 2009b) and many infected persons now live extended periods of time (Palella 
et al., 1998). Several drugs have been developed for the treatment of HIV/AIDS and currently 
there are seven classes of antiretroviral drugs based on the site and mechanism of action (Arts 
and Hazuda, 2012). 
1.  Non-nucleoside reverse transcriptase inhibitors (NNRTIs), which inhibit viral replication by 
binding directly onto the reverse transcriptase enzyme thus preventing the transcription of 
viral RNA to DNA. Examples are Nevrapine (NVP), etravirine and efavirenz (EFV). 
2. Nucleoside reverse transcriptase inhibitors (NRTIs), which incorporate themselves into the 
DNA of the virus, thereby stopping the building process. The resulting DNA is incomplete and 
cannot encode a new virus. Examples are Lamivudine (3TC), stavudine (d4T) zidovudine (ZDV) 
and abacavir (ABC). 
3. Nucleotide reverse transcriptase inhibitors (NtRTIs), which act at the same stage of the viral 
life cycle as the NRTIs, but do not require to be phosphorylated for effective antiretroviral 
activity. Examples are Tenofovir Disoproxil Fumarate. 
4. Protease inhibitors (PIs), which work at the last stage of the virus reproduction cycle. They 
prevent HIV from being successfully assembled and released from the infected CD4 cell. 
Examples are Saquinavir (SQV), Ritonavir (RTV) and Indinavir (IDV). 
5. Fusion inhibitors (Entry inhibitors), which prevent the HIV particle from infecting the CD4 
cell. An example is Enfuvirtide (T-20). 
6. Integrase inhibitors, which interfere with the ability of the HIV DNA to insert itself into the 
host DNA and thereby copying itself. An example of this class is Raltegravir 
7.  Chemokine receptor antagonist (CCR5 antagonist) which are CCR5 antagonists. These drugs 
bind to the CCR5 receptors thereby blocking its binding to gp120.  An example of this class is 
Maraviroc.  
In order to prevent resistance and increase efficacy, the combination of three or more drugs 
from at least two different classes acting on at least two different points in the viral replication 
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cycle is recommended for therapy. This combination is called highly active antiretroviral 
therapy (HAART). Currently the first line combination in use in the treatment of HIV/AIDS in 
Nigeria comprises of 2NRTI+1NNRTI. A typical combination in use in Nigeria is 
Stavudine+Lamivudine+Nevirapine or Zidovudine+Lamivudine+Nevirapine (FMOH, 2005b; 
Nwauche et al, 2006a). 
 
Zidovudine
Lamivudine
Nevirapine
Chemical structures of ARVs in use in Nigeria
Source: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4463
 
Figure 1.7 Chemical structures of the ARVs in use in Nigeria. 
 
1.9 Malaria/HIV interactions. 
Malaria has been associated with a rise in viral load (Kublin et al, 2005, Hoffmann 1999) and a 
fall in CD4 cell count (Mermin et al, 2006) potentially worsening the clinical course of people 
with HIV infection. An important study from Malawi by Kublin et al, (2005) showed that HIV-1 
plasma viral loads were significantly higher in patients with malaria infection than in those 
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without and these levels remained higher for up to 10 weeks after treatment. The increases in 
viral load were greatest in those with clinical malaria and high levels of parasitaemia. This is 
supported by another Malawian study which revealed that HIV-1 viral burden is higher in 
patients with Plasmodium falciparum than in controls and thus viral burden can in some 
patients be partly reduced with antimalarial therapy (Hoffman et al., 1999). 
1.9.1 The Nigerian situation 
Eni et al, (2005) in a study in Ahmadu Bello University Teaching Hospital, Kaduna, Nigeria                 
observed that 70% of HIV-1 patients have concurrent malaria parasitaemia compared to HIV-
negative adults and children which are 22.5% and 57.5% respectively.  
In another study of Seroprevalence of malaria infection among human immunodeficiency virus 
patients in Ondo state, Western Nigeria by Onifade and Ogudare (2006), it was observed that 
33.5% of HIV patients examined was positive for malaria and the highest prevalence of malaria 
infection in the patients was 66.7% for age range 0-9 years.  In a study on the prevalence of 
malaria as a co-infection in HIV infected individuals in South Eastern Nigeria, (Onyenekwe et al., 
2007) showed 3X higher prevalence of Plasmodium falciparum malaria in symptomative HIV 
seropositive group compared to seronegative group. Another study in Nnewi a sub-urban town 
in South-Eastern Nigeria reports 46.7% prevalence in asymptomatic-malaria in HIV-positive 
patients compared to 26.9% in HIV-negative group (Ukibe et al, 2010).  A more recent study in 
Jos, North Central Nigeria,  established a 24% prevalence of malaria parasitaemia in HIV-
positive adults compared to 9% in HIV-negative controlled group (Iroezindu et al., 2012). 
HIV infection impairs T-cell immunity, which is of crucial importance for antimalarial responses 
(Graziosi et al., 1998). On the other hand, malaria infection activates T cells, potentially 
promoting HIV replication (Xiao et al., 1998, Froebel et al., 2004).  Since increased HIV RNA 
levels are associated with accelerated disease progression, malaria could potentially facilitate 
faster progression to AIDS and death (Tkachuk et al., 2001). In areas of stable malaria 
transmission, (areas where transmission of malaria is intense and continuous, though seasonal 
variations may occur) malaria infection rates and the  frequency of clinical illnesses (fever and 
other findings) appear to be increased in HIV infected adults particularly those with 
immunosuppression as measured by low CD4 T cell counts. A study involving Ugandan adults, 
observed that  the odds of  parasitemia, and risk of malarial fever increased with decreasing 
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CD4 cell count, such that individuals with CD4 cell counts<200cells/µl were more than twice as 
likely to suffer malarial fever as individuals with >500 cells/µl (Whitworth et al., 2000, French et 
al., 2001). Increased prevalence of severe malaria has also been reported in HIV-infected adults 
in South Africa (Cohen et al, 2005).  
Malaria/HIV interactions have been clearly demonstrated in young children in whom malaria 
induced anaemia leads to blood transfusions which may transmit HIV (Kublin et al., 2005, 
Mermin et al., 2006). In pregnant women also HIV contributes to higher malaria infection rates, 
higher parasite density, more clinical illness, more anaemia and diminished response to 
treatment (ter Kuile et al., 2004). A more recent study on malaria in HIV observed that HIV-1 
infected malaria patients had lower haemoglobin (Hb) compared to HIV-1 uninfected patients 
(Van Geertruyden et al., 2009). It is thought that malaria/HIV interaction is a contributing factor 
to the reversal of the gradual declines in malaria mortality in the 1990s, the period during 
which HIV was at its peak (UNICEF, 2003).  
The control of malaria parasitaemia in untreated individuals is immune mediated, and this 
prevents most malarial infections from becoming clinically apparent in semi-immune adults in 
endemic areas (Whitworth, 2006). This in addition with the reports cited suggests that HIV-
associated immunosuppression interferes with parasite control. The above report also stated 
that HIV infection may reduce the efficacy of immunity which protects persons with 
parasitemia from clinical disease and may reduce the effectiveness of the acquired protective 
immune response that prevents parasitemic persons from developing clinical illness (Hewitt et 
al, 2006).  
With the above reports and records it can be predicted that the efficacy of antimalarial therapy 
will be lower in immunosuppressed individuals co-infected with HIV and malaria living in 
regions of stable transmission. Increasing parasite burdens and reduced host immunity, both of 
which occur with HIV infection, are associated with increased treatment failure rates (WHO, 
2006a). A Ugandan study (Kamya et al., 2006) observed that HIV-1 infection was associated 
with a >3-fold hazard ratio [HR] increased risk of clinical treatment failure of adults treated with 
three different antimalarial regimen including an ACT. In a study of delayed clearance of 
Plasmodium falciparum in patients with human immunodeficiency virus co-infection, Birku et 
al, (2002) demonstrated a prolongation in fever and parasite clearance time in adults following 
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Artemisinin treatment for uncomplicated malaria. Further study (Kamya et al., 2001) 
established clinical failure to chloroquine therapy in HIV-positive children in comparison with 
HIV- negative children. This decrease in response to antimalarial therapy in immunosuppressed 
individuals could be attributed to the fact that HIV infection impairs T- cell immunity, which is 
of crucial importance for antimalarial responses (Graziosi et al., 1998). It could also be because 
of increased susceptibility to malaria re-infection or because of recrudescence of infection 
since antimalarial therapy is most effective in individuals who already have some acquired 
immunity (Hewitt et al., 2006, Diallo et al., 2007).  
1.9.2 Influence of HIV on the emergence of antimalarial drug resistance. 
An important factor that influences drug resistance is host immunity and in HIV-infected people 
there is reduced immunity. Other factors contributory to drug resistance are frequency at 
which resistance mutation occurs in a population and the number of parasites exposed to 
drugs. In HIV-positive individuals, there is increased probability of malaria infection progressing 
to symptomatic illness and to higher parasite densities, thereby increasing the probabilities of 
treatment being required and thus of contact between parasites and the drug (Whitworth et 
al., 2000, French et al., 2001, Patnaik et al., 2005). The resulting effect is increased drug 
exposure and thus selective drug pressure. Prolongation in fever and parasite clearance time as 
established by (Birku et al., 2002), higher risk of treatment failure (Kamya et al., 2001) and 
higher rates of recrudescence (Van Geertruyden et al., 2006, Shah et al., 2006) accelerate the 
spread of resistant parasite biomass in both symptomatic patients and asymptomatic HIV-
infected people. 
The WHO Technical consultation Geneva, Switzerland advocates that research be carried out to 
investigate the treatment of malaria among people living with HIV to determine whether a 
reduced response to antimalarial treatment among HIV-infected people increases malaria case 
fatality rate. (WHO, 2004a).  
Management of co-infection with malaria and HIV is a major challenge to public health yet 
potential drug-drug interactions between antimalarial and antiviral regimen have not been 
adequately investigated in people with both infections. Djimde and Lefevre (2009) in their 
study on the pharmacokinetics of artemether-lumefantrine (Coartem) stressed the need for 
additional data on the pharmacokinetics of artemether-lumefantrine in patients undergoing 
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HIV/AIDS chemotherapy. The mortality and morbidity of the two diseases is already high, and if 
the interaction of the treatment undermines the efficacy of the antimalarial drug, it will 
increase the outcome risks and may require the need to modify and optimize therapy and may 
even worsen the problem of drug resistance, or could result in the elevation of the 
concentration of the antimalarial leading to a possible increased toxicity. On the other hand, 
the elevation may be an advantage in enhancing the antimalarial effect especially with 
antiretrovirals that possess antimalarial activity (Parikh et al., 2005, Soyinka et al., 2010, 
Nsanzabana and Rosenthal, 2011). The choice of antimalarial drug for the treatment of HIV-
positive patients therefore is of utmost importance considering the dangers of co-morbidity 
but sufficient pharmacokinetic and parasitological evidence to make this choice is currently 
lacking.  Dosages of ACTs currently used for the treatment of malaria are based on trials among 
HIV- negative people.  
As well as drug-drug interaction between antimalarials and antiretroviral drugs, there is no 
clear understanding of the importance of resistance to antimalarials in HIV-infected individuals. 
The influence of host factor on resistance particularly immune status cannot be over-
emphasised. (Diallo et al., 2007, Travassos and Laufer, 2009). Since studies have shown that 
drug resistance is usually genetically related because of polymorphic changes, and is influenced 
by host immune status, therefore there is need to design studies to address relationship 
between immune status and drug resistance.  
The pfmdr1 allele NFD at codons 86, 184 and 1246 which has been linked to AL selection, 
tolerance and treatment failure in several studies even in Nigeria (Humphreys et al, 2007; 
Happi et al, 2009) was found in about 20% of the few Nigerian samples obtained from the 
Malaria reference laboratory. There is little or no information of the mdr86N selection and the 
prevalence of the NFD haplotype in the Niger Delta particularly among HIV-positive people. A 
study on Nigerian children by (Happi et al., 2009) established the selection of Plasmodium 
falciparum multidrug resistance gene 1 allelles in asexual stages and gametocytes by 
artemether-lumefantrine. None of these studies involved HIV-positive individuals.  
Also widespread use of trimethoprim-sulphadoxine (TS) as prophylaxis among  HIV-positive 
patients may  be placing sulfonamide selective pressure for alleles at the dhps locus that are 
not directly related to antimalarial use (Sutherland et al., 2009).  Any impact of dhps mutations 
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on AL treatment outcome is expected to be indirect only since AL action is independent of the 
folate pathway in the parasite. Sutherland et al, (2009) identified a novel haplotype dhps I431V 
found only in Nigerian isolates. This study will involve further investigation of this haplotype to 
establish its presence and evaluate the prevalence in Nigerian subjects in the Niger Delta 
region. 
Results of the studies above were obtained from HIV-negative individuals. As earlier stated, 
host factors especially immunity play a major role in the influence of drug resistance (Diallo et 
al., 2007, Travassos and Laufer, 2009). There is therefore need for such studies to be carried 
out in HIV-positive individuals because of their immunosuppression. The paucity of data 
regarding the use of this drug combination in HIV-positive subjects calls for investigation which 
this research is designed to address.  
1.10 Justification. 
Given the high prevalence of these two diseases in Nigeria and in consideration of the reducing 
effects of this interaction on the response to therapy, it is imperative to design studies that will 
investigate and analyse the cohorts of HIV/malaria infected patients and their treatment. There 
seems to be a paucity of data on the use of antimalarial drugs on HIV-positive patients on 
antiretroviral therapy particularly with the regards to drug-drug interactions between ARVs and 
antimalarial drugs in addition to the influence of the HIV status on the drug response with 
reference to resistant markers. The study (Brentlinger et al., 2007) on the challenges in the 
prevention, diagnosis and treatment of malaria in HIV-infected adults in sub-Saharan Africa 
advocated for a study on description of longitudinal response of CD4 cell count and HIV viral 
load to malaria in persons taking highly active antiretroviral therapy. Therefore there is need to 
assess the effect of different CD4 cell count levels on the efficacy of the drug in HIV-infected 
individuals in order to establish the success of therapy to the level of infection. Our study 
involved the evaluation of CD4 cell count levels of the HIV subjects before and after treatment 
of the asymptomatic-malaria with AL. 
1.11 Rationale for study: 
Earlier studies on AL use have not focused on its use in HIV subjects and there is an urgent need 
for this study in HIV-positive patients with malaria. Recent studies (Kredo et al., 2011, Byakika-
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Kibwika et al., 2012, Huang et al., 2012) on HIV-positive volunteers who were not infected with 
malaria support the view that drug-drug interactions are important in the management of 
patients with co-infection. This study therefore is being carried to analyse/evaluate the 
antimalarial effect of artemether-lumefantrine in HIV-positive and HIV-negative adult patients 
in this region.  
Since the deployment of AL as first-line in 2005, studies have established its high cure rates in 
the treatment of uncomplicated malaria in Nigeria (Meremikwu et al., 2006, Sowunmi et al., 
2007). Resistance studies (Falade et al., 2005, Falade et al., 2008, Happi et al., 2009) have 
established an association of either treatment failure or slow clearance with polymorphisms in 
the pfmdr1 gene.  As at date and time of our study, none of these studies involved the inclusion 
of HIV-subjects.  There is paucity of data on AL malaria treatment of HIV-positive patients in 
Nigeria especially in Rivers state, Niger Delta where there is a high prevalence (6.0%) of HIV 
compared to the national prevalence of 4.1% (FRN, 2012). The study was designed to address 
this paucity and establish a current status of markers to resistance of AL in this very important 
region of the country. Therefore monitoring of the resistance markers related to the drugs is of 
vital importance in order to sustain their use in Nigeria.  
Summarily, information is lacking in the areas of in vivo drug-drug interactions between 
antimalarials and ARVs, the impact of ARVs on malaria parasites, interaction between resistant 
parasites and HIV and the impact of asymptomatic-malaria on HIV infection as well as its 
significance to the spread and transmission of resistant parasites. The study is therefore 
designed to address some of these gaps and possibly generate more questions for further 
studies. 
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1.12 Research Questions 
 Are there any associations at enrolment between drug resistant P. falciparum and the 
use of medication for either HIV treatment or prevention of opportunistic infections 
with particular reference to the use of TS prophylaxis? 
 Are there any drug-drug interactions between the ARVs and the antimalarials and if 
there is, does it have any impact on parasitaemia? 
 Are there any differences between the HIV-positive and HIV-negative people in the 
selection pattern of mutations on the mdr1 and crt genes? 
 Is there any evidence of persistent parasitaemia being higher in HIV-positive individuals 
than in the control group at day 3 or day 28? 
 Does AL treatment of asymptomatic malaria infected adults with HIV provide any 
benefit on the immunity of the HIV-positive people in terms of CD4 count? 
 
1.13 Objectives 
 To measure and compare the prevalence of different dhps haplotypes in association 
with 431V in the two different groups and test for possible associations with recent use 
of TS. 
 To compare the pharmacokinetics of AL based on the day 7 blood concentrations and 
bioavailablity of lumefantrine in HIV-positive and HIV-negative adults. Studies have 
shown that the D7 plasma level concentration is an important predictor of the efficacy 
or treatment failure of AL (Ezzet at al, 2000).  
 To investigate the prevalence in both HIV-positive and HIV-negative adults of parasites 
carrying molecular markers of resistance known to be selected by AL treatment.   
 To evaluate CD4 cell counts as an indicator of impact of AL on HIV chemotherapy.  
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2.1. Study design 
A 28-day study was designed to assess the use of artemether-lumefantrine in the treatment of 
asymptomatic malaria infection in HIV-positive and HIV-negative adult Nigerians residing in Port 
Harcourt, Niger Delta Region. The study was patterned after the classic WHO, 2003 however 
treatment outcome was based only on parasitologic and not therapeutic outcome definitions 
since the participants are asymptomatic (Kublin et al., 2003). 
2.1.1. Nigeria Geography 
Nigeria consists of a Federal Capital Territory and 36 states which are further divided into 774 
local government areas.  It is divided into six geo-political regions: North Central, North East, 
North-West, South-East, South-South and South. Nigeria is made up of 374 ethnic groups (NPC, 
2012). Nigeria was a federation of three regions (Northern, Western and Eastern) before it 
gained its independence from the Colonial British government in October 1960.  
Nigeria is in the West African sub-region, lying between latitudes 4˚16’ and 13˚53’ north and 
longitudes 2˚40’ and 14˚41’ east. It is bordered in the north by Niger Republic, in the east by the 
Republic of Chad and Cameroun, in the west by the Republic of Benin and in the south by the 
Atlantic Ocean. It has a total surface area of approximately 923,768 square kilometers and 
800km of coast line. Nigeria has two main seasons, the dry seasons which occur from October to 
March and the wet or rainy season occurring from April to September with peak of the rains 
between May and July when malaria transmission is very intense. Transmission is throughout 
the country and 97% of the population is at risk. The main vector for transmission is Anopheles 
gambiae and A. funestus, A. arabiens are also commonly encountered predominantly in the 
north while A. melas is found in the mangrove coastal zone (PMI, 2011).  
2.1.2. Study Area 
The study was carried out in two sites; the University of Port Harcourt Teaching Hospital (UPTH) 
and the Braithwaite Memorial Specialist Hospital (BMH) both in Port Harcourt, Nigeria. The 
study was conducted from September 2010 to September 2011. Port Harcourt is the capital of 
Rivers State. It lies along the Bonny River in the Niger Delta 41 miles upstream from the Gulf of 
Guinea, rich in the nation’s oil resources and it is the TREASURE BASE of the nation. The region 
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is dotted with oil and gas activities which attract many foreigners and migrant workers and 
commercial sex workers follow the camp (Nwauche and Akani, 2006). These socio-economic 
conditions contribute to a high seroprevalence of HIV infection (6.0%) which is higher than the 
national prevalence (FRN, 2012).  
Port Harcourt exhibits lengthy and heavy rain seasons and very short dry seasons with average 
temperatures between 25˚C-28˚C. Due to this vulnerability, there is an increased interaction 
with malaria which is already endemic in Nigeria especially in the Niger Delta as a result of its 
mangrove swamp forest vegetation where transmission is year round (PMI, 2011). Annual 
rainfall in this area averages more than 3,550 millimeters in the Niger Delta. The epidemiology 
of malaria/ HIV co-infection and interaction has not been studied in this area.  
University of Port Harcourt Teaching Hospital shares a wall with the University Park of the 
University of Port Harcourt; it is sandwiched between the Port Harcourt International Airport, 
the New Calabar River and the East- West Express Road. The hospital has 30 departments and 
has a bed compliment of about 800, the largest referral hospital in Niger Delta. The hospital 
runs HIV adult clinic on two days of the week (Wednesdays and Thursdays). The Braithwaite 
Memorial Hospital is the state specialist hospital right in the city metropolis and has a 350 bed 
compliment. Its HIV clinic days are Tuesdays and Thursdays. 
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 Figure 2.1 Geographic location of study 
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2.1.3. Recruitment of Participants and sample collection 
A temporary clinic was established in an office in the hospital to allow some privacy for the 
study. Patients who visited both hospitals came from all over the Niger Delta region since both 
are the two largest hospitals in the state. Information sheet about the study was given to the 
participants and the purpose of the study was thoroughly explained to them. Self-administered 
questionnaires were given to obtain family and social history or any clinical history of the 
participants that may be of importance to the study (Annexe 6 & 7) 
2.1.4. Inclusion criteria 
Participants were recruited if they met the following eligibility criteria:  
 Aged between 16-65 years, 
 Willingness to have HIV status confirmed from clinical records or by a point-of-care test. 
 Positive for P. falciparum by microscopic examination of a blood film  
 Provision of a signed informed consent form.  
2.1.5. Exclusion criteria 
Excluded from the study were  
 People aged 15 years and below 
 People with complicated malaria that is evidenced by cerebral involvement like 
convulsions, vomitting etc,  
 Pregnancy and severe underlying disease requiring specific therapeutic intervention. 
The cohort of our study participants were asymptomatic malaria parasite carriers recruited 
from HIV-positive participants and the HIV-negative group.  HIV- positive participants were 
recruited from the HIV adult clinic of both hospitals. HIV-negative participants were recruited 
from the hospital communities including staff and students. HIV-negative participants were 
screened and confirmed virus-negative with the use of the HIV Determine point-of-care test 
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(Alere Medical Co. Ltd Matshuhidai-shi, Chiba, Japan). Each was then screened for malaria by 
standard microscopy. Permission for the study was obtained from the Ethics Committee of the 
University of Port Harcourt Teaching Hospital (UPTH) Port Harcourt, the Braithwaite Memorial 
Specialist Hospital (BMH), Port Harcourt and also the London School of Hygiene and Tropical 
Medicine, London. 
2.1.6. Primary analysis 
The study was designed to look at the association of the polymorphism at the dhps I431V with 
TS use, specifically 
• Associations at enrolment between drug resistant falciparum and the use of medication 
for HIV treatment and prevention of opportunistic infection. 
• Evidence of persistent parasitaemia at day 3 or day 28 being more common in HIV 
participants than in the HIV-negative control group. 
2.1.7. Secondary analysis 
• Any drug-drug interactions between ARVs and AL and if so does it have any impact on 
parasitaemia 
• Any benefit of AL treatment of malaria-infected adults with HIV in terms of improved 
immunity based on CD4 cell count level  
2.1.8. Sample size calculation 
The study was designed based on carriage of parasite genetic markers of antimalarial drug 
resistance of the dhps gene. Sample size was calculated to be 229 of which 143 should be HIV-
negative arm and 86 will be HIV-positive arm respectively. The calculation was based on the 
prevalence of the dhps I431V mutant found from the survey of clinical cases in Lagos, Nigerian 
(Sutherland, unpublished data). Based on the hypothesis that there will probably be an 
increased number of these mutations among HIV-positive people because of the use of TS for 
prophylaxis, and using a power of 80% to extrapolate with a 95% confidence interval, the 
estimated sample size was 86 for the HIV-positive group and 143 for the HIV-negative group. 
Our enrolment figure of 370 based on microscopy was higher than the calculated sample size 
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however the PCR confirmed number fell far below this number. Sample size calculation was not 
possible to calculate for the secondary analysis because there is no idea of parasitological 
impact of the drug in HIV-positive persons (or how effective the parasitological impact is in 
relationship to lumefantrine levels) since the study is exploratory to generate a first estimate of 
sample size which can be used to design other studies. 
2.2.0 Materials for field work 
2.2.1 Sample collection 
• Cotton wool 
• Methylated spirit  
• Syringe and needles 
• Lancet 
• Glass slides 
• EDTA Bottles 
• Hand gloves 
• RDT kit (First Response, PREMIER Medical Corporation Limited, Kachigam, Nani 
Daman (UT) 396 215. India 
• RDT kit (Paracheck, Orchid Biomedical Systems, M46/47, Phase 111 B, Verna 
Industries Estate Verna, Goa 403 722, India 
• Microscope 
• Filter paper for PCR:  Printed filtermat A Glass fibre filter size 102x258mm. 
WALLAC Oy. Turku Finland  
• HIV Determine point-of-care test (Alere Medical Co. Ltd Matshuhidai-shi, Chiba, 
Japan). 
• 10% w/v Giemsa stain prepared in buffered distilled water at pH 7 
• Coartem (Novartis Pharma, Nigeria) 
2.2.2. CD4 tests 
• CD4 mAb PE (monoclonal antibody to human CD4) 
• EDTA bottle 
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• No Iyse buffer 
• Partech Cyflo Counter FCM System (Partech GmbH. Otto-Hahn-StraBe 32. D-
4816 Munster. Germany). 
2.2.3. WBC/PCV analysis 
• Full automatic blood counter ( PCE-201(N)   ERMA INC. Tokyo) 
• Haematology Autoanalyzer Model: MicroS 60 CS/CT 8 (Horiba ABX Diagnostics, 
France).  
2.2.4. Lumefantrine concentration 
• Liquid chromatography mass spectrometry (LCMS) Thermo Finnigan LCQ 
instrument 
• 0.75M Tartaric acid (Fisher Scientific, UK) 
• Filter paper (Glass microfibers paper, Fisherbrand FB59431, Fisher Scientific, 
UK)  
• 20mM MeOH formate buffer, pH 2.7 (85:15 Fisher Scientific, UK) 
• Dionex Acclaim® 120 3μm C18 (4.6 x 150 mm, with 120 Å pore size, fitted with a 
Nitrogen gas 
2.3. Field work methods 
Enrolled patients were treated with AL containing 20mg artemether and 129mg lumefantrine in 
a fixed dose combination (‘Coartem ®’Novartis Pharma, Nigeria) according to manufacturer’s 
dosing regimen of 4 tablets twice daily for 3days for persons with weight>35kg. Patients were 
advised to eat before taking the tablets. Most of the patients took their first dose under 
supervision at the site having been pre-informed to eat before coming. Subsequent doses were 
self-administered by participants with instructions to take the drug with food and also how to 
take the drug, the second dose 8 hours after, and the rest at 12hr interval for the next two days. 
A medication chart (Table 2.2) of how to take the drug was given to each participant on the day 
of enrolment. This was used to check for compliance on the follow up days. Compliance was 
found to be >95% of the participants. Patients were followed up till day 28 and were contacted 
by phone to remind them of coming for the sampling the following day in addition to ensuring 
they have taken their medication. Finger prick blood was collected on days 1,2,3,7 and 28 for 
blood spots on filter paper for PCR (Printed Filtermat Glass fibre filter size 102x258mm. WALLAC 
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Oy. Turku Finland), thick smears on days 1, 2, 3, and 28 and venous blood additionally on day 28 
for CD4.  
Table 2.1 Sampling table for each patient 
 D0 D1 D2 D3 D7 D28 
RDT +      
Thick film + + + + + + 
CD4 +     + 
WBC +   +   
Lume. Conc.     +  
Filter paper + + + + + + 
 
 
 
Fig.2.2. Flow chart of sampling method 
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Table 2.2 Patient’s record of drugs taken 
Days Morning Evening 
D0   
D1   
D2   
 
2.3.1. Diagnosis of malaria (Microscopy) 
The definitive diagnosis of malaria was based on the demonstration of plasmodium parasites in 
the blood. Immediately after collecting finger-prick blood samples, thick blood smears were 
prepared on two glass slides fixed in methanol and stained with 10% w/v Giemsa for 30minutes 
while patients were waiting. Initial microscopy was carried out by microscopists on the thick 
blood smear since low parasitaemia can be more readily identified by thick film. The stained 
slides were washed under slow running water, air dried on a slide rack and examined in oil 
immersion under light microscope at x100 magnification. Asexual parasites were counted 
against 200 white blood cells (WBCs).  Parasite density was calculated as number of parasites 
per microlitre of blood by multiplying the number of parasites with 8000/µl (the assumed 
number of WBCs per microlitre of blood) and then dividing by 200 (Greenwood and Armstrong, 
1991). 
2.3.2. Diagnosis of malaria (RDT) 
About 5µl of whole blood was added into the well of the RDT kit and two drops of the assay 
buffer was added into the well. Result was interpreted within 20 minutes based on the 
indication of the bands presented.  
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2.3.3. Determination of CD4 levels 
CD4 cell count tests were carried out in Port Harcourt on venous blood collected from HIV-
positive patients using the Partech Cyflo Counter FCM System (Partech GmbH. Otto-Hahn-
StraBe 32. D-4816 Munster. Germany). Using a dry sterile syringe, 5mls of venous blood was 
collected from participants into EDTA (coagulant) bottles and mixed. Briefly, 20µl of whole 
blood were collected from the EDTA bottle and mixed with 20µl of CD4 mAb PE (Monoclonal 
antibody to human CD4) in a Partec test tube and mixed gently, then incubated at room 
temperature in the dark for 15 minutes. 800µl of no Iyse CD4 buffer was added and shaken 
gently. Blood sample was analysed using a Partec cyflow counter. 
2.3.4. Evaluation of WBCs and PCV 
The WBC count and PCV of the blood samples in the EDTA bottles were analysed in Port 
Harcourt using Haematology Autoanalyzer Model: MicroS 60 CS/CT 8 (Horiba ABX Diagnostics, 
France). Briefly, 10µl of blood was aspirated and delivered into the WBC chamber for first 
dilution. 28.3µl of diluted blood was delivered into the RBC chamber for the RBC/PLT 
measurement.  
2.3.5. Evaluation of lumefantrine levels using Liquid chromatography mass spectrometry 
(LCMS) 
Capillary blood samples were taken on day 7 from finger prick of participants. 100μl of blood 
were measured using a pipette and dropped on a filter paper (Glass microfibers paper, 
Fisherbrand FB59431) pre-treated with 0.75M tartaric acid (Fisher Scientific). The papers were 
allowed to air-dry and then stored in individual pouches with a silica desiccant to absorb 
moisture. The preserved papers were transferred to the London School of Hygiene and Tropical 
Medicine. 
Filter paper adsorbed blood samples were analysed for lumefantrine using liquid 
chromatography mass spectrometry (LCMS; Thermo Finnigan LCQ instrument) following a 
modified protocol based on previously published methods (Blessborn et al., 2007). Briefly 
bloodspots were extracted in methanol / water (4:1; 350 μl), and the extracts were filtered 
through a cotton wool plug. Each sample (20μl) was separated on a Dionex Acclaim® 120 3μm 
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C18 (4.6 x 150 mm, with 120 Å pore size, fitted with a guard column) and eluted with 
ammonium formate (20mM, pH 2.7 and methanol (v/v; 85:15) isocratically at a flow rate of 
500μl/min. The column temperature was maintained at 35°C. The electron spray ionisation (ESI) 
source was operated in positive mode with the capillary temperature set to 350°C and sheath 
and auxiliary gas (nitrogen) flow rates of 60 and 20 arbitrary units respectively. Peak identity 
was confirmed by using blood spiked with lumefantrine standards (0-30 μg/ml), adsorbed onto 
filter paper and extracted in the same manner as the patient samples. Quantitation was 
performed using selective ion monitoring for the transitions m/z 530 to 512. Lower limit of 
detection (LLOD) was determined to be 0.1μg/ml, lower limit of quantification (LLOQ) 1.0 μg/ml 
and upper limit of quantification (ULOQ) 20.0 μg/ml (Blessborn et al, 2007). 
2.3.6 Assaying of Trimethoprim-Sulphamethoxazole (TS) using High Performance Liquid 
Chromatography (HPLC) 
Filter paper adsorbed blood samples were analysed for trimethoprim and sulphamethoxazole 
using high performance liquid chromatography (HPLC) with photodiode array (PDA) detection. 
Separation and quantification of components of the formulations was achieved using a Dionex 
UltiMate 3000 HPLC system (Thermofisher, UK) with its built in software, Hertfordshire, UK. 
Separations were carried out utilising a GENESIS AQ 4 µm column (150 x 4.6 mm, Grace 
Materials Technologies, Cranforth, UK) eluting with ammonium formate (10 mM, pH 2.7) and 
acetonitrile (v/v; 17:83 to 25:75 down to 17:83 over 6.0 mins) at a flow rate of 1.5 ml/min, 
passing through the UV-photo-diode array detector (UV-PDA; DAD 3000) set at 275 nm. 
Peak identity was confirmed by measuring the retention time, spiking the sample with 
commercially available standards and determination of absorbance spectra using the photo 
diode array detector (PDA). Chromatographic data was generated by Chromeleon (Dionex 
software) and typical chromatograms generated for the commercially available standards in 
blood adsorbed onto tartaric acid treated filter papers.  Trimethoprim elutes at 4.11 min and 
sulphamethoxazole at 6.06 min.  
2.4. Materials for molecular Biology Techniques 
2.4.1. DNA extraction 
• Nuclease –free molecular grade water (Sigma, Aldrich, UK) 
• Phosphate Buffered Saline (1% PBS tablet) each tablet dissolved in 200mls 
distilled water 
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• 0.5%  saponin ( Sigma, Aldrich, UK  0.5g of saponin dissolved  in 100mls water) 
• 6% Chelex-100 (50% Glycine, N-(carboxymethyl), reaction products with 
chloromethylated divinylbenzene-styrene polymer+35-50% of water) (Sigma, 
Aldrich, UK).  6g chelex dissolved in 100ml water) 
2.4.2. PCR 
• Nuclease-free molecular grade water (Sigma, Aldrich, UK) 
• 10x  NH4 Buffer (Bioline, UK): 160mM NH4)2SO4, 670mM Tris-HCI (pH8.8 at 25°C) and 
stabilizers 
• 500mM KCl Buffer (Bioline, UK): 50 mM KCl, 100 mM Tris-Cl (pH 8.8 at 25°C), 15 mM 
MgCl2 and stabilisers. 
• 50mM MgCl2 (Bioline, UK): 160mM NH4)2SO4, 670mM Tris-HCI (pH8.8 at 25°C), 15 mM 
MgCl2 and stabilizers 
• 10µM of each primer (Eurofin, MWG Operon Germany): 10µl of stock primer (100pM) 
+90 µl water 
•  5 µM of each probe (Eurofin, MWG Operon Germany): 5 µl stock probe (100pM) +95 µl 
water 
•  10µM of each dNTP (Bioline, UK): 10µl of stock primer (100pM) +90 µl water 
• 1 Unit Biotaq DNA polymerase (Bioline, UK) 
• 10µM of each probe (Eurofin, MWG Operon Germany): 10 µl stock probe (100pM) +90 
µl water 
2.4.3. Detection of amplified DNA  
• 1.2%, 1.5% and 2% agarose gel (Sigma, Aldrich, UK): agarous in 100ml 5xTBE 
• 5xTBE (Tris-Borate–EDTA Sigma,Aldrich, UK): Tris 
(hydroxymethyl)naminomethane + Boric acid 
2.4. 4. Purification and sequencing of amplified DNA products 
• 10x FastAP Buffer (Fermentas, USA): 100mM Tris-HCl (pH 8.0 at 37°C), 50mM 
MgCl2, 1 M KCl, 0.2% Triton X-100 and 1mg/ml BSA 
• FastAP (Fermentas, USA): Thermosensitive alkaline phosphatase, supplied in 
20mM Hepes-NaOH (ph 7.4), 1mM MgCl2, 0.1 mM ZnCl2 , 0.1% Triton X-100 and 
50% (v/v) glycerol 
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• Exo-1 (Fermentas, USA): Exonuclease-1 supplied in 20mM Tris-HCl (pH 7.5), 
0.1Mm EDTA,  1Mm DTT and 50% (v/v) glycerol 
• BigDye Terminator v3.1 (Applied Biosystems, UK) 
• 5x BigDye Sequencing Buffer (Applied Biosystems, UK) 
• 3M NaOAc (Sodium acetate Sigma Aldrich) 
• Absolute Ethanol (Analytical grade, Fisher Chemicals, UK) 
• 70% Ethanol (70ml absolute  Ethanol Analytical grade, Fisher Chemicals, UK  + 
30ml water) 
• Hi-Di  formamide (Applied Biosystems, UK) 
• 1.5ml sterilised microcentrifuge tubes. 
2.4. 5.  Reference samples used 
Plasmodium falciparum samples used as positive controls were obtained from the Malaria 
reference Lab (MRL). 
• 3D7, 
• 7G8  
• International standard (IS)  
• Nuclease –free  molecular grade water was used as negative control 
 
2.5. Molecular analysis using polymerase chain reaction (PCR) 
2.5.1. DNA extraction using Chelex method 
DNA was extracted from filter papers (Glass fibre Printed filtermat filter size 102x258mm. 
WALLAC Oy. Turku Finland) containing patients’ blood using the Chelex extraction method. 
Approximately 7mm disc of blood spots were cut from the filter papers using a Harris Uni-Core 
hole punch into 96-deep well plates. Aseptic technique was observed by flaming in between 
punching of each sample to avoid contamination. 1ml of 0.5% Saponin freshly prepared by 
dissolving Saponin in  1x Phosphate Buffer Saline (PBS) was used to soak the filter paper spots in 
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the deep well plates, covered with aluminium seal and incubated overnight at 37 oC to release 
haemoglobin into the PBS while parasite DNA  remained on the filter paper. Plate was 
centrifuged at 4000 rpm for 2minutes. Saponin and debris were removed and 1ml of freshly 
prepared 1x PBS was added to each well. This was centrifuged again and then washed with 
1xPBS until the filter paper was cleared of haem. 150µl of 6% Chelex 100 was added to each 
well and heat sealed with a foil then incubated in water bath for 30 minutes. Plate was 
centrifuged at 4000rpm for 2minutes to spin down the Chelex and the remaining filter paper. 
Approximately 120µl of DNA supernatant was removed into sterile pre-labelled plates and 
stored in-20oC freezer.   
2.5.2. DNA extraction using QIAamp DNA Mini kit) 
In the bid to extract more and cleaner DNA, the QIAamp mini kit was used to extract DNA from 
some filter paper samples. Using a single-hole paper punch, 6mm circle was punched out from a 
dried blood spot into a 1.5ml microcentrifuge tube containing 180 µl of Buffer ATL and 
incubated at 85 oC for 10mins.  This was centrifuged briefly to remove drops from inside the lid. 
20 µl of proteinase kinase K stock solution, vortexed and incubated at 56 oC for 1 hour and 
centrifuged again to remove drops from inside the lid. 200 µl of buffer AL was added to the 
sample, vortexed to mix thoroughly and incubated at 70 oC for 10 minutes, then centrifuged. 
200 µl of absolute ethanol was added to the sample, mixed thoroughly by vortexing and 
centrifuged to remove drops from inside the lid. The mixture was carefully applied to the 
QIAamp Mini spin column (in a 2ml collection tube) without wetting the rim. The cap was closed 
and centrifuged at 600x g (8000rpm) for 1 minute. Mini spin column was placed in a clean 2ml 
collection tube while the tube containing the filtrate was discarded. QIAamp Mini spin column 
was carefully opened and 500 µl Buffer AW1 added without wetting the rim. Cap was closed 
and centrifuged at 600 x g (8000rpm) for 1 minute. The QIAamp Mini spin column was placed in 
a clean 2ml collection tube and the collection tube containing the filtrate discarded. QIAamp 
Mini spin column was carefully opened and 500 µl Buffer AW2 added without wetting the rim. 
Cap was closed and centrifuged at full speed (20,000 x g; 14,000 rpm) for 3 minutes. Column 
was placed in a new 2ml collection tube discarding the old collection tube containing the 
filtrate. This was centrifuged at full speed for 1 minute. QIAamp Mini spin column was placed in 
a clean 1.5ml Buffer AE or distilled water and incubated at room temperature for 1 minute, 
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then centrifuged at 6000 x g (8000rpm) for 1 minute.  The eluate containing the extracted DNA 
was stored in -20oC freezer.     
2.5.3. Designing of primers 
New Primers were designed for some samples where amplification was not possible with the 
regular primers using PCR Primer Design tool, (Eurofin, MWG Operon Germany). Primers 
flanking codon 1246 of the pfmdr gene and codons 431 and 540 of the pfdhps gene were 
designed. Gradient PCR was performed using standard P. falciparum controls 3D7 in order to 
ascertain the best conditions for the PCR. Primers were run at different annealing temperatures 
and PCR conditions. The primer that gave the best and clearer band on the UV agarose gel was 
chosen with the conditions used and was then adapted as the choice primer for the PCR. Primer 
sequences are listed in Table 2.1 below. 
2.5.4. Amplification of DNA products using primers and Nested PCR 
PCR amplifications were carried out to investigate the prevalence of parasites carrying 
molecular markers of resistance and/or tolerance before and following AL treatment in both 
the HIV-positive and the HIV-negative cohort. The various genes were analysed in the samples 
using nested PCR since nested PCR is much more sensitive for confirmation of Plasmodium 
falciparum parasitaemia infection (Snounou et al., 1993b). Different primers were employed for 
these reactions for both the nested, heminested and the unnested PCR reactions and purchased 
from Eurofins MWG, Operon Germany.  
2.5.5. PCR protocol for small subunit ribosomal RNA (SSU rRNA) gene amplification 
Amplification of the SSU rRNA gene of the Plasmodium falciparum was carried out on extracted 
DNA to assess the positivity of P. falciparum (Snounou et al., 1993a).  Briefly described, 0.5 µl 
each of primers rplu5new and rplu6 (Eurofins, MWG Operon, Germany), consisting of primer 
mix that could be used to detect any of the 5 Plasmodium species were added into a 20 µl 
reaction mixture consisting of Nuclease-free water, 10.5 µl, 2.0µl 10x NH4 Reaction Buffer 
(Bioline, UK), 0.8 µl 50 mM MgCl2, 0.5 µl 10mM dNTPs (Bioline, UK), 0.20µl BioTaq DNA 
Polymerase (Bioline, UK). 5 µl of DNA was added to each reaction mixture. PCR reactions was 
carried out under conditions and primers listed in Table 2.1 below. The amplified product was 
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nested using primers rfal1 and rfal2 in order to identify the Plasmodium falciparum species. The 
nested reaction consists of 14.5µl of water, 2.0µl 10x NH4 Reaction Buffer (Bioline, UK), 0.8 µl 
50 mM MgCl2, 0.5 µl 10mM dNTPs (Bioline, UK), , 0.5 µl each of primers rplu5new and rplu6 
(Eurofins, MWG Operon, Germany), 0.20µl BioTaq DNA Polymerase (Bioline, UK) and 1 µl of 
nest 1 amplified product. PCR conditions and primer sequences used are listed in Table 2.1 
 2.5.6. PCR protocol for pfmdr1 gene at codons 86, 184, 1034, 1042 and 1246. 
Using nested PCR and employing outward and inward primers, DNA samples extracted on days 
0, 3 and 28 samples that were positive by microscopy were screened for polymorphisms at 
codons 86, 184, 1034 and 1042 of the pfmdr1 gene. The analysis were carried out on both pre 
and post treatment samples. Each unnested reaction mixture consisted of Nuclease-free water, 
14.8 µl, 2.5µl 10x NH4 Reaction Buffer (Bioline, UK), 1.0 µl 50 mM MgCl2, 0.5 µl 10mM dNTPs 
(Bioline, UK), 0.5 µl 10µM Forward Primer (Eurofins, MWG Operon, Germany), 0.5 µl 10µM 
Reverse primer (Eurofins, MWG Operon, Germany), 0.20µl BioTaq DNA Polymerase (Bioline, 
UK). 5 µl of DNA was added to each reaction mixture. However in the nested reaction, 18.8 µl of 
water was used and 1 µl of nest 1 amplified product. PCR conditions and primer sequences are 
listed below.  
The outward primers FN1 and REVC1 and nested primers MDR2/1 and NEWREV1 (Humphreys 
et al., 2007). were used to screen for the polymorphisms at codons 86 and 184 while outer 
primers  MDRF2F1 and MDRF2R1 and nested primers MDRF2F2 and MDRF2R2 (Humphreys et 
al, 2007) were employed for the screening of mutations for the region flanking 1034 and 1042. 
Polymorphisms at codons 1246 were screened using the designed fragment 4 primers (F4N1(F), 
F4N1(R), F4N2(F) F4N2(R) as described above in addition to the primers MDRF4N1 and 
MDRF4R1 and MDRF4N2 (Dlamini et al., 2010). This was necessary because amplification was 
difficult in some samples due to very low parasitaemia since the patients were asymptomatic. 
Primers F4N1 (F) and F4N2(R) were used for the primary reaction while F4N2 (F) and F4N2(R) 
were employed for the nested reaction.  
The primary reaction mixture consisted of 13.8 µl of nuclease-free water, 2.5µl 10x NH4 
Reaction Buffer (Bioline, UK), 1.0 µl 50 mM MgCl2, 0.5 µl 10mM dNTPs (Bioline, UK), 1.0 µl 
10µM Forward Primer (Eurofins, MWG Operon, Germany), 1.0 µl 10µM Reverse primer 
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(Eurofins, MWG Operon, Germany), 0.20µl BioTaq DNA Polymerase (Bioline, UK) and 5 µl of 
DNA was added to each reaction mixture. 5 µl of DNA was added to each reaction mixture. 
However in the nested reaction, 17.8 µl of water was used instead and 1 µl of nest 1 amplified 
product. PCR conditions and primer sequences are listed below. 
2.5.7. PCR protocol for pfdhps gene 
Due to the low parasitaemia among our study participants and poor quality of DNA, various 
protocols were used in order to get a good yield of high quality DNA. DNA extracted from day0 
samples were screened using different protocols and primers for the dhps gene for mutations 
flanking codons 431, 436, 437, 540, 581 and 613.  
2.5.7.1. Protocol 1 
A 25 µl reaction mixture containing, 14.8µl Nuclease-free water, 2.5µl 10x NH4 Reaction Buffer 
(Bioline, UK), 1.0 µl 50 mM MgCl2, 0.5 µl 10mM dNTPs (Bioline, UK), 0.5 µl 10µM Forward 
Primer DHPSN1, 0.5 µl 10µM Reverse primer DHPSN2 (Pearce et al, 2003) 0.20µl BioTaq DNA 
Polymerase (Bioline, UK), and 5 µl of DNA was prepared for the primary PCR. The nested PCR 
mixture consisted of 18.8 µl Nuclease-free water and 1 µl of the nest 1 product with the 
forward primer DHPSR2 and the reverse primer DHPSR/ (Pearce et al, 2003). 
2.5.7.2. Protocol 2  
Primary PCR mixture consisted of 2.5 µl of DNA instead of the regular 5 µl, 15.3 µl  nuclease-free 
water, 2.5 µl 10X KCL, 2.5 µl 2mM dNTPs 1.0 µl 10µM Forward Primer DHPSN1, 1.0 µl 10µM 
Reverse primer DHPSN2 (Pearce et al., 2003), 0.20µl BioTaq DNA Polymerase 5U/ µl (Bioline, 
UK). The nest 2 PCR reaction mixture consists of 16.8 µl water and 1.0 µl nest 1 product, 1.0 µl 
10µM each of primers DHPSR2 and DHPS R/ in addition to the other materials as in nest1. 
Primer sequences and cycling conditions are listed below.  
2.5.7.3. Protocol 3 
The dhps gene was split into two fragments for the samples with very low DNA. Primers were 
designed to capture the polymorphisms at codons 431 and 540 respectively. Primary PCR 
mixture for the amplification for the region flanking codon 431 consisted of 14.8 µl Nuclease-
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free water,   2.5µl 10x NH4 Reaction Buffer (Bioline, UK), 1.0 µl 50 mM MgCl2, 0.5 µl 10mM 
dNTPs (Bioline, UK), 0.5 µl 10µM Forward Primer DHPSV1F, 0.5 µl 10µM Reverse primer 
DHPSV1R, 0.20µl BioTaq DNA Polymerase (Bioline, UK). 5 µl of DNA was added to each reaction 
mixture. However the second reaction was heminested since we used the same reverse primer 
DHPSV1R while the forward primer was DHPSV2F and consists of 18.8 µl of water and 1 µl of 
nest 1 amplified product for the 431 protocol. The 540 protocol reaction mixture for the 
primary reaction consists of 13.8µl Nuclease-free water,  2.5µl 10x NH4 Reaction Buffer (Bioline, 
UK), 1.0 µl 50 mM MgCl2, 0.5 µl 10mM dNTPs (Bioline, UK), 1.0 µl 10µM Forward Primer 
DHPS540F1, 1.0 µl 10µM Reverse primer DHPS540R1, 0.20µl BioTaq DNA Polymerase (Bioline, 
UK) and 5 µl of DNA. The secondary reaction was also heminested consisting of forward primer 
DHPS540F, DHPS540R2 and 1.0 µl nest 1 product in addition to the other components.  The 
primer sequences and cycling conditions are listed below Table 2.2. 
2.5.8. Protocol for the pfdhfr gene 
Primers DHFRM1 and DHFRM7 were employed for the detection of polymorphisms on the dhfr 
gene for the primary reaction, while DHFRM3 and DHFRM9 (Pearce et al., 2003) were used for 
the nested PCR. 25 µl of reaction mixture was prepared for both reactions but primary mixture 
contained 14.8 µl nuclease free water and 5 µl DNA, while the nested contained 17.8 µl and 1 µl 
DNA from nest 1 amplicon. Additionally, both mixtures consisted of 2.5µl 10x NH4 Reaction 
Buffer (Bioline, UK), 1.0 µl 50 mM MgCl2, 0.5 µl 10mM dNTPs (Bioline, UK), 0.5 µl 10µM Forward 
Primer, 0.5 µl 10µM Reverse primer, 0.20µl BioTaq DNA Polymerase (Bioline, UK). Cycling 
conditions and primer sequences are listed in Table 2.2.  
2.5.9. Genotypying of pfcrt 
Due to the low parasitaemia of the samples, the DNA samples were first nested before using a 
multiplex double-labelled probe real time amplification method to analyse the samples. 
Employing forward primer CRTP1 and reverse primer CRTP2, pfcrt gene was amplified at 5’ 
untranslated region (UTR) up to 88 to detect the wild type haplotype CVMNK and the other 
haplotypes CVIET and SVMNT commonly found at codons 72-76 on the pfcrt gene. A 25 µl 
reaction mixture consisting of 12.8 µl Nuclease-free water, 2.5µl 10x NH4 Reaction Buffer 
(Bioline, UK), 1.0 µl 50 mM MgCl2, 2.5 µl 10mM dNTPs (Bioline, UK), 0.5 µl 10µM Forward 
Primer 0.5 µl 10µM Reverse primer, 0.20µl BioTaq DNA Polymerase (Bioline, UK), and 5 µl of 
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DNA was prepared for the primary PCR. Protocol and primer sequences are listed below in 
Table 2.2.  
2.5.9.1. Real time PCR (qPCR) for pfcrt gene 
Polymorphisms at codons 72, 74, 75 and 76 of the pfcrt genes were assessed using real time 
PCR protocol, primers and probes as described by (Gadalla et al., 2010). Briefly, a 25 µl master 
mix of 0.5µl each of probes FAM, JOE and ROX corresponding to haplotypes CVMNK, CVIET and 
SVMNT respectively, 0.375 µl primers CRTD1 and CRTD2, 15.55 µl nuclease-free water, 2.5µl 
10x NH4 Reaction Buffer (Bioline, UK), 2.75 µl 50 mM MgCl2, 0.5 µl 10mM dNTPs (Bioline, UK), 
0.20µl BioTaq DNA Polymerase (Bioline, UK), and 1 µl of the nest 1 product was prepared for 
the qPCR. Three DNA positive samples 3D7, 7G8 and DD2 were used to provide the 
corresponding sequence desired for control. Nuclease-free water was used as negative control. 
0.1ml strips of 4 tubes (Rotorgene) were used for the reaction. Tubes were inserted on a metal 
rack of 72 wells and placed on ice to prevent the fluorescence of the probes. Into each 0.1ml 
tube (Rotorgene) were added 24 µl of reaction mixture and subsequently 1 µl of nest 1 
product. Each sample was duplicated to ensure accurate result. Reaction was carried out on the 
Rotorgene RG 3000 (Corbett Research, Australia).  The cycle threshold (CT) was set above the 
negative control and in the middle of the exponential phase of the positive controls. Then the 
CT was determined for each sample accordingly (Gadalla et al, 2010). The probes and conditions 
used for the reaction are listed in Table 2.4.   
2.6. Gel Electrophoresis of DNA amplification products 
The amplified products were separated and visualized under gel electrophoresis using ethidium 
bromide. Different percentage agarose (Sigma, Aldrich, UK) gels depending on the size of the 
product being expected were prepared in Tris-Borate (TBE) and EDTA solution. This was stained 
with ethidium bromide (Sigma, Aldrich, UK) in order to identify the amplified bands of the DNA 
and poured into a gel tank. 5µl of each sample of DNA was mixed with 5µl of 5X loading buffer 
and loaded into the wells and ran along with hyperladder IV (Bioline, UK) to estimate the band 
size. After migration, the DNA was visualised by placing the gel under ultraviolet (UV) 
illuminator and the images were captured and recorded.   
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2.7. Purification of PCR products 
Using EXOFAP (Fermentas, UK) protocol, products from the nested PCR were cleaned to remove 
the impurities and products like excess primers, dNTPs that could interfere with the sequence 
product. A 5µl mixture containing FasTAP buffer, FasTAP and Exo-1 nuclease prepared in 
proportions as specified in the protocol, was added to 5µl of nest 2 product in a PCR plate, 
vortexed briefly and reaction was carried out in the thermocycler at 37°C for I hour and 72°C  
for 15minutes.  
2.8. Sequencing of PCR products 
Amplified PCR products were sequenced using the BIG DYE sequencer protocol ABI PRISM 
Applied Biosystems as described below. Briefly, cleaned PCR products were directly sequenced 
in a bar-coded plate with 5x BigDye sequencing buffer and Big DyeTM Terminator v3.1 in a 
mixture that includes double distilled water, either forward or backward primers with the 
BigDye and 5x BigDye sequencing buffer, (two reactions were prepared for each sample). The 
samples were run in a thermocycler machine using the BigDye protocol under the following 
conditions: 26 cycles 95°C for 0.30min, ramp 1 °C per second to 50.0°C, 55°C for 0.15min, ramp1 
°C per second to 60.0°C, 60 °C for 4.0 min and , ramp1 °C per second to 96.0°C.           
Following the BigDye reaction, a post-sequencing clean-up was carried out by preparing a 
mixture of double distilled water (24.5μl), absolute ethanol (62.5μl) and 3M sodium acetate 
(3.0μl). 90μl of this mixture was added to each 10μl reaction mixture in the 96-well plate, 
vortexed briefly and left in the fridge for 20 minutes to allow the extension products to 
precipitate. This was centrifuged at 4000rpm for 30 minutes at 4°C. The plate was inverted onto 
a blue paper roll after removing seal and then drained quickly in the centrifuge at 50rpm for 
1minute. 150 μl of ice cold 70% ethanol was added and plate was covered with PCR seal and 
inverted five times then centrifuged again at 3000rpm for 10minutes at 4°C. Further draining of 
plate was done again inverted on a blue paper roll and centrifuged at 50rpm for 1 minute. Plate 
was removed and allowed to dry on the table. 10 μl of HiDi formamide (Applied Biosystems, UK) 
was added to each well. Plate was sealed and stored at -20°C and submitted for sequencing 
with ABI PRISM 3730 Automated Sequencer. Sequences were examined using CHROMAS 
software version 1.6.1 (Technelysium, Australia). Both forward and reverse sequences were 
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viewed and aligned using ClustalW software and the corresponding 3D7 gene from 
PlasmoDB.org as a standard reference clone to detect any mutation in the gene.  
2.9. Parasite clearance time (PCT) 
Using real time quantitative method, parasite clearance time was measured for some samples. 
Briefly described, a 20 µl master mix consisting of 0.2µM each of the probes (MWG-Biotech), 
0.3 µM forward and reverse primers (Beshir et al., 2010b), 5.5mM MgCl2 buffer (Bioline), 0.3 
µM dNTPs (Bioline), 10x NH4 buffer (Bioline), 1 unit of Biotaq DNA polymerase (Bioline), 
nuclease-free water (Sigma-Aldrich) and 5 µl DNA was added into tubes inserted on a metal 
rack of 72 wells and placed on ice to prevent the fluorescence of the probes. Parasite negative 
blood and nuclease-free water were used as negative control while the positive control was INT 
parasite DNA. The reactions were run in triplicates on a Rotorgene RG 3000 (Corbett, Australia) 
under the following conditions 95°C for 6minutes, 40 cycles of 95°C for 15secs and 60°C for 1 
min. The probes are listed in Table 2.4. 
2.10 Statistical Analysis 
All data collected were entered into spread sheets and analysed in STATA version 11 (Stata 
Corp., Madison WI). Continuous variables that were normally distributed were analysed using 
student t-test while those that were not normally distributed and continuous data were 
analysed using Wilcoxon’s rank sum test. Also categorical comparisons in 2-by-2 format were 
performed using the χ2 distribution and Fischer’s exact test where any value was less than 5. 
Mutations on the different genes were analysed to evaluate the associations on the alleles and 
the haplotypes using 95% CI around the odd ratios (OR). P-values below 0.05 were considered 
significant.   
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Table 2.3 PCR primer sequences and reaction conditions for the nested amplification of 
pfdhps, pfdhfr, pfcrt and pfmdr1 genes. 
Gene Primers Sequence PCR product size PCR conditions 
 
pfcrt 
72-76 
Forward 
CRTP1 
 
5’-CCGTTAATAATAAATACACGCAG--3' 
 
 
546 
 
 
94°C for 3mins / 
(94°C for 30s, 
56°C for 30s, 
62°C for 60s) 
x35cycles/ 
62°C/5mins 
 
Reverse 
CRTP2 
 
5'- CGGATGTTACAAAACTATAGTTACC-3'   
 
 
pfcrt 
72-76 
Forward 
CRTD1 
 
5'-AGGTTCTTGTCTTGGTAAATTTGC-3' 
 
 
164 
 
 
 
95°C for 6min / 
(95°C for 15s – 
55°C for 60s ) 
x40cycles 
 
Reverse 
CRTD2 
 
5'-CAAAACTATAGTTACCAATTTTG-3'   
 
pfmdr1 
fragment1 
86 and 184 
 
Outer 
forward   
FN1/1 
5'-ACA AAA AGA GTA CCG CTG AAT-3' 
 
 
 
 
578 
 
94°C for 3min / 
[94°C for 30s – 
55°C for 30s – 
65°C for 1 min] 
x30cycles / 
65°C for 
5min/15°C for 
5min 
 
Outer 
reverse   
REV/C1 
5'-AAA CGC AAG TAA TAC ATA AAG TC-3'   
 
Nested Frag 1 
MDR2/1 
 
5'-ACA AAA AGA GTA CCG CTG AAT-3' 
 
 
534 
 
94°C for 3min / 
[94°C for 30s – 
55°C for 30s – 
65°C for 1 min] 
x30cycles / 
65°C for 
5min/15°C for 
5min 
 NEWREV1 5'-AAA CGC AAG TAA TAC ATA AAG TC-3'   
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Gene Primers Sequence PCR product size PCR conditions 
 
primary 
Frag 3 
1034, 1042 
 
 
 
MDRF3N1 
 
 
 
 
5’-GCA TTT TAT AAT ATG CAT ACT G-3’ 
 
 
 
 
94oC for 
3min/[94oC for 
30s-56oC for 
60s-65oC for 
50s]x30cycles/6
5oC for 
5min/15oC for 
5min 
 MDRF3R1 5’-GGA TTT CAT AAA GTC ATC AAC-3’   
 
 
Nested Frag  
3 
MDRF3N2 
 
5’-GGT TTA GAA GAT TAT TTC TGT A-3’ 
 
 
 
 
Same as 
primary 
 MDRF3R1 5’-GCA TTT TAT AAT ATG CAT ACT G-3’   
 
Primary Frag 
4 
1246 
MDRF4N1 
 
5’-CAA ACC AAT CTG GAT CTG CAG-3’ 
 
 
94oC for 
3min/[94oC for 
30s-53oC for 
60s-65oC for 
40s]x30cycles/6
5oC for 
5min/15oC for 
5min 
 
 
 MDRF4R1 5’-CAA TGT TGC ATC TTC TCT TCC-3’   
 
Nested Frag 4 
1246 
MDRF4N2 
 
5’-GAT CTG CAG AAG ATT ATA CTG-3’ 
 
194 
94oC for 
3min/[94oC for 
30s-55oC for 
60s-65oC for 
40s]x30cycles/6
5oC for 
5min/15oC for 
5min 
 
 
 MDRF4R1 5’-CAA TGT TGC ATC TTC TCT TCC-3’   
Primary Frag 
4 
1246 
F4N1(F) 5’- CAG CAA TCG TTG GAG AAA CAG 
 
397 
 
94oC for 
3min/[94oC for 
30s-55oC for 
60s-65oC for 
40s]x30cycles/6
5oC for 
5min/15oC for 
5min 
 
 
 F4N1(R) 5’ GCA GCA AAC TTA CTA ACA CG   
Nested Frag 4 
1246 F4N2(F) 5’ CAAACCAATCTGGATCTGCAGAAG  
Same as 
primary 
 F4N2(R) 5’-CAA TGT TGC ATC TTC TCT TCC-3’   
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Gene Primers Sequence PCR product size PCR conditions 
 
pfdhps 
 
 
DHPSN1 5'- GATTCTTTTTCAGATGGAGG-3' 
 
 
770 
93°C for 
5min/[93°C for 
20s – 55°C for 
30s–68°C for 
75s] x40cycles / 
65°C for 5min 
431,436,437, 
540, 613 DHPSN2 5'- TTCCTCATGTAATTCATCTGA-3'   
 DHPS-R1 5'-AACCTAAACGTGCTGTTCAA-3' 711 
93°C for 
5min/[93°C for 
30s – 56°C for 
30s–68°C for 
75s] x 30cycles 
/ 72°C for 5min 
Nested DHPS-R/ 5'-AATTGTGTGATTTGTCCACAA-3'   
 DHPSV1F 5'-GCTTAAATGATATGATACCCG-3' 369 
950C for 
3min/[95oC for 
30s-50oC for 
30s-650C for 
60s]x 39 
cycles/65oC for 
1min 
 
431, 436, 437 DHPSV1R 5'- CAGGTACTACTAAATCTCTTT-3' 
 
135  
 DHPSV2F 5'-AACCTAAACGTGCTGTTCAA-3'  Same as primary 
 
DHPS 
540F1 5'- GAG GAA ATC CAC ATA CAA TG-3'  
950C for 
3min/[95oC for 
30s-48oC for 
45s-720C for 
60s]x 39 
cycles/72oC for 
1min 
 
DHPS 
540R1 5'- CGT CAT GAA CTC TTA TTA GA-3' 474  
540, 580, 613 DHPS540R2 5'-TCC TCA TGT AAT TCA TCT G-3' 
 
372 
950C for 
3min/[95oC for 
30s-48oC for 
45s-720C for 
60s]x 29 
cycles/72oC for 
1min 
 
DHPS 
540F1 5'- GAG GAA ATC CAC ATA CAA TG-3'   
 DHFR_M1 5'-TTTATGATGGAACAAGTCTGC-3'  650 
 
93°C for 5min / 
(94°C for 30s – 
54°C for 60s – 
65°C for 60s] 
x41cycles/ 65°C 
for 5min/15°C 
for 5min 
 DHFR_M7 5'-CTAGTATATACATCGCTAACA-3'   
pfdhfr 
50,51,59,108,
164 
DHFR_M9 5’-CTGGAAAAAATACATCACATTCATATG-3’  594 
950C for 
5min/[93oC for 
30s-56oC for 30s-
680C for 75s]x 30 
cycles/75oC for 
5min 
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Gene Primers Sequence PCR product size PCR conditions 
 DHFR_M3 5’- TGATGGAACAAGTCTGCGACGTT-3’   
 rPLU5new 5’- CYTGTTGTTGCCTTAAACTTC-3’  
950C for 
5min/[58oC for 
2min-72oC for  
2min-940C for 
1min]x25 
cycles/58oC for 
2min-72oC 
for5min 
 rPLU6 5’- TTAAAATTGTTGCAGTTAAAACG-3’   
Snounou 
 
rFAL1 
5’-TTAAACTGGTTTGGGAAAACCAAATATATT-
3’ 
 
1200 
950C for 
5min/[58oC for 
1min-72oC for  
1min-940C for 
1min]x30 
cycles/58oC for 
1min-72oC 
for5min 
 rFAL2 5’- ACACAATAGACTCAATCATGACTACCCGTC-3’ 205  
 
Table 2.4 Probes used to amplify pfcrt haplotypes CVMNK, CVIET and SVMNT 
Primer/Probe 5’ Fluorophore Sequence 3’ Quencher 
crtCVMNK FAM TGT GTA ATG AAT AAA ATT TTT GCT AA BHQ2 
crtCVIET JOE TGT GTA ATT GAA ACA ATT TTT GCT AA BHQ2 
crtSVMNT ROX AGT GTA ATG AAT ACA ATT TTT GCT AA BHQ2 
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Table 2.5 Primers and probes of gene fragments of HummTuBB used for the PCT 
 
Primer/Probe 
 
Sequence 
 
Strand 
 
Length 
 
Primer Tm 
 
Modification 
HumTUUB_F1 TACATACCTTGAGGCGAGCA forward 20 59.44  
HumTUUB _R1 GATCTGGTTGCCACATTGAC reverse 20 58.94  
HumTUUB _P1 TGGATGTGCACGATTTCCCTCA reverse 22 68.04 
5'Fam - 
3'Tamra 
HumTUUB _F2 AAGGAGGTCGATGAGCAGAT forward 20 58.85  
HumTUUB _R2 GCTGTCTTGACATTGTTGGG reverse 20 59.14  
HumTUUB _P2 TTAACGTGCAGAACAAGAACAGCAGCT forward 27 68.08 5'Joe -  3'Tamra
HumTUUB _F3 CACTTTCAAGGGAGGTGTCA forward 20 58.69  
HumTUUB _R3 CAGATGGGACAGATCCTCCAG reverse 20 59.05  
HumTUUB _P3 TCCATTTCAATCTCCCTCCAAGCTCT forward 26 68.14 
5'Rox - 
3'Tamra 
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Chapter Three 
----------------------------------------------------------------- 
Treatment of asymptomatic malaria-infection 
inHIV-positive and HIV-negative adults in Port 
Harcourt, Nigeria 
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3.1 Rationale 
Artemether-lumefantrine (AL), the currently recommended therapy for malaria treatment, was 
introduced in Nigeria in 2005 as the first line regimen for uncomplicated malaria. Its use in 
Nigeria goes beyond prescription by physicians since the drug is easily obtained without 
prescription over the counter from pharmacies and medicine stores. Various studies (Falade et 
al., 2005, Falade et al., 2008, Happi et al., 2009) on the use of artemether-lumefantrine (AL) in 
the treatment of uncomplicated malaria in Nigeria have been reported all of which have 
established an association of either treatment failure or slow clearance of parasitaemia.  As at 
date and time of our study, none of these studies involved the inclusion of HIV-subjects who 
are known to harbor more resistant parasites due to the increased drug pressure (Whitworth 
et al., 2000, French et al., 2001).  
The overlap of malaria and HIV in sub-Saharan Africa is a major public health challenge and 
management of the co-infection may be compounded by potential drug-drug interactions that 
could result in the co-administration of antimalarials and antiretrovirals. Kredo et al, (2011) 
established an elevated lumefantrine level in HIV-infected adult volunteers receiving nevirapine 
who were not infected with malaria parasite but were treated with AL indicating an interaction 
between nevirapine (NVP) and AL. This report though very interesting has not been confirmed 
in malaria infected patients. There is paucity of data on AL malaria treatment of HIV-positive 
patients and this is particularly of importance in Nigeria especially in Rivers state, Niger Delta 
where there is a high prevalence (6.0%) of HIV seropositivity compared to the national 
prevalence of 4.1%. The study was designed to address this paucity and establish a current 
status of markers to resistance of AL among this vulnerable group of people in this very 
important region of the country.  
Asymptomatic-malaria infection is very common in adults in endemic regions due to acquired 
immunity as a result of continued exposure to malaria infection. These asymptomatic P. 
falciparum carriers do not seek medical treatment and as such act as fundamental reservoirs of 
parasites thereby contributing to the persistent transmission of malaria (Zoghi et al., 2012). 
They remain infective longer than the treated symptomatic patients and the infections are 4-5  
times more prevalent (Alves et al., 2005). Asymptomatic-malaria parasitaemia carriage is 
prevalent in sub-Saharan Africa (Bottius et al., 1996, Smith et al., 1994) and persons with long 
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term carriage are found in the population even during periods of low level transmission (Roper 
et al., 1996, Zwetyenga et al., 1999).   
Diagnosis of asymptomatic-malaria is not standardised therefore the most widely used method 
is the identification of parasite in peripheral thick blood smears and the absence of clinical 
symptoms (Leoratti et al., 2008).  
In clinical practice especially in sub-Saharan Africa, testing, treating and tracking of malaria is 
limited to symptomatic cases which are the clinical disease states hence majority of the 
antimalarial drugs used are targeted at the erythrocytic stage of the parasite. However some of 
these drugs have gametocytocidal properties. Therefore adequate action against the 
persistence of malaria in endemic regions should include the administration of gametocytocidal 
drugs as well as the incorporation of the LLINs, IRS and ITNs (Laishram et al., 2012). There is 
need to identify, treat and control asymptomatic-malaria which may trigger clinical disease and 
reduce immunity of the HIV patients thereby making them more susceptible to infections. 
It has been suggested that community screening and treatment of asymptomatic-malaria 
with AL may reduce malaria transmission significantly (Kern et al., 2011) and treatment of 
the infective parasite reservoir of asymptomatic individuals may be an important 
intervention strategy (Laishram et al., 2012) and could also be a means of reducing malaria-
associated morbidity (O'Meara et al., 2006). Though the immediate benefit of treating 
asymptomatic-malaria parasite carriers with AL is reduction of transmission, an additional 
benefit is that there may be fewer cases of clinical malaria in children below five years of 
age  (Ogutu et al., 2010).      
3.2 Asymptomatic-malaria infection in Nigeria 
There are few studies on asymptomatic-malaria infection in Nigeria, and many of the studies 
are mostly in children and pregnant women. An earlier study in south-Western Nigeria reports, 
26.5% prevalence (Salako et al, 1990), while a 22.5% prevalence was reported among school 
children in Kaduna, Northern Nigeria (Orogade et al, 2002) closely related to the 27.5% among 
school children in Port Harcourt (Jeremiah et al, 2007). However a study (Eke et al, 2006) 
reported a prevalence of 33.1% among adults in Aba, a town about 69 kilometres north of Port 
Harcourt. A more recent study (Otajevwo, 2013) among University students in mid-Western 
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Nigeria reports a very high prevalence of 76.8% and it is closely related to the 83.3% result 
obtained also among undergraduates in a Lagos university (Okwa and Ibidapo, 2010), and 
80.4% in Abia state (Kalu et al, 2012). These later reports are quite alarming however the 
diagnosis was based on microscopy, which could have resulted in many false positives. This 
underlines the importance and relevance of the study of asymptomatic-malaria and its 
contribution to the spread of malaria in Nigeria, thereby necessitating the need for the 
treatment of asymptomatic-malaria infection. 
 The control of malaria in any endemic area would entail not only scaling up interventions in 
the areas of vector control but there is also need to prevent selective transmission of parasite 
resistant strains through the administration of drugs that can minimise gametocyte emergence 
(Sutherland et al., 2005). AL is a drug with known gametocytocidal properties and it is the first-
line drug for the treatment of uncomplicated malaria in Nigeria hence the choice of its use in 
the study. This is an unmatched case-control study comparing HIV-positive adults attending 
ARV treatment clinic to HIV-negative healthy volunteers drawn from the hospital and 
University community comprising both staff and students but not hospital patients who were 
confirmed negative by HIV rapid serological test. Volunteers from both groups who were 
positive for P. falciparum by microscopy were treated with AL. The purpose of the study was to 
evaluate the antimalarial effect of AL treatment on asymptomatic P. falciparum infection in 
both groups of people in addition to the assessment of the molecular markers associated with 
AL. In this chapter, the parasitological study groups are described and compared and 
parasitological outcomes on day 3 and day 28 are presented.  The results of the study will 
provide preliminary data that could form a basis for the assessment of drug resistance and 
treatment failure and could be contributory to the malarial control measures in Port Harcourt 
Nigeria.  
3.3 Results  
Patients who visited both hospitals came from all over the Niger Delta region since both are the 
two largest hospitals in the state. Finger prick blood samples were used for RDT and also to 
prepare thick film on Giemsa stained glass slide. Parasite count was made by counting the 
number of asexual forms of the parasites relative to number of WBCs assuming total WBCs of 
8000/µl based on parasites counted over 100 high power visual fields. The results of the RDT 
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showed only 10% (46/459) positive. Using microscopy as the standard procedure for diagnosis, 
a total of 459 participants were screened for the study. Out of this number, 314 HIV-negative 
people were screened and 242 of these met the inclusion criteria and were found positive for 
P.falciparum and therefore recruited into the study.  
In the HIV-positive arm of the study, 145 people with previously confirmed HIV infection 
attending either the UPTH or the BMH HIV adult clinics were screened for malaria by 
microscopy and 128 of these were found positive for P. falciparum and were recruited having 
met the inclusion criteria. The total number of people enrolled in the study from both hospitals 
based on positive microscopy was 370/459 (81%). A total of 459 people were screened on both 
arms. 238 people completed the study up to the 28 day follow-up as shown in the flow chart 
(Fig. 3.1). The baseline characteristics of study population are summarised in Table 3.1.  
 
 
Figure 3.1 Flow chart of the study  
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Table 3.1 Baseline characteristics of study population 
 HIV-positive HIV-negative Total 
No. screened 145 314 459  
MP positive 128  242  370  
Mean PCV (%) 34.44 (16-50, SD:6.13) 37.09 (23-50, SD:5.32) 36 (16-50, SD:5.8) 
Mean WBC  
(x 10
9
/l) 
4.74 (1.4-16.8, SD:1.9) 4.62 (1.3-10.9, SD:1.29 4.66(1.3-16.8, SD: 1.54) 
Mean age (yrs) 37 (22-66) n=119 37 (17-65) n=225 35 (n=344) 
Mean CD4 d0 
(Cells/mm
3
) 
413 (32-1593, SD:253) N=96   
Mean Wt  
(Kg) 
66.3 (40.92) SD:1.3, 
n=77 
67.5 (25-100) SD:12.8 
n=146 
67 (25-100, SD:12.2) 
n=224 
Mean parasite 
density 
(parasites/µl) 
2530  
(SD: 640.7, n=128) 
1229  
(SD: 180.1, n=242). 
 
 
3.3.1 Demographic and questionnaire data 
Our cohorts of patients were from the two largest hospitals in Rivers State. Family and social 
history of the participants were obtained from the self-administered questionnaires given. The 
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results of the various pieces of information obtained were analysed using Excel and STATA and 
are presented below with the use of histograms.  
3.3.1.1. HIV and Sex distribution 
Analysis of the questionnaire data, our observation is that a higher proportion of our study 
subjects were female from the demography of the study as shown in Fig. 3.2 below. 
 
Figure 3.2 HIV status and Sex distribution 
3.3.1.2. HIV and age distribution 
The information obtained from the questionnaire data showed that the age range for the 
entire participants (n=343) was 16-67 with the mean age of 35. In the HIV group, the mean age 
was 37 in the range of 22-67. The highest prevalence of HIV was found among the age group 
30-39, the lowest was among participants >60.  There was no record of HIV positivity in the 
subjects below 20.  
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Figure 3.3 HIV status and age distribution 
3.3.1.3. HIV and Education level 
Analysis of our questionnaire data shows that the level of education in the two groups is 
different. There were more people with tertiary education in the HIV-negative group than the 
HIV-positive group probably because most of our HIV-negative recruits were from the 
University community of students and staff. Even though the HIV-positive clinic from where the 
HIV-people were recruited serves every class of persons, the results of the analysis of the HIV-
positive group, using the chi square test, show that the level of education has a strong 
relationship to HIV status. (P=0.000). The highest percentage in the education level amongst 
the participants was found in those with secondary education (35.38 %). 
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Figure 3.4 Level of education attained in the two groups 
3.3.1.4. HIV and Occupation 
Our study participants were recruited from various works of life including civil servants, traders, 
business men and women, teachers, oil workers and students. Considering the fact that the 
study venue was a University/ teaching hospital environment, many of our participants were 
students and these were mostly among the HIV-negative group. The survey of the occupation 
of our HIV participants revealed that the highest prevalence of HIV was found in traders 
(25.44%) followed by business men/women (21.05%), least in housewives (1.75%).  
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Figure 3.5 Distribution of Occupation among the study participants in the two groups. 
3.3.1.5. HIV and Marital status 
Our study participants were single or married; amongst who were those who were either 
divorced or widowed people. Results analysis showed that HIV positivity was more prevalent 
among married people.  
 
Figure 3.6 Relationship of HIV and marital status 
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3.3.1.6. Duration of HIV disease and duration of taking the ARV 
Out of 103 people that responded to the question, 77.7% of the HIV subjects had been positive 
for greater than one year. Observation also showed that 56.7% of the HIV participants had 
been on ARVs for greater than 2 years duration.       
 
Figure 3.7 Number of HIV persons and their duration of the illness *N=103 
 
 
Figure 3.8 Number of HIV persons and their duration of taking ARV drugs *N=104 
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3.3.1.7. Insecticide treated net (ITN) and TS use   
Result shows that ITN use is not common among our study participants, being that only 18.5% 
(58/313) out of the total number that responded to the question use ITN regularly. A higher 
percentage was found in the HIV group where it was almost double (14.1% vs 27.1%). Our 
observation on the basis of questionnaire responses is that only 27.2% of the HIV-positive 
people use TS regularly. 
 
 
Figure 3.9 Use of Insecticide treated nets among study participants *N=313 
3.3.1.8. Use of antimalarial drugs among study subjects 
Self-medication is very common in Nigeria and this is seen from the table below. Out of 459 
people screened for the study, 133 had taken antimalarial drug, while 44 had not taken.  282 
did not indicate therefore there is no data on their previous usage of antimalarial drug. The 
percentages of people that had taken antimalarial drug within the last three months prior to 
the study were similar in both the HIV-positive and the HIV-negative control groups. Out of the 
108 HIV-negative group that responded, 76.7% (83/108) had taken antimalarial drug while in 
the HIV-positive group, the percentage that had taken antimalarial was 72.5% (50/59). The 
results also indicates that 64% (85/133) of the persons that had taken antimalarial drug were P. 
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falciparum negative on day 0 and the remaining 36% (48/133) were positive despite the prior 
intake of antimalarial drug. Observation from the table below shows that the most commonly 
used medication was SP followed by AS and AL.  
Table 3.2 Antimalarial drugs taken by subjects within the previous three months of the study 
Antimalarial Drugs taken in the last 3 months HIV-positive HIV-negative Total 
None 19 25 44 
AL 8 20 28 
AQ 3 0 3 
AQ+AL 1 0 1 
AQ+AS 1 2 3 
AQ+AS+AL 0 2 1 
AS 10 19 29 
AS+AL 1 0 1 
CQ 2 1 3 
CQ+SP+AL 1 0 1 
PD 2 0 2 
TS 2 0 2 
SP 13 28 41 
SP+AL 2 5 7 
SP+AS 3 7 10 
SP+AS+AL 1 0 1 
Total 69 108 177 
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3.4 CD4 cell count Results 
CD4 cell count results were obtained from 93 HIV-positive participants with a mean average 
413 (SD 257; 11-1593). Paired peripheral blood CD4+ T-cell counts at both day 0 and day 28 
were available for the 56 of these volunteers. Over 28 days following, we observed a mean 
increase of 107.3 cells per µl (95% CI 53.8 – 160.8; P = 0.0002) in 68% (38/56) of the people. 
This was observed in patients PCR-positive for P. falciparum (N = 14) and those PCR negative 
(N=24). However, in 32% (18/56) of these volunteers, there was a reduction in the CD4 cell 
count results.  
Table 3.3 CD4 range and PCR positivity for P. falciparum 
CD4 cell count Range Frequency  Number P. falciparum 
PCR positive 
<200 16 6 
200-349 21 8 
350-500 32 15 
>500 24 14 
Total 93 43 
 
The overall mean Cd4 cell count obtained among our subjects was 413cells/µl. The women had 
a higher mean of 432 (32-1593, sd 283) compared to 369 (82-623, sd 163) for the men. 
3.5. WBC/PCV Results 
The WBC  for the HIV-positive  group was found to be 4.74 x 109/1 (range 1.4-16.8 ) SD 1.90 
consistent with the result 4.51±  1.82 x 109/1 (range 0.9-8.2 x 109/1) previously obtained by  
Erhabor et al, (2004) among HIV patients in Port Harcourt. The study reports mean 
haemoglobin (Hb) of 10.25 ±1.97g/dl (range 6.31-14.2 g/dl) for HIV-positive patients and this 
approximates to about 30.75 PCV but there was no report of Hb values in the HIV-negative 
people. In the present study, PCV was measured to establish the Hb levels. Since malaria is a 
major cause of anaemia in endemic areas (Lee et al., 2008) the measure of Hb is very important 
because it provides information on the clinical state or severity of the infection.  
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Table 3.4 Mean PCV results for both groups 
Mean PCV D0 D28 
HIV-negative  36.8 (25-50, sd=4.5): n=134 39 (30-47, sd=7.0): n=5 
HIV-positive 34.8 (16-50, sd=5.7): n=107 33 (28-38, sd=7.1): n=2 
 
3.6. PCR diagnosis result    
Using the PCR as a more reliable test for parasite presence, we observed that a high proportion 
of enrolees (61.1%) were actually aparasitaemic. Using Fischer’s exact test, there was evidence 
to show that HIV-positive people were more likely to be parasitaemic at day 0 (P = 0.006). This 
reflects the higher parasite densities and the likelihood of parasites being correctly identified 
by the screening microscopists. Follow up results up to days 3 and 28 days after treatment 
revealed that the HIV-positive group were also more parasitaemic. This was more evident on 
day 28 (OR=2.6; P=0.007). 
We analysed the first 180 samples using small subunit ribosomal RNA (SSU rRNA) gene 
amplification nested PCR protocol (Snounou et al., 1993a) to assess the sensitivity compared to 
pfmdr1. Our results (Table 3.6) show that nested PCR amplifying fragment 1 pfmdr1 showed 
more positive results than the 18S ribosomal subunit and it is well validated in our laboratory 
for sequencing, so we chose to use it to identify positives. The higher Pfmdr1 positivity was not 
due to contamination since all the negative controls in the PCR were negative. Comparing this 
with the pfdhps gene, we found that 89.5% of pfmdr1 negatives were negative as well by 
pfdhps, while 62.5% of pfmdr1 positives were also positive by pfdhps (Table 3.7). RDT results 
were very poor and unreliable, only 8% (12/150) of the first 150 samples were positive using 
the First Response kit. 
 
105 
 
Table 3.5 PCR Results for days 0, 3 and 28 
 Microscopy PCR +ve (D0) PCR +ve (D3) PCR +ve (D28) 
HIV+ve 128   62/128 (48.4%) 
 
16/62 (25.8%) 23/62 (37.0%) 
HIV-ve 242 82/242 (33.9%) 
 
8/82 (9.8%) 14/82 (18.3%) 
Total 370 144/370 (38.9%) 
 
24 37  
 
 
 
Table 3.6 Small subunit ribosomal RNA (SSU rRNA) gene amplification of DNA from pre-
treatment (day 0) samples 
Method 
Used 
 SSU rRNA assay  
Total   Positive (n) Negative (n) 
 
Pfmdr1 
assay 
 
Positive (n) 
 
15 
 
   35 
 
50 
Negative (n) 4 126 130 
 
 Total (N) 19 161 180 
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 Table 3.7 Comparison of pfdhps and pfmdr1 assay sensitivity 
  Pfdhps assay 
mdr1 Positive (%) Negative (%) 
Negative 10.5 89.5 
Positive 62.5 37.5 
 
3.6.1. Parasite carriage and HIV status duration 
Analysis of the pre and post-treatment PCR results using mdr1 86 results, shows that HIV-
positive subjects who had indicated having HIV sickness duration for greater than one year 
were found to be more parasitaemic on both day 0 and day 28 as seen in Table 3.8. 
Table 3.8 Duration of HIV status and parasitemia carriage. 
Sickness Duration Mdr 86 (d0) Mdr 86 (d28) 
1. less 3 months 2 0 
2. 3mths -6mths 2 0 
                3. 6mths-1yr 1 1 
 4. greater than 1yr 28 6 
Total 33 7 
This observation was also made among study subjects who had been on ARV drugs for greater 
than 2 years as shown in Table 3.9. 
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Table 3.9 Duration of ARV and parasitaemia carriage   
ARV  Duration Mdr 86 (d0) Mdr 86 (d28) 
1. less than 6 months 3 0 
2. 6mths -1yr 2 2 
3. 1yr-2yrs 7 0 
4. greater than 2yrs 21 5 
Total 33 7 
 
Analysis of the various genes amplification of the samples revealed that the prior use of 
antimalarial drugs by some of the study participants affected the presentation of the 
haplotypes obtained as shown in Table 3.10 
Table 3.10 Antimalarial drugs taken by participants with the presenting haplotypes from 
mdr1, crt, dhps and dhfr genes 
Sample ID HIV status Antimalarial d0_haplotype d3_haplotype d28_haplotype 
4 1 AS NYD+CVIET+IRNI   
7 1 SP VAG+NYD+IRNI   
10 1 PD VAG+NFD   
12 1 SP+AS VAG+NYD+YYD+IRNI NY  
13 1 SP VAG+NYD+NFD+CVIET+IRNI   
14 1 AL NYD+CVIET+IRNI   
22 1 AL NYD   
23 1 AL NYD   
24 1 AS VAG+NYD+IRNI   
26 1 CQ+SP+AL ISG+IRNI   
27 1 AS+AL ISG+NYD+CVIET   
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Sample ID HIV status Antimalarial d0_haplotype d3_haplotype d28_haplotype 
30 1 SP IAG+NYD+IRNI   
34 1 SP+AL+AS IAG+VAG+NYD+NFD+IRNI   
36 1 SP IAG+NYD+IRNI NFD  
37 1 TS CVIET+IRNI   
38 1 SP CVMNK   
42 1 AS ISG+CVIET   
43 1 SP  NYD NYD 
45 1 CQ IRNI   
49 1 CQ   NYD 
50 0 AL ISG+IRNI   
54 1 AL ISG+VSG   
66 0 SP+AS VAG+YFD+IRNI   
76 0 AS IAG+NYY=IRNI   
77 0 AL VAG+NFD+CVIET+IRNI   
84 0 AL NYD   
86 0 AL NYD   
97 0 SP+AL+TS ISG   
99 1 AS ISG+NY+NFD   
108 0 AL CVIET   
127 1 SP ISG+NYD  NYD 
137 0 AS ISG   
147 1 SP+AL+TS NFD NYD  
171 0 AQ NYD+IRNI   
207 0 SP+AL NY+CVIET   
210 1 AQ+AS NFD+CVIET   
253 1 SP ISG+CVIET   
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Sample ID HIV status Antimalarial d0_haplotype d3_haplotype d28_haplotype 
326 0 SP NYD+IAG+CVIET+IRNI   
372 0 SP CVMNK   
374 0 AS CVMNK   
383 0 SP+AS CVMNK   
388 0 SP CVMNK   
413 0 SP CVMNK   
420 0 SP CVMNK   
 
 3.7. Discussion 
In this study, results before and 28 days after treatment revealed that the HIV-positive group 
were more parasitaemic as shown in Table 3.5. This corroborates with studies that HIV-positive 
people harbour more parasitaemia (Withworth et al, 2000; Shah et al, 2006). The 48.4% 
parasitaemia observed in the HIV-positive group on day 0 was very close to the 46.7% reported 
by Ukibe et al, (2010) but was however much higher than that observed (2.11%)  by  (Akinbo 
and Omoregie, 2012) in a study on HIV-positive asymptomatic malaria adults in Benin City, 
Nigeria and equally higher than the 24% prevalence reported by (Iroezindu et al., 2012) among 
HIV adults living in  Jos, North central Nigeria. Parasitaemia prevalence among the HIV-negative 
group in the Jos study was 9% at variance with the 33.9% obtained in our result. Our result was 
not a population-based study and was limited by small sample size. Also we do not know 
whether the Jos result was based on PCR. The slightly lower percentage of parasitemia 
obtained in the Jos study could be due to the fact that this was just detection by microscopy 
knowing that PCR sensitivity is about 100 times higher than microscopy (Snounou et al, 1993a, 
Snounou et al, 1993b).  Additionally the increased rainfall and the mangrove vegetation of the 
Niger Delta (our study area) compared to the Guinea savannah in the Jos area could also be 
confounding factors for the higher prevalence obtained in the study. 
Our HIV participants were predominantly females consistent with demographics of HIV/AIDS 
with many published reports (Anafi et al, 2008; (Ekouevi et al., 2013, Collins et al., 2009, Hwang 
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et al., 2012, Abdool Karim et al., 1992). They were comprised of 69.3% females and 30.7% 
males. This agrees with the report (NARHS, 2007) of higher prevalence among women due to 
higher vulnerability and infections in all age groups. One of the key drivers in HIV distribution is 
the entrenched danger of inequalities and inequities. This is often seen in the areas of 
economic dependency for women, because in most societies men have greater control and 
access to productive resources (FRN, 2012). As a result of this, women do not have right to 
determine sex choice or right over her own body. In sub-Saharan Africa, 61% of the people 
living with HIV/AIDS are women (WHO, 2009b). This is visibly seen as the feminization of AIDS 
where for every HIV-positive young man, there are three HIV-positive young women. Reports 
have shown that a young woman in Africa is up to eight times more likely to acquire HIV than a 
young man (UNAIDS, 2010). In Nigeria the prevalence rate in females is 4.0% compared to 3.2% 
in men (FRN GARPR, 2012). The other aspect of this imbalance is seen in the area of violence 
against women and girls which include forced sex, rape, forced marriages, physical assault and 
humiliation or intimidation (ICA, 2006).   
Demographic data obtained from the present study, revealed highest prevalence of HIV in the 
age range of 30-34 years corresponding to the UNGASS, 2010 report that HIV/AIDS was highest 
in the age range 30-34 years in the urban region. This was also established in the HIV/AIDS 
prevalence disaggregated  age and sex report  with the highest prevalence in the age group 30-
39 in both males and females ( NARHS, 2007), in consonance with the results obtained.  
On the basis of questionnaire responses, our observation is that education has an influence on  
the serostatus of our HIV-positive subjects. The influence of education as seen from the result 
is an important factor that should be addressed with regards to the spread of HIV. The result 
shows that a greater percentage (54%) of our HIV study participants were those with secondary 
education. National results report that highest prevalence of HIV in women is found among 
those with primary and secondary education (FMOH, 2010). This class of people are mainly 
junior workers and they mostly commute between the villages and the city since they may not 
be able to maintain their families in the city. This invariably exposes them to higher sexual risk 
behaviour. The females in this group are not able to determine sex choice because of economic 
dependence on the men and societal pressure. Also they are more likely to be un-informed of 
the health facilities available to them.   
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Migration in addition to some other factors has been reported as one of the key driving factors 
of HIV (Abdool Karim et al, 1992; UNDP, 2010). Traders and business people by the nature of 
their occupation are migrants so they are more exposed to HIV. The report (Husken and Heck, 
2012) of higher vulnerability of female fish traders in Zambia to HIV, due to the fact that they 
regularly travel to remote fishing camps to purchase fish, highlights this issue. In Malawi, AIDS 
is believed to have spread along major trading and transporting centres (Guebbels and Bowie, 
2006).  Another group of people who are migratory are students. The slightly high prevalence 
among the students is indicative of this lifestyle. HIV/AIDS is a disease that is driven by poverty 
and this explains why the unemployment is a major contributing factor to increased HIV 
prevalence. The data shows that the junior civil servants and the unemployed group in this 
study also have relatively high prevalence and this is consistent with the 3.1% prevalence of 
HIV infection among unemployed individuals previously reported in Port Harcourt, Nigeria 
(Ejele et al, 2005d).j 
Significant continued unfaithfulness by both partners in the marriage relationship is a major 
factor that exposes both partners to increased risk of HIV, hence the higher prevalence seen 
among married people. This is inter-related to the economic dependence of women on their 
husbands for sustenance thereby not being able to determine sex choice even where 
unfaithfulness is very evident. The cultural aspect of polygamy in the society places additional 
pressure on the women resulting to ‘inbreeding’ within the family and spread of HIV in the 
society. The relatively high number of widowed people in the group is a further indication of 
the consequences of this lifestyle in the society.  
The result of the study revealed that a greater majority of our HIV subjects (77.7%) have been 
established as being HIV positive for longer than one year and thereby many of them have 
been on long-term ARV therapy, the longest duration of the persons on ARV being greater than 
two years (56.7%). Analysis of results shows that participants who have been established to be 
HIV-positive for greater than one year and who also had been on ARV for a longer duration 
were more parasitaemic before and after treatment as seen in Table 3.7. The most probable 
explanation of this result may be that the longer duration of HIV status has possibly reduced 
the immunity of the participants such that they are more likely to harbour parasites. Despite 
the longer duration of taking ARVs, these patients still harboured more parasites even after 
treatment with AL.  
112 
 
The indiscriminate use of antimalarial drugs ranging from artemisinin monotherapy to the use 
of ACTs and other combination drugs from the study is a major issue in Nigeria. This calls for 
more awareness on the dangers of self-medication with the implicating consequences of 
increased drug resistance. The result shows that this indiscriminate use of antimalarial drug 
affected the percentage of parasitaemia/ the low parasitaemia recorded in many of the 
samples, hence it is not very possible to properly establish the correct percentage of  
Plasmodium falciparum parasitaemia in the study area. Of more serious concern is the 
increased possibility of antimalarial drug resistance as a result of increased drug pressure. This 
was evidenced by the various haplotypes presented from the four different gene sequences 
analysed (Table 3.10). 
The mean CD4 cell count obtained among our subjects was 413cells/µl consistent with earlier 
result 415cells/µl reported by Fehintola et al, (2012).  However it was at variance from an 
earlier value of 314 cells/µl obtained in HIV adults in Port Harcourt (Erhabor et al, 2005). The 
study did not classify the gender of the subjects so we are not able to make adequate 
comparison, however the report stated that healthy women had higher values than the men. In 
our results, the mean CD4 count for women was 432 (sd 283), and 369 (sd 163) for the men. 
This corroborates many reports that have demonstrated that women have higher CD4 values 
than men (Bussmann et al., 2004, Lugada et al., 2004, Maini et al., 1996, Mair et al., 2008). The 
observation of higher prevalence of parasitaemia among patients with CD4 cell count 350-500 
is at variance with other studies that have indicated an inverse relationship between CD4 cell 
count and parasitaemia level. We do not have any explanation to this however we are aware 
that many factors influence CD4 count cells and some of the factors include time of sample 
collection and sex. To the best of our abilities and within the circumstances of our study, we 
took the samples at the times of presentation of the participants but some of the samples were 
not analysed at the right time due to the peculiar challenges we encountered in the course of 
the study. This may have contributed to the disparity in the results. 
 The increased CD4 cell count results 28days after treatment with AL suggests that there was an 
improvement in the immune status of the patients after treatment with AL since an improved 
CD4 result is a good measure of immune status of patients (Kublin et al., 2005, Patnaik et al., 
2005, Mermin et al., 2006, Mair et al., 2008). Use of CD4 cell count level as a measure for 
monitoring of ART has been proved to be a good measure in resource limit areas where viral 
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load measure is not economical due to limited financial empowerment (Jourdain et al., 2013). 
The improved CD4 cell count after AL administration goes to underline the need for the 
treatment of asymptomatic-malaria infection thereby reducing the potential to progress to 
clinical stage of malaria.  
Observation of the PCV levels which were measured to establish the Hb levels, shows that HIV-
negative control group had higher mean PCV level than their HIV-positive counterparts. This 
agrees with the report of an earlier study of haematological parameters in Port Harcourt, 
Nigeria (Erhabor., et al., 2004) 
Despite the higher use of ITN, the HIV-positive subjects were still more parasitaemic than their 
negative counterpart before and after treatment in contrast to studies that have established 
that use of ITN reduced malaria infection in people living with HIV/AIDS (PLWHA) in Nigeria 
(Olowookere, et al, 2013). Our observation on the basis of questionnaire responses is that only 
27.2% of the HIV-positive people use TS regularly.  
3.8 Findings and recommendations 
Treatment of asymptomatic P. falciparum malaria is of primary importance as stated earlier for 
the management and control of malaria in endemic areas especially in HIV- positive patients. In 
sub-Saharan Africa, testing, treating and tracking of malaria is limited to symptomatic cases. 
Studies on AL, the first-line treatment in Nigeria have neither included asymptomatic-P. 
falciparum carriers nor HIV-positive patients. This study was able to show the presence of 
asymptomatic- malaria parasitaemia carriers among the study participants in both HIV-positive 
and HIV-negative people in this area of the country where there has been little or no published 
data. As at the time and date of our study, treatment of asymptomatic-P. falciparum malaria 
infection especially among HIV-positive subjects have not been reported in Nigeria. The results 
of the study contribute to the limited data on the following: AL use, the malaria/HIV interaction 
in addition to the drug–drug interactions between ARVs and antimalarial drugs in Port 
Harcourt, Niger Delta region of Nigeria and will serve as a template for larger studies.  
The use of PCR which is a very powerful tool for detecting asymptomatic-malaria infection is 
not feasible in the field hence we depended absolutely on microscopy for diagnosis. This 
resulted in very poor recruitment because of the several many false positives we recorded. 
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Parasitological data obtained from microscopy has revealed a very great need for well-
established study involving the training of personnel, better diagnostic measures and enabling 
environment to obtain data that will show the true picture of malaria prevalence in the 
environment and could help influence policy towards achieving the goal of the elimination of 
malaria.  
The result of the study was able to show that there is significant presence of asymptomatic-
malaria infection in both HIV-positive and HIV-negative people in the study area and highlights 
the very important need for the study of malaria epidemiology and molecular markers of 
resistance in the Niger Delta area. Due to its peculiar terrain and vegetation being mostly 
surrounded by creeks and rivers there is a great need to invest in studies in this area especially 
with the high number of migrant workers in this region due to the high level of oil and gas 
resources in the area. 
There is need to identify, treat and control asymptomatic-malaria which triggers the clinical 
disease and reduces the immunity of the HIV patients thereby making them more susceptible 
to infections resulting in increased morbidity and mortality in HIV patients and consequently 
increased presence of resistant strain of parasites in the environment. 
Key drivers like education, poverty, marital status, age that play relevant roles in HIV 
prevalence have been highlighted from this study. There is need for more aggressive awareness 
campaigns against the socio-cultural and socio-economic factors that promote HIV spread in 
our environment. 
The indiscriminate use and misuse of antimalarial drugs as seen from the study is a major area 
of concern with regards to the role it plays in the spread of antimalarial drug resistance. 
Enforcement of laws that will discourage these attitudes by stakeholders and governing bodies 
will help to prolong the life of the ACTs so that it does not end up like chloroquine and the 
older antimalarial drugs.  
Even though chemotherapy is one of the major control measures for the treatment of malaria, 
other control measures such as the use of ITNs, IRS, SMC, larvicides and use of window netting 
should be promoted and encouraged in the environment so as to reduce the burden of malaria 
in the country. The study showed that only 18.5% of the study participants use ITN, a very poor 
115 
 
number for an endemic region. The poor use of TS chemoprophylaxis among HIV subjects in 
the study area is a very important issue that needs to be addressed in order to improve 
mortality and reduce co-morbidity of malaria in HIV-positive subjects. National guidelines 
recommend the use of TS for prophylaxis against opportunistic infections both in adults and 
children.  
3.9 Limitations to our study 
Being the first time the study was carried out in our environment, we were faced with 
numerous challenges some of which we were not able to surmount.  There were several factors 
that imposed significant limitations on this study and therefore led to some flaws in our results 
as shown below. 
A major weakness of our study was the poor quality of enrolment microscopic diagnosis, such 
that the majority of participants had infact failed a major inclusion criterion. Although 
microscopy for years has been the gold standard for diagnosis of malaria, but in many 
developing countries, it is not very reliable because the microscopists are not sufficiently 
trained and the reagents may be of poor quality. Although we employed senior microscopists 
who were attached to the hospital, they failed to make appropriate diagnosis as we had many 
false positives.  This proved to be a major flaw in our study, and had two main impacts; first the 
study was greatly underpowered to evaluate any parasitological outcomes as so many 
participants were actually uninfected with P. falciparum. Secondly we were not able to analyse 
parasite densities with any confidence, and thus were left with the binary variable of PCR 
positivity as the remaining reliable measure of malarial infection. 
Further, by this method we cannot rule out the possibility that some of our positive PCR 
reactions on post-treatment blood samples were detecting gametocytes of P. falciparum only. 
These sexual stage parasite forms are infective to Anopheles sp. mosquitoes, but do not 
contribute to clinical malaria symptoms and cannot divide. Gametocytes are well known to 
survive in a minority of AL-treated patients after clearance of the actively dividing asexual 
parasite stages (Bousema et al., 2006, Sutherland et al., 2005). Nevertheless,  a  recently  
described persistence of asexual parasites in asymptomatic Ghanaian school children treated 
with ACT, suggests that sub-clinical parasitaemia may be more difficult to clear than previously 
thought (Dinko et al, 2013).  
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Constraint of funds resulted in our not being able to train microscopists specifically for the 
research and could not employ enough microscopists as well as phlebotomists therefore we 
depended on the hospital staff. 
During the period of sample collection, there were several adverse conditions such as 
kidnapping of doctors which resulted to many industrial actions by the hospital staff thereby 
leading to the disruption of the study severally especially in the area of sample analysis and the 
necessary follow-up for some patients. A major aspect of this was in the analysis of CD4 cell 
count levels where the accuracy of the result is influenced by the time of collection and storage 
of sample as established by the significant decrease in CD4 count from baseline by as much as 
10% at day 4 in a Ugandan study (Kabengera et al., 1994). Due to the industrial actions, many 
of our samples were not analysed on the days of collection but were stored and analysed later. 
This may have resulted in reduced levels as was observed in many of the day 28 CD4 results 
being lower than the day 0 results. On some of these days the hospital was closed down such 
that we could not collect samples on those days and consequently we have a lot of incomplete 
data. 
Another major factor that impeded on sample collection, storage and analysis was that of 
frequent power outages in the hospital. Here, the frequent power outages affected the storage 
of some samples, filter papers and the RDT kits further contributing to the poor yield of results 
obtained. 
The terrain of the city of Port Harcourt especially in and around the Choba area where the 
Teaching Hospital is located is rather bumpy, leading to frequent traffic congestion on the 
roads. This made it very difficult for some of our participants to present themselves on follow-
up days and equally difficult for us to visit their homes to collect the samples ourselves. 
We experienced frequent break down of the machines and equipment that were deployed for 
sample analysis due to the fact that we did not have access to especially dedicated ones for 
research purposes. Since we had to use the same ones that were used for routine hospital 
work, some of the machines were overworked leading to frequent break downs. This ultimately 
resulted in disruption of adequate sample collection and analysis.  
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Part of our limitations was the nature of filter paper used. Our observation was that in the 
course of extraction of DNA using Chelex method, some of the filter papers were degraded and 
therefore we could not adequately extract the DNA. There was a possibility of retained chelex 
in the supernatant of the DNA used for the PCR and this would affect the quality of DNA 
extracted.  
Notwithstanding the limitations, the work has provided a template for larger studies of AL use 
and the malaria/HIV interactions in the environment particularly in the creek regions of the 
area where we did not include in our studies. Moreover, even though the study is  not a 
population survey, information obtained contributes to the demographic data available  in the 
assessment of HIV/AIDS  in the region. 
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  Pharmacokinetics of lumefantrine in HIV-
positive and HIV-negative adults based on day 
7 blood concentrations 
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Part of the work described in this chapter has been published in the Antimicrob.  Agents 
Chemother. September 2013 57:9 4146-4150 
4.1 Rationale 
Malaria /HIV interaction has been ignored as a major public health issue and particularly so in 
areas of endemic malaria where there is also geographic overlap with HIV such as are obtained 
in sub-Saharan Africa. Of particular importance is the potential drug-drug interactions involved 
in the management of the co-infections as a result of co-administration of the drugs for the 
treatment of both infections which have not been adequately investigated. The mortality and 
morbidity of the two diseases is already high, and if the interaction of the treatment 
undermines the efficacy of the antimalarial drug, it will increase the outcome risks and may 
require the need to modify or could result in the elevation of the concentration of the 
antimalarial leading to a possible increased toxicity. On the other hand, the elevation may be an 
advantage in enhancing the antimalarial effect especially with antiretrovirals that possess 
antimalarial activity (Parikh et al., 2005, Nsanzabana and Rosenthal, 2011, Soyinka et al., 2010).  
Increased use of the highly active antiretroviral therapy (HAART) means a higher potential of 
drug-drug interactions and yet not much is known about these interactions because there have 
been very few publications on this very important subject. Classes of antiretroviral drugs 
include the neucloside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTI), protease inhibitors, fusion inhibitors, integrase inhibitors and 
chemokine receptor anatagonists. However the first-line drugs currently in use in Nigeria 
involve the use of 2 neucloside reverse transcriptase inhibitors (NRTIs) and 1 non-nucleoside 
reverse transcriptase inhibitors (NNRTI), the most common being a fixed dose combination of 
lamivudine, zidovudine and nevirapine. In situations of adverse drug reaction to nevirapine the 
patient is given efavirenz which is another NNRTI.  
There are reports of drug-drug interactions between ARVs and the antimalarial quinine in 
Nigeria. Nevirapine was reported to cause a reduced exposure of quinine (Soyinka et al., 2009, 
Uriel and Lewthwaite, 2011) while the administration with ritonavir resulted in its four-fold 
increase (Soyinka et al, 2010). Quinine is used in Nigeria as a second line drug for severe 
malaria. Fehintola et al, (2012) reported an increase in artesunate exposure in asymptomatic-
malaria HIV-infected Nigerian adults on nevirapine who were given artesunate-amodiaquine.  
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The choice of antimalarial drug for the treatment of HIV-positive patients therefore is of utmost 
importance considering the dangers of co-morbidity but sufficient pharmacokinetic and 
parasitological evidence to make this choice is currently lacking. Our study is the first involving 
parasitological implication.  
Table 4.1 Antimalarial and antiretroviral interactions available in literature 
Study  Drugs used Subjects Outcome 
Khaliq et al, 2001 Mefloquine + ritonavir Healthy volunteers Decreased exposure  of ritonavir 
German et al, 2007 Artesunate-amodiaquine 
+ efavirenz 
Healthy volunteers Increased exposure of 
amoadiaquine and decreased 
exposure to DEAQ 
German et al, 2009.  Artemether-
lumefantrine + lopinavir-
ritonavir 
 HIV-un-infected 
healthy volunteers 
2-3 fold increase in lumefantrine 
exposure 
Soyinka et al, 2009 Quinine + nevirapine Healthy volunteers Significant decrease in quinine 
concentration 
Soyinka et al, 2010 Quinine +ritonavir Healthy volunteers 4-fold increase in quinine 
concentration 
Soyinka & Onyeji, 2010 Proguanil + efavirenz Healthy volunteers 
 
Increased exposure of proguanil 
Kredo et al, 2011 Artemether-
lumefantrine + 
nevirapine 
HIV-infected 
patients without 
malaria on 
nevirapine therapy 
Increased day 7 lumefantrine 
concentrations and decreased 
artemether and DHA exposure 
Fehintola et al, 2012 
 
Artesuante- 
amodiaquine + 
nevirapine 
HIV-positive adults 
without malaria 
Increased exposure to DHA and 
artesunate 
Huang et al, 2012 Artemether-
lumefantrine + efavirenz 
Healthy volunteers Reduced exposure of DHA  and 
day 7 lumefantrine level 
Byakika-Kibwika et al, 
2012a 
Aretmether-
lumefantrine+ efavirenz 
or nevirapine 
HIV-infected adults Reduced exposure to DHA, 
artemether, lumefantrine and 
nevirapine 
Byakika-Kibwika et al, 
2012b 
 
Aretmether-
lumefantrine+ lopinavir-
ritonavir 
HIV-infected adults Increased lumefantrine exposure, 
but decreased artemether 
exposure 
Kakuda et al, 2013 
 
Artemether-
lumefantrine + etravirine 
or darunavir/ritonavir 
Healthy volunteers Reduced plasma concentration of 
artemether , lumefantrine and 
DHA 
Chijioke-Nwauche et al, 
2013 
Artemether-
lumefantrine + 
nevirapine 
HIV-positive 
asymptomatic -
malaria positive and 
negative adults 
Elevated day 7 lumefantrine 
concentration  
Tommasi et al, 2011 Atovaquone/proguanil + 
etravirine/saquinavir 
HIV-positive adult in 
malaria prophylaxis 
Marked increase in etravirine and 
saquinavir concentrations 
Scarsi et al, 2014 Artesunate + 
amodiaquine 
HIV-positive adults 
without malaria 
Reduced exposure to 
amodiaquine and desethyl 
amodiaquine (DEAQ) 
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4.2 Pharmacology of lumefantrine and nevirapine  
Lumefantrine is a racemic mixture of a synthetic flourene derivative of the aryl amino-alcohol 
family. Lumefantrine has a similar mechanism of action to halofantrine probably due to 
similarities in structure and pharmacokinetic properties, but unlike halofantrine, lumefantrine 
is very safe as it does not prolong the electrocardiographic QT interval (van Vugt et al., 1999). It 
was first synthesized and registered in China and is now commercially available only in co-
formulated product with artemether as coartemether (Annerberg et al., 2005). Peak plasma 
concentrations are observed 6-8 hours after oral administrations. Lumefantrine is metabolized 
mainly by CYP P450, 3A4 isoform to its active metabolite desbutyl-lumefantrine (Ezzet et al, 
1998) and it is eliminated very slowly with a terminal half-life of 4-6 days in P. falciparum 
malaria and about 2-3 days in healthy individuals (WHO, 2008). Concentration of lumefantrine 
persists in plasma for >20days (Ezzet et al, 1998). 
Nevirapine in a non-nucleoside reverse transcriptase inhibitor and acts by blocking the 
polymerisation of viral RNA to DNA through its binding to the enzyme reverse transcriptase. It 
is well absorbed after oral administration. With a biovailabilty >90%, its maximum 
concentration is reached 4 hours after the oral dose. It is widely distributed in the body, highly 
lipophyllic and about 60% bound to plasma proteins. Metabolism of Nevirapine is primarily 
through the induction of CYP 450 enzyme mainly 3A4 isoform but also 2B6 to its major 
metabolites 2-hydroxynevirapine and 3-hydroxynevirapine and excretion is primarily through 
the kidney. It induces the CYP3A4 and 2B6 by approximately 20-25% which leads to auto-
induction. The auto-induction leads to approximately 1.5 to 2 fold increase in the clearance of 
NVP which continues in longer duration of treatment. In addition to this, there is a decrease in 
the terminal half-life from 45 hours after a single dose to about 25-30 hours following multiple 
dosing and during steady state dosing (Cooper and van Heesjvik, 2009). Even though NVP is 
primarily an inducer of CYP 450, it may also inhibit the system.  
A previous study (German et al., 2009) on drug-drug interactions in ARVs assayed the levels of 
lumefantrine, artemether, dihydroartemisin (DHA) and the protease inhibitors 
lopinavir/ritonavir in the co-administration of the drugs in healthy volunteers. They reported a 
non-significant trend towards the decrease of artemether when co-administered with 
lopinavir/ritonavir and a decrease (P=0.02) in DHA. However there was 2-3 fold increase in the 
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lumefantrine concentration but the concentrations of LPV and RTV were not significantly 
altered. None of the participants were parasitaemia-positive.  
After our study design protocol was approved and recruitment commenced, published reports 
of similar studies became available. The study by, Kredo et al, (2011) examined the impact of 
nevirapine on artemether-lumefantrine pharmacodynamics in 18 HIV-infected adult volunteers 
receiving nevirapine and 18 naive controls who were not infected with malaria parasite. They 
reported evidence of enhanced lumefantrine levels. This interesting result is yet to be 
confirmed in a large study with malaria-infected patients. The result is at variance with the 
more recent study also among HIV-infected adults in Uganda who did not harbour malaria 
parasites (Byakika-Kibwika et al., 2012) which reported a reduced exposure to artemether, 
DHA, lumefantrine and NVP, however there was no difference in day 7 lumefantrine 
concentrations with NVP. A more recent study among healthy volunteers involving AL co-
administration with a single dose of etravirine a similar drug to NVP established a 
reduction in artemether and DHA after 8hours and 13% of lumefantrine after 264 hours 
(Kakuda et al, 2013). 
4.3 Results  
167 study participants (68 HIV-positive and 99 HIV-negative) who were confirmed P. falciparum 
positive had their day 7 samples collected during follow-up. Nested PCR performed to confirm 
microscopy revealed that 78.1% were actually aparasitaemic (Table 4.1). Analysis of the day 7 
lumefantrine concentrations in the study, showed elevated levels of lumefantrine in the HIV-
positive subjects as reported in the paper (Chijioke-Nwauche et al., 2013).  Initial expectation 
was that there would be lower lumefantrine levels in HIV-positive participants since nevirapine 
is an enzyme inducer. However, contrary to the expectation, our results revealed higher levels 
in agreement with Kredo et al, (2011). Despite the higher lumefantrine concentration in the 
HIV-positive participants, there was no advantage in the parasite clearance over the HIV-
negative control group. HIV status was found to have a significant effect on the lumefantrine 
concentration 7 days after treatment (Wilcoxon rank sum test z=2.830, P=0.0046).  
 
123 
 
0
5
10
15
20
Pe
rip
he
ra
l b
lo
od
 
LU
M
 
n
M
HIV negative (N = 99) HIV positive (N = 68)
Day 7 lumefantrine concentration, by HIV status
 
Figure 4.1 Day 7 lumefantrine concentration in AL-treated participants. Mid-line of each box-plot is the 
median, with the edges of the box representing the inter-quartile interval. Whiskers delineate the 5th and 
95th percentile. Lumefantrine was below the normal limits of detection in five individuals, all in the HIV-
negative group. 
*mean day 7 concentration for HIV-negative arm=2.75µM (equivalent to 1454.59ng/mL); HIV-positive 
arm=3.55 µM (equivalent to 1877.74ng/mL) 
Table 4.2 Parasite carriage by microscopy and PCR in 68 HIV-positive and 99 HIV-negative 
individuals   
HIV status  No of individuals PCR positive for 
P.falciparum on day  
 
 
28                  0                 3                    
 
Positive 
(n=68) 
Negative 
(n=99) 
  
20  
 
12 
 
12 
  
17  
 
8 
 
12 
 
*67 of these individuals were receiving daily nevirapine anti-retroviral therapy, and one received 
efavirenz. All HIV-positive patients also received the nucleoside reverse transcriptase inhibitors 
lamivudine and zidovudine. 
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Assessment of day 0 parasitaemia using qPCR for some samples (both HIV-positive and HIV-
negative) did not show any evidence that higher starting parasitaemia increased the likelihood 
of an individual remaining PCR-positive for P. falciparum on day 3. 
Table 4.3 Summary of initial parasitaemia of both HIV-positive and HIV-negative participants. 
Patients 
Parasitemia on D0 
Min Max Mean Median 
d3 -ve (n=10) 0.98 33.22 5.80323 5.50 
d3 +ve (n=7) 1.48 94.61 8.95335 5.29 
 
4.4 Discussion 
The paucity of data in respect of drug-drug interactions between ARVs and antimalarial drugs 
makes it a little difficult to make conclusions however certain patterns are expected a priori. 
The result from the study (German et al., 2009) of 2-3 fold increase in lumefantrine level in co-
administration of AL with lopinavir/ritonavir is expected a priori since ritonavir is a potent 
CYP3A inhibitor.  
The recent study (Huang et al., 2012) indicated a significant reduction in day 7 lumefantrine 
concentration in co-admnistration with efavirenz in malaria un-infected participants similar to 
the findings of Byakika-Kibwika et al, (2012) in Uganda. The difference in result obtained could 
be as a result of the co-infection with malaria in some of our participants in addition to the 
concurrent use of nevirapine by our participants for duration greater than 6 months. Efavirenz 
and nevirapine are known inducers of cytochrome P450 3A4 and both act through the same 
route, however nevirapine additionally has an ability to auto-induce itself. The auto-induction 
leads to approximately 1.5 to 2-fold increase in the rate of clearance of NVP which is 
maintained in longer duration of treatment. In addition to this, there is a decrease in the 
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terminal half-life from 45 hours after a single dose to about 25-30 hours following multiple 
dosing (Cooper and van Heeswijk, 2007). In the HIV patients, this decrease in terminal half-life 
and the 1.5 to 2 fold increase in the clearance of nevirapine could result in a reduced 
concentration of the drug present in the system, thereby making less of the drug available to 
induce the enzyme so that there will be higher concentration of lumefantrine not metabolised 
but rather remain present in the blood. 
 A small number of P. falciparum-infected HIV patients failed to clear parasitaemia in our study 
despite the apparent elevated lumefantrine concentration in peripheral blood. This could be 
due to the same issue of the host immune status (WHO, 2006a). Byakika-Kibwika et al, (2012) 
infers that the difference between the lumefantrine in their study and that of Kredo et al 
(2011) could be due to inter-individual variability as a result of differing genetics thereby 
underlining the importance of the assessment and influence of HIV status on pharmacokinetics 
of drugs. Additionally they opined that this was in contrast to the Kredo study where the 
subjects had CD4 cell counts >200 cells/mm3 and were on stable ART making the subjects 
somewhat similar to ours. Our study participants were on stable ART for durations longer than 
6 months and had a mean CD4 cell count of 411 cells/mm3 (sd 257) with a very wide range 
between 11-1593.  
Another possible reason for the failure to clear the parasites despite the apparent increased 
lumefantrine concentration could be due to a possible reduced exposure of artemether and 
DHA as established in the Ugandan study (Byakika-Kibwika et al., 2012). Artemether and DHA 
exert their pharmacological properties in the first 48hours of treatment to clear the parasite 
biomass leaving behind the residual parasites to the longer acting partner drug lumefantrine 
(Ezzet et al., 1998, Djimdé and Lefèvre, 2009). Our observation was that by day 3 and 28, the 
HIV-positive people had more parasites that were not cleared than the HIV-negative group 
(day3: OR: 3.2, P=0.011; day 28: OR: 2.86, 0.007). This may suggest that these parasites were 
not cleared by artemether or DHA and were therefore left to be cleared by the partner drug 
lumefantrine, so that even with a higher lumefantrine level the parasites that escaped the 
artemether were still not cleared probably suggesting that the inability to do so was a result of 
slow clearance of artemisinin (Dondorp et al., 2009). 
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Report (Farnert et al., 2012) of AL failure in a returning Japanese worker from Tanzania despite 
adequate lumefantrine level is another case which cannot easily be explained. The authors 
however suggest that the failure could be due to reduced sensitivity to lumefantrine even 
though the suboptimal concentration of desbutyl-lumefantrine (the metabolite of 
lumefantrine) and a missed dose could not be ruled out. Even though, this result was not 
obtained in HIV-positive patients, it brings to light the possibility of the influence of this 
metabolite in parasite clearance. 
The scope of our study neither includes the assessment of parasite clearance time nor the 
measurement of the concentrations of artemether or DHA. Moreover since the subjects in our 
study were asymptomatic-malaria adults with very low parasitaemia, measurement of parasite 
clearance is very difficult. This is easier in symptomatic clinically ill patients with high 
parasitaemia concentration. Also we did not measure the level of desbutyl-lumefantrine which 
has been shown to exhibit more potent in vitro antimalarial activity than lumefantrine and 
could possibly be a better marker for assessment of treatment failure of AL (Wong et al., 2011). 
As a result of this incomplete information therefore we cannot conclusively state any definite 
reason for the inability to clear parasite despite the higher lumefantrine concentration. A larger 
and more detailed pharmacokinetic study will throw more light on these unanswered 
questions.  
With regards to the influence of food intake on the measured lumefantrine concentrations, 
even though the administration of AL was unsupervised, I do not think this has any impact on 
the lumefantrine concentration of the HIV-positive people since the situation was similar on 
both arms of the study. Moreover the mean lumefantrine levels in both arms exceeded the 
270ng/ml used as a threshold concentration to predict treatment failure (Ezzet et al, 1998). It is 
also known that AL has high cure rate irrespective of being given under supervision with food 
or not (Piola et al., 2005, Dunyo et al., 2011). Moreover, according to Djimde and Lefevre, 
(2009) standard African diets or even breast milk are sufficient to meet the need of very small 
dietary fat necessary to ensure adequate lumefantrine absorption. 
One of the areas of concern about the parasite clearance could be the parasitaemia level at the 
onset of the study before treatment, whether the initial parasitaemia could be a confounding 
factor. In order to evaluate the baseline parasitaemia of study participants, assessment of day 0 
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parasitaemia using qPCR was performed for some samples both of HIV-positive and HIV-
negative (8 individuals (including 5 HIV+) who were subsequently PCR-positive on day 3, and 15 
who had cleared parasites by day 3 (including 9 HIV+). Established primers (Beshir et al., 2010b) 
were used to amplify both the parasite gene and the human gene. The baseline parasitaemia 
on both the samples that cleared parasites and those that did not on day 3 (Table 4.2) were 
very low and there was no significant difference in their levels so I propose that initial 
parasitaemia is not a cofounding factor.  
In conclusion, among the few studies on drug-drug interactions between ARVs and 
antimalarials, the question about treatment failure in HIV-infected patients on ARVs treated 
with artemisinin has not been addressed and therefore none has been able to establish the 
impact of these interactions on the parasite clearance. Many issues raised from the present 
study still remain unanswered so there is need to design further studies to provide answers to   
questions about what happens to the nevirapine, the possible influence it has on parasitological 
outcome and why the lumefantrine levels are increased. Our study was an attempt to answer 
some of the questions; unfortunately our sample size does not have the power to address these 
issues conclusively.  
Even though, we were able to show that there was an elevated day 7 lumefantrine 
concentrations in HIV-positive NVP-treated participants compared to their HIV-negative 
counterpart who did not receive NVP, we found no evidence of parasitological benefit of the 
higher plasma levels of lumefantrine. This is a preliminary study and the results are consistent 
with the reports of Kredo et al, (2011). This is the first study of NVP-AL interactions in both 
malaria and HIV co-infected patients. Therefore we advocate the need for further studies on the 
ARV and antimalarial interaction in malaria/HIV co-infected patients detailing full 
pharmacokinetic study in relation to parasite clearance. 
4.5 Limitations to the study 
The major limitation was the inability to calculate parasite clearance time (PCT) and this is 
closely related to the low parasitaemia of the study participants since they were asymptomatic-
malaria adult people. As result of this we could not calculate parasite reduction ratio so as to 
associate the levels of lumefantrine with parasite clearance. 
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5.1 Introduction 
The emergence of artemisinin resistance has become a major threat to the treatment of 
malaria. As at date, the artemisinins stand as the mainstay of treatment of uncomplicated 
malaria since the failure of chloroquine, partly because of the rapid beneficial reduction of 
parasite biomass in the first 48 hours of malaria infection. Studies (Noedl et al., 2008, Dondorp 
et al., 2009, O'Brien et al., 2011, Malmberg et al., 2013a), have demonstrated reduced 
susceptibility of Plasmodium falciparum to artemisinin derivatives leading to delayed clearance. 
The implication of this is that the partner drugs such as lumefantrine, amodiaquine, 
piperaquine, mefloquine also are more likely to develop resistance because of the higher 
parasite biomass exposed to these drugs. 
Single nucleotide polymorphisms of the pfmdr1 gene particularly the 86N allele have been 
associated with in vivo resistance to lumefantrine in several studies (Sisowath et al, 2005; 
Humphreys et al, 2007; Lekana-Douki et al, 2011; Gadalla et al, 2011; Malmberg et al, 2013) 
and less sensitivity to artemisinin in vitro (Duraisingh et al, 2000a; 2000b). Studies on 
artemether/lumefantrine (AL) have established an association of the NFD (86, 184, 1246) 
haplotype (Humphreys et al., 2007, Happi et al., 2009) with decreased in vitro lumefantrine 
sensitivity and also  in vivo post treatment of Ugandan children (Dokomajilar et al., 2006). The 
haplotype is associated with treatment failure. A more recent study by (Gadalla et al., 2011) 
reported the selection of the haplotype in samples collected from Sudan 14 days after 
treatment with AL.  
Plasmodium falciparum strains sensitive to chloroquine show the ancestral haplotype CVMNK 
at amino acids 72-76 on the pfcrt gene. The most common variant of this gene, has three 
substitutions and encodes the haplotype CVIET, but in vitro experiments suggest that crucial 
change at the K76T codon is the most important. (Fidock et al., 2000, Djimde et al., 2001a, 
Warhurst, 2003). Increased prevalence of 76K in countries where chloroquine has been 
withdrawn for a long time indicates a restoration of chloroquine sensitivity in these areas 
(Wang et al, 2005; Laufer et al, 2010). Pfcrt modulates parasite susceptibility to a variety of 
drugs such as quinine, mefloquine and artemisinins (Sidhu et al., 2002) whose sensitivity are 
equally affected by mutations or change in copy number in the mdr1 gene (Cooper et al., 2002, 
Cooper et al., 2005). Studies (Basco and Le Bras, 1993, Duraisingh et al., 2000a) reported a 
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cross-resistance and inter–relationship with an inverse sensitivity to CQ among these drugs 
thereby emphasizing a relationship between pfcrt and pfmdr1 genes. This inverse relationship 
is also seen between CQ and lumefantrine, where the decrease in lumefantrine activity is 
associated with the selecton of wild types pfcrt-76K and pfmdr1-86N, suggesting that the use of 
AL is likely to lead to the selection of more CQ-susceptible parasites (Mwai et al., 2009, 
Sisowath et al., 2009, Eyase et al., 2013). 
The involvement of modified pfcrt gene 72-76 in clinical AQ failure (Beshir et al., 2010a, Sa and 
Twu, 2010) and the role of pfcrt modifications in conferring hypersensitivity to MFQ (a partner 
drug in ACT) and halofantrine (also structurally related to lumefantrine) (Johnson et al., 2004) 
calls for a close monitoring of this marker in areas where AL is in use especially with the reports 
of replacement in pfmdr1 of the mutant allele 86Y (Tyrosine) by the wild type 86N (Asparagine) 
or the reversal to 86F (Phenylalanine) in some regions of Africa, (Kublin et al., 2003, Dlamini et 
al., 2010, Gadalla et al., 2011). This association is believed to be as a result of removal of CQ 
pressure. 
Sutherland et al, (2002) in a study of Gambian children also reported that gametocytes 
emerging after treatment with CQ carry a mixture of the mutant strain of the pfmdr1-86 and 
that of the pfcrt-76 gene confirming the linkage disequilibrum shown earlier in Nigeria (Adagu 
and Warhurst, 2001).  The study further emphasises the importance of determining the alleles 
of the genes associated with resistance in the analysis of CQR at population level and shows 
that other genotypic changes such as pfmdr1 mutations can be advantageous to the resistant 
parasites or may be essential in some parasite populations (Warhurst, 2001b). Further 
relationship is in the fact that wild type pfcrt 76K and pfmdr1 86N alleles have been associated 
with a five-fold increase in lumefantrine inhibitory concentration (IC50) in vitro and also found 
to be selected for after treatment with AL in vivo in Kenya and Sudan (Mwai et al., 2009, 
Gadalla et al., 2011). 
CQR was first reported in South-Western Nigeria in 1977 (Olatunde, 1977) and it increased by 
2005 to 96% in the six geo-political zones of the country, hence the ban on CQ and subsequent 
adoption of ACTs as first-line treatment. However the use of Chloroquine (CQ) for self-
medication against malaria is still very much in practice in Nigeria despite this ban. In spite of 
the National policy on ACT, a report indicates that 70% of children were treated with 
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chloroquine or SP (NPC & NMCP, 2012). This is because CQ is cheap and is easily obtained from 
pharmacies and medicine stores without prescription. A more recent study (Efunshile et. al, 
2011) of the resistance pattern of CQ in Nigerian children reported 96.9% of the pfcrt 76T allele 
thereby indicating that CQ resistance is still an important issue in the country. 
In the light of the reports (Kublin et al., 2003, Laufer et al., 2006) of the return of chloroquine-
senstive strains of P. falciparum parasites twelve years after withdrawal of CQ, there is need to 
monitor molecular marker status for this drug which has been very effective in the past so as to 
ascertain its present resistant status in Nigeria. The increasing use of Amodiaquine in Nigeria 
for monotherapy (field observation) as well as it being a partner drug of artesunate-
amodiaquine, the second line ACT in Nigeria calls for a close monitoring of the SVMNT 
haplotype which is generally implicated in amodiaquine resistance (Warhurst, 2003, Sa et al., 
2009, Beshir et al., 2010a).  
In our pilot study with DNA samples from imported cases of Nigerian origin, obtained from the 
Malaria reference laboratory (MRL), we detected the NFD haplotype in 20% of cases. No study 
to date has focused on the prevalence of this haplotype in Nigerian HIV-positive patients 
treated with AL. Our study evaluated this haplotype in this vulnerable group which are of great 
importance in the spread of antimalarial drug resistance because of their tendency to harbor 
higher parasitaemia (ter Kuile et al., 2004). This chapter provides some data and information on 
the prevalence baseline marker in this area on which future regular surveillance may be based.  
The present study analysed the pre-and post-treatment samples collected for the presence of 
pfmdr1 mutations to assess any allele, mutation or haplotype of interest with regards to the 
response to treatment with AL to identify any genotype selected after treatment, particularly 
the wild type allele 86N of the pfmdr1 gene which has been associated with decreased 
sensitivity to lumefantrine in vitro (Duraisingh et al., 2000a) and a strong indicator of AL 
treatment failure or slow clearance (Sisowath et al., 2005, Humphreys et al., 2007). 
This chapter therefore deals with the investigation of the polymorphisms of Pfcrt genes among 
HIV-positive and HIV-negative adults and information of the possible associations between 
point mutations on the pfmdr1 gene. The implications of these findings in the management of 
CQR and amodiaquine resistance in the environment are discussed.  
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5.2 Rationale 
The ACTs (AL and AS-AQ) have both been established to have high cure rates for the treatment 
of uncomplicated malaria in Nigeria (Meremikwu et al., 2006, Sowunmi et al., 2007). Therefore 
monitoring of the resistance markers related to the drugs is of vital importance in order to 
sustain their use in Nigeria. Since the adoption of AL as the first-line treatment for 
uncomplicated malaria, various studies (Falade et al., 2005, Falade et al., 2008, Happi et al., 
2009) on its use in Nigeria have been reported all of which have established an association of 
either treatment failure or slow clearance with polymorphisms in the pfmdr1 gene.  As at date 
and time of our study, none of these studies involved the inclusion of HIV-infected subjects. 
There are no published studies on AL malaria treatment of HIV-positive patients in Nigeria. This 
situation is highlighted in Rivers state, Niger Delta region of Nigeria, where there is a high 
prevalence (6.0%) of HIV infection compared to the national prevalence of 4.1% (FRN, 2012). 
The study was designed to address this paucity of data and establish the current status of 
markers to resistance of AL in this very important region of the country.   
5.3 Results 
A total of 459 participants who visited both hospitals were interviewed. Participants came from 
different parts of the Niger Delta region. Out of this number, the HIV-negative people screened 
were 314 and 242 of these were found positive for Plasmodium falciparum by microscopy, 
while 145 HIV-positive people were screened and 128 who were positive by microscopy were 
recruited. The total number of filter papers collected on day 0 was 391. 21 persons out of the 
391 people who gave their samples decided to opt out of the study because they were not 
willing to be finger pricked any more therefore the number of people enrolled in the study was 
reduced to 370. 
5.3.1 Pfmdr1 polymorphisms 
DNA was extracted from the 391 filter papers collected and screened by PCR for the mutations 
on the pfmdr1 gene. A total of 68, 66 and 79 out of these samples were successfully amplified 
by PCR and mutant sequences obtained at codons 86, 184 and 1246 on the pfmdr1 gene 
respectively. All the samples showed only wild type on codons 1034 and 1042. Molecular 
analysis of the sequences showed a predominance of the wild type asparagine (86N) allele with 
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a 75% (51/68) prevalence compared to 13.2% (9/68) of tyrosine (86Y) in a pure form and 12% 
(8/68) of mixture or other alleles on day 0 (Table 5.1). Post-treatment samples collected during 
follow-up on days 3 and 28 were analysed for mutations on the same loci, and the sequences 
show similar pattern with 96.9% (31/32) 86N and a reduction of the 86Y to 3.1% (1/32) on day 
3. 
Baseline distribution of polymorphisms at locus 184 showed a high prevalence of 184Y (53%, 
35/66) in its pure form as against 36.4% (24/66) of 184F. This pattern was maintained at day 3 
after treatment (Table 5.2) while at codon 1246 there was a higher prevalence of 1246D (90.1% 
,80/88) and 5.7%, 5/88 of 1246Y in pure form on day 0. None of the post-treatment samples 
harboured any mixed allele on locus 184 or 1246 (Tables 5.2 & 5. 3).  
 
Table 5.1 Distribution of 86 polymorphism on days 0, 3 and 28 among HIV-positive and HIV-
negative groups. 
  N Y NY F FY Total 
D0 HIV+ve 31 5 1 0 0 37 
 HIV-ve 20 4 1 1 5 31 
D3 HIV+ve 22 1 0 0 0 23 
 HIV-ve 9 0 0 0 0 9 
 HIV+ve 7 0 0 0 0 7 
D28 HIV-ve 1 0 0 0 0 1 
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Table 5.2 Distribution of 184 polymorphism on days 0, 3 and 28 among HIV-positive and HIV-
negative groups. 
 
 
Table 5.3 Distribution of 1246 polymorphism on days 0, 3 and 28 among HIV-positive and 
HIV-negative groups. 
  F Y FY Total 
D0 HIV+ve 10 23 3 36 
 HIV-ve 14 12 4 30 
D3 HIV+ve 4 19 0 23 
 HIV-ve 5 4 0 9 
 HIV+ve 4 3 0 7 
D28 HIV-ve 0 0 0 0 
  D Y DY Total Total 
D0 HIV+ve 38 1 1 40  
88  HIV-ve 42 4 2 48 
D3 HIV+ve 19 1 0 20  
34  HIV-ve 11 3 0 14 
 HIV+ve   16 3 0   19  
        28 
 
D28 HIV-ve  9 0 0  9 
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Analysis of the sequence for the selection of pfmdr1 on different loci, revealed a very strong 
selection for the mdr86N wild type conferring resistance against AL with an OR of 8.77 (CI=1.2-
380; P=0.016,) at day 3 after treatment. Further analysis also showed such selection in the HIV-
positive group but this was not significant with an OR of 3.05 (CI=0.8-12.85 P=0.063).  
However with the allele mdr86F, analysis showed strong evidence that HIV-negative group 
have a higher probability of harbouring this polymorphism. (P=0.0051). 
 Assessment of the day 0 pre-treatment samples, results showed 12 different haplotypes either 
in single or mixed forms. The most prevalent haplotype of the pre-treatment sample was the 
NYD (40%) in the pure form but also in combination with other haplotypes followed by (13%) of 
NFD (Table 3). This pattern was similar in both the HIV-positive and the control group. Post-
treatment samples on days 3 and 28 revealed only NYD and NFD haplotypes with NFD being 
slightly higher than the NYD on day 28. A rare haplotype ‘FFD’ was detected in the pre-
treatment samples day 0, this was as result of the polymorphism 86F which has recently been 
reported in Swaziland and Afghanistan (Dlamini et al, 2010; Beshir et al, 2010).  
 
Table 5.4 mdr1 Haplotypes on days 0, 3 and 28 
 
  NFD NYD NFD/NYD Others Total 
D0 HIV+ve 2 14 3 2 21 
 HIV-ve 2 4 1 5 12 
D3 HIV+ve 2 12 0 2 16 
 HIV-ve 4 4 0 1 9 
 HIV+ve 3 3 0 0 6 
D28 HIV-ve 1 0 0 0 1 
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Using the STATA case control study analysis for the results, the following were observed 
 A very strong selection for mdr86N wild type after treatment at day3. 
                      OR ratio of 8.77; 95% CI: 1.2-380; P=0.016  
 Weak evidence to show this selection in HIV-positive group 
                             OR: 3.05; 95% CI: 0 .8-12.85;     P=0.063 
 A strong evidence that HIV-positive patients had a higher probability of carrying the 
NYD haplotype    OR: 4.8; 95% CI:  1.37-17-3;     P=0.005 
 A weak evidence to show that there is a selection of NFD at D28  
                              OR: 4.2; 95% CI: 0.549-33.470;     P=0.085  
 There was no evidence of selection of NFD at D3 
 No evidence for selection for 86N at day 28 from the analysis 
 
5.3.2 Pfcrt polymorphisms 
Results of our study show that in the day 0 pre-treatment samples, pfcrt76T is still more 
prevalent (72.6%) than the 76K in the study area and the HIV-positive harbour more of this 
mutant group than the HIV-negative hence the wild type Crt76K was found to be less common 
among the HIV group (Table 5.5) however this difference was not significant (OR: 2.5; 95% CI: 
0.824-7.95; P= 0.0722). A larger study may probably give a more significant result.  
Only two pfcrt 72-76 haplotypes: the wild type CVMNK and the mutant type CVIET in their 
single and mixed forms were observed in both the pre-treatment samples but both presented 
as single forms in the post-treatment samples. There was no presence of the minor haplotype 
CVMNT (Vieira et al, 2004) which has been previously reported in isolates from South-Western 
Nigeria (Gbotosho et al., 2012), Papua New Guinea (Mehlotra et al., 2001) Brazil and Peruvian 
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Amazon (Huaman et al., 2004, Fidock et al., 2000). Also we did not detect any SVMNT the 
haplotype commonly associated with AQ resistance (Beshir et al., 2010a, Sa and Twu, 2010, 
Fidock et al., 2000) which later has also been reported in Angola (Gama et al., 2010) and in 
Ghana (Mehlotra et al., 2008).  
Table 5.5 Distribution of crt polymorphisms from day 0 samples 
  crt76T crt76K Total 
HIV-ve 30 14 44 
HIV+ve 22 6 28 
 In analysing the associations between the pfmdr186 and pfcrt76 alleles, we found no evidence 
of an association between mdr86N and crt76K, neither was there any between mdr86Y and 
crt76T. 
Table 5.6 Haplotypes of pfcrt gene 
 
 
 
  CVMNK CVIET CMNK/CVIET Total 
D0 HIV+ve 6 20 2 28 
 HIV-ve 22 15 8 45 
 HIV+ve 1 4 0 5 
D28 HIV-ve 2 3 0 5 
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5.3.3 New mutations  
Sequence analysis of the gene samples to detect mutations flanking codons 86, 184, 1034, 1042 
1nd 1246 using Chromas software, revealed three novel non-synonymus mutations in three 
pre-treated samples on the pfmdr1 gene at amino acid positions 73, 97 and 164 (Fig. 5. 4). The 
control sample 3D7 is depicted by the consensus chromatogram while the samples with the 
mutations are identified by their numbers. These chromatograms were confirmed on the 
Geneious software. 
Sample 059:    Serine to Leucine (S97L)  
Change in nucleotide from Cytosine to Thymine at position 290 resulted in amino acid change 
from serine to leucine (S97L) 
Sample 207A: Phenylalanine to Serine (F73S) 
Nucleotide change from Thymine to Cytosine at position 218 resulted in amino acid from 
phenyl alanine to serine (F73S) 
Sample 425: Glycine to Arginine (G165R)  
Nucleotide change from Guanine to Adenine at position 493 resulted in amino acid change 
from glycine to arginine (G165R) 
The three new mutations on the pfmdr1 gene at positions F73S, S97L and F165R are all 
apparently associated with the 86Y and the 184Y. 
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Figure 5.1 New mutations in samples 059, 207A and 425 
Chromatograms are from Geneious ver. 5.5.5 
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5.3.4 Parasite Clearance. 
Using the PCR as a more reliable tool, we assessed the parasite clearance after treatment 
with AL based on positivity on any gene, we observed that 74.3% (107/144) of the samples 
that were PCR-positive on day 0 had cleared their parasites by day 3 while 25.7% (37/144) 
of the participants still harboured parasites that were detected by day 28 and 62.2% 
(23/37) of these were from the HIV-positive patients (Table 5.7).  
The HIV-positive group had a lower parasite clearance by days 3 and 28. By day 3, HIV-
positive group still harboured 25.8% (16/62) of the initial parasites and by day 28, 37.1% 
(23/62) of the parasites were yet to be cleared.  On the whole, HIV-positive participants 
had 62.9% (39/62) clearance while the HIV-negative control group had a clearance of 82.9% 
(68/82).  
There is evidence from day 3 positivity to show that HIV-positive patients are slower to 
clear sub-patent parasites after AL treatment (CI=1.177-9.340; OR=3.22; P=0.011). This was 
more evident on day 28 with a higher P value (CI=1.239-6.727; OR=2.86; P=0.007). The 
total parasite clearance was 74% (107/144).  
Table 5.7 Parasite clearance at days 3 and 28 in the different groups 
 Day 0 Day 3 Day 28 
HIV+ve 62 16 23 
HIV-ve 82 8 14 
Total 144 24 37 
 
5.4 Discussions 
The results of the study reveal a high prevalence of 86N in pre-treatment samples and its 
very strong selection after treatment at day 3 with an OR ratio of 8.77 (P=0.016, CI=1.2-
380). There is also weak evidence to show this in the HIV subjects after stratification (Table 
5.1, P=0.063). A larger sample size with a higher power may provide a clarification. 
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 The prevalence of 86N has been suggested as a first step to lumefantrine tolerance and its 
selection as a strong indicator of AL treatment failure or slow clearance (Sisowath et al., 
2005, Humphreys et al., 2007, Mwai et al., 2009). There was no evidence of this selection at 
day 28.  
Mutant allele 86Y has been associated with enhanced  sensitivity to AL and resistance to 
CQ and AQ in West African countries like Nigeria, Guinea Bissau and The Gambia, (Adagu et 
al, 1995a, 1997; Adagu et al., 1996, Duraisingh et al, 1997); and also in Kenya and Thailand 
(Spalding et al., 2010, Lopes et al., 2002). In the result of this study, there was a 23.5% 
(16/68) prevalence of 86Y at day 0 both in the pure and mixed form but only one allele of 
86Y remained by day 3 out of the 16 originally present at day 0 thereby showing that the 
fitness of the parasite carrying 86Y mutation was greatly reduced after treatment with AL. 
It has been proposed that the 86Y exerts its effect in the presence of crt76T thereby 
increasing the fitness of parasite resistance (Djimde et al., 2001a, Wellems and Plowe, 
2001, Tinto et al., 2003). On the other hand, there is increased sensitivity of Plasmodium 
parasites to arylaminoalcohols with the presence of the mutant 86Y and its presence is 
favourable for chloroquine resistance (Duraisingh et al., 2000a).   
The absence of mutant in positions 1034 and 1042 is in agreement with the study of 
(Folarin et al., 2008) in south-Western Nigeria. These mutations are well known in South 
America where it has been shown with mutant pfcrt to confer high grade resistance to 
chloroquine (Zalis et al., 1998, Huaman et al., 2004). Earlier studies in Nigerian isolates 
(Adagu et al, 1995a, (Adagu et al., 1995, Happi et al., 2003), did not detect the 1246Y 
mutation which has been associated with CQR and AQR in South American and East African 
isolates (Foote et al., 1990, Zalis et al., 1998, Holmgren et al., 2007, Dokomajilar et al., 
2006, Humphreys et al., 2007).  
 Our results showed that the NFD haplotype which has been associated with AL slow 
clearance, increased tolerance and treatment failure (Dokomajilar et al., 2006, Sisowath et 
al., 2007, Humphreys et al., 2007) was found to be more prevalent in HIV-positive patients 
however the haplotype NYD had a higher prevalence in the overall population. The slight 
selection of NFD haplotype by day 28 is indication that AL tolerance or failure is not very 
evident in this part of Nigeria even among the HIV-positive people. This could be probably 
because AL has not been in long-term use in Nigeria, having been introduced in 2005. 
However there is need for close monitoring of AL use especially following the report of the 
NFD haplotype in South-Western Nigeria among children (Happi et al, 2009). 
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The high prevalence of 76T in pre-treatment samples is consistent with high rates usually 
obtained in chloroquine-resistant high endemic areas (Djimde et al., 2001a, Duah et al., 
2007, Mlambo et al., 2007). In contrast to an earlier study (Folarin et al, 2008) of children 
treated with CQ, there were 30% (3/10) of crt76K in the post-treatment (day 28) sample 
which interestingly had been found at day 0 to contain the mutant 76T, 2 being isolates 
from HIV-negative participants while the third was from a HIV-positive patient. The 
presence of the wild type 76K in the post-treatment samples possibly indicates the gradual 
restoration of chloroquine-senstive strains with the longer use of AL in Nigeria in contrast 
to Folarin’s study in 2008 which was carried out not many years after the introduction of 
ACTs (AL or ASAQ) as first-line treatment.  
Our results show an unexpected presence of six cases of the N86F in the pre-treatment 
samples and these are all from the HIV-negative people. This polymorphism was reported 
in clinical isolates from Afghanistan (Beshir et al., 2010a) and in samples from Swaziland 
(Dlamini et al., 2010). These mutations mostly presented as a mixed infection with 86Y. The 
significance of this is not clear but suggests the need for investigations of new mutations 
for close monitoring of antimalarial drug resistance. The possible explanation of this is that 
the withdrawal of CQ may result in the change from tyrosine (Y) which is associated with 
CQR to phenylalanine (F) because they are more structurally related and are both aromatic 
in nature. Selection of 86N is more prevalent where AL is in use. It is noteworthy that the 
HIV-positive group had a higher prevalence of this allele while the HIV-negative group had a 
higher prevalence of the 86Y in both pure and mixed form.  
From this study, there is evidence to show that among adult patients with asymptomatic-
malaria infection in Port Harcourt Nigeria, the HIV-negative control group had a higher 
parasite clearance than their HIV-positive counterparts (Table 5.7; CI: 1.239-6.727; OR: 
2.86; P=0.007). Parasite clearance is dependent on factors such as host factors, the parasite 
as well as initial parasitaemia and drug factors (White, 1997, Anderson et al., 2010). A 
major host factor that plays a role is host immunity (Djimde et al., 2003) hence adults in 
endemic regions who have acquired immunity by virtue of several exposures (Whitworth et 
al., 2000) are able to clear their parasites even without treatment. The immunosuppression 
that is prevalent in HIV-positive persons may lower the immunity acquired as adults 
thereby reducing their ability to clear parasite. This is probably why the HIV-positive 
patients had higher parasitaemia at the end of treatment. It has been hypothesised that 
chronic asymptomatic-malaria infections are non-immunogenic (Dinko et al., 2013) as 
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against symptomatic infections (Djimde et al, 2003; Diallo et al, 2007). This could possibly 
explain why there was a high percentage of sub-patent parasites that remained uncleared 
in our study participants by day 28 as against the high parasite clearance (93.9%) previously 
reported in AL-treated symptomatic malaria infants in Ibadan Nigeria (Falade et al., 2005). 
Our results show that even in semi-immune persons, there is inability to completely clear 
sub-patent parasites after treatment with AL as also observed in the Ghanaian children 
treated with dihydroartemisinin and piperaquine in the Dinko et al (2013) study. These 
results were not coordinated with microscopy readings since our initial diagnosis based on 
microscopy was flawed by very many false positives. Follow-up studies with microscopy 
parasite clearance and PCR is urgently needed in addition to in vitro drug resistance studies 
to demonstrate these associations.  
The CQR mutant crt76T was found to be more prevalent than crt76K in our study area 
despite the official change to ACT in 2005 and this was higher in the HIV-positive group. 
The high prevalence of this allele corroborates the recent study in Lagos, South-west 
Nigeria (Efunshile et al., 2011) indicating a 96% prevalence of crt76T. High prevalence of 
crt76T is not surprising since this is still obtainable in most parts of Africa where CQ is still in 
use. The higher prevalence of the crt76T (though not significant) in the HIV-positive group 
before and after treatment is suggestive of the fact that the HIV-infected people have more 
selection of the mutant allele CVIET after treatment with AL possibly due to increased drug 
pressure. A larger study may indicate a more significant result.  
The continued use of a drug in a locality confers a selective advantage to any parasites 
carrying resistant genes for that drug and leads to higher transmission rates of the drug 
resistant genes (Handunnetti et al., 1996, Sutherland et al., 2002, Hallett et al., 2006). This 
explains the high prevalence of crt76T, despite the official change from chloroquine use to 
ACTs because chloroquine use is still very common in Nigeria. One can infer that the 
presence of molecular markers of chloroquine resistance keeps AL efficacy up (Sutherland 
et al., 2011, Raman et al., 2011). For efficient control of antimalarial drug resistance, there 
is need to reduce the drug pressure through improving the ways the drugs are used 
especially in the face of self-medication and misuse of drugs.  
The result of our field work study shows that AL was the third most commonly used 
antimalarial by our study participants, albeit without prescription. Adding up this finding 
from the field observation and selection of mdr86N, there is therefore need for close 
monitoring of AL use in order to assess the level of resistance being developed in Nigeria. 
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Further studies are needed to confirm these findings especially since there is no published 
report of AL efficacy in the Niger Delta region. This is particularly important with regards to 
the HIV-infected persons who exhibited lower parasite clearance. Our summation is that 
further studies be carried out with a larger sample size among HIV-infected malaria 
patients so as establish the impact of the mdr86N and crt76T selection as well as the 
parasite clearance following treatment with AL in order to curtail the threat to AL efficacy 
in the area. 
The findings of this study therefore serve as additional information to the scarce data 
available on the use of AL in Nigerian adults especially in the Niger Delta where there is no 
published data, and should help to form a data basis of calculating sample size for a larger 
study. 
5.5 Limitations to the study 
The study aimed to investigate the molecular markers related to AL treatment with 
particular reference to polymorphisms on the pfmdr1 gene. In order to ascertain whether 
the polymorphisms that remain after 28 days treatment are recrudescent parasites or new 
infections, there is need to genotype for polymorphic regions of surface antigens msp1 and 
msp2 in the pre and post treatment isolates. Therefore one major limitation to this study 
was the inability to do this PCR correction. This was due to poor yield of DNA because of 
very low parasitaemia. As a result of this we could not differentiate between new infections 
and recrudescence. Additionally the scope of our study did not include the investigating of 
copy numbers another factor associated with AL treatment failure. 
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Chapter Six 
-----------------------------------------------------------------------------------------------------
Antifolates and their molecular markers in 
asymptomatic-malaria Nigerian adults. Drug 
assays for trimethoprim; any relationship 
with dhps_431V?  
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6.1. Rationale  
Antifolate drugs are very important in malaria control because of their use in the 
prophylaxis of malaria in people at higher risks of malaria infection such as pregnant 
women, children, infants and HIV-infected persons. The concept of preventive treatment of 
malaria intermittently (IPT) as recommended by WHO (2004; 2006; 2009) for the treatment 
and prevention of malaria infection or clinical episodes in vulnerable persons has been 
proved to be very efficacious in several studies in infants (IPTi) (Schellenberg et al., 2005, 
Gosling et al., 2009, Aponte et al., 2009). IPT in pregnancy (IPTp) helps prevent maternal 
anaemia and reduces neonatal mortality (Shulman et al., 1999, Menendez et al., 2010). It 
was also found to improve cognitive ability of semi-immune Kenyan school children and 
reduced annual incidence rate of clinical malaria in children in Mali (Clarke et al., 2008, 
Dicko et al., 2008). The drug of choice for intermittent treatment is 
Sulfadoxine/pyrimethamine (SP), however later studies have included a partner other drug 
in addition to SP. This was evidenced by the recent study in Senegal with the use of AQ+SP 
which reported lower incidence of parasiatemia in areas where it was used for seasonal 
malaria chemoprevention (SMC), formerly IPTc (Lo et al., 2013). IPT was adopted in Nigeria 
in 2005 as part of the national guidelines for the prevention of malaria in pregnant women 
(IPTp) in line with the WHO recommendation that pregnant women living in high 
transmission areas should receive at least two doses of SP for IPTp after quickening, the 
first noted movement of the foetus, (FMOH, 2005). However studies have shown that IPTp 
use among pregnant women in Nigeria is still very low (Akinleye et al., 2009, Efunshile et 
al., 2011, Ugwu et al., 2013). 
Malaria in pregnancy and the impact of placental Plasmodium falciparum infection with 
consequent low birth weight (LBW), maternal anaemia, intrauterine growth restriction and 
preterm delivery (Steketee et al., 2001) is a major concern in sub-Saharan Africa. The non-
compliant use of SP-IPT therefore will invariably increase the burden of these risks 
contributing substantially to infant deaths globally in the malaria-endemic regions.  
In addition to its use in intermittent preventive treatment, SP is also given in combination 
with AQ (AQSP) and this combination has been found to be more efficacious than 
artemether-lumefantrine (AL) regimen in preventing recurrent P. falciparum malaria in 
Burkina Faso (Zongo et al, 2007). 
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6.2. Resistance to antifolates 
 Considering the importance of antifolates in IPT, there is a great need of the understanding 
and monitoring of resistance in the areas where they are in use. Since the introduction of 
SP in the early 1980s as a result of chloroquine failure (Roper et al., 2003), there have been 
increased reports of resistance to this drug especially in East and southern Africa. 
Pyrimethamine resistance was earlier recorded and this was subsequently followed by 
sulfadoxine resistance in the early 90s (Omar et al., 2001, Kublin et al., 2002, Naidoo and 
Roper, 2010). Substitutions on the target enzymes dhfr and dhps have long been 
established as source of resistance in these drugs (Cowman et al., 1988, Kublin et al., 2002, 
Bwijo et al., 2003, Karema et al., 2010). In contrast to the principle of accumulation or 
efflux of drugs by transporters as obtained in the quinolones, resistance to the antifolates is 
due to altered affinity at the drug target as a result of single or multiple mutations on the 
genes (Wang et al., 1997). 
Triple mutations in the dhfr gene at codons N51I, C59R and S108N have been associated 
with reduced efficacy of pyrimethamine and the additional mutation on the 164 codon 
from Isoleucine to Leucine (I164L) results in the highest level of resistance to 
pyrimethamine (Ahmed et al., 2006). However the dhfr I164L is not very common in Africa 
but has only been reported in some parts of East Africa (Nzila et al., 2005, Juliano et al., 
2008).  
Similarly, mutations at various points on codons 436, 437, 540, 581 and 613 on the dhps 
gene in various combinations especially result in decreased sulfadoxine efficacy. Acquisition 
of the quintiple mutants (dhfr N51I/C59R/S108N/dhps A437G/K540E) is associated with 
increased risk of SP resistance and treatment failure (Kublin et al., 2002) as found in some 
parts of East Africa. The occurrence of dhps A581G in addition to A437G or A437G+ K540E 
confers, higher resistance to sulfadoxine (Naidoo and Roper, 2010).  
A non-synonymous mutation at position 431 of the dhps gene involving a change from 
isoleucine to valine (I431V) was observed in three isolates from imported cases of P. 
falciparum of Nigerian origin in UK (Sutherland et al., 2009). Preliminary data from the 
study shows that in several cases the mutation  I431V was found with three other 
mutations  S437G, A581G and A613S presenting as VSGKGS and VAGKGS; and rarely 
occurred with A581 presenting the haplotype VAGKAA. We hypothesize that the use of  
trimethoprim/sulfamethoxazole (TS) prophylaxis in HIV-positive patients may be placing 
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additional sulfonamide selective pressure for new alleles at the pfdhps locus that are not 
directly related to antimalarial use (Sutherland et al, 2009). The study was designed based 
on the hypothesis that HIV-positive patients are infected with parasites that are selected by 
the drugs they take, including ARV and TS, therefore their pfdhps genotypes will differ from 
that of the HIV-negative patients. We therefore decided to measure and compare the 
prevalence of different dhps haplotypes including I431V in the two different groups and 
look for any evidence of association with recent use of TS. 
The misuse of antibiotics and antimalarial drugs is very common in Nigeria. Despite the ban 
of SP and the subsequent adoption of ACTs as first-line treatment for malaria, its use is still 
very common in Nigeria being one of the cheapest antimalarials available. Furthermore, TS 
a structurally related drug to SP which is usually given to HIV-positive people for 
prophylaxis against opportunistic infections, shows cross resistance with pyrimethamine 
and trimethoprim in in vitro P. falciparum culture (Iyer et al., 2001, Khalil et al., 2003). It is 
the cheapest antibiotic in use in Nigeria and can easily be obtained over the counter 
without prescription. Its misuse in the country could result in increased incidence of 
resistance to SP and therefore endanger the prophylactic use of SP for IPTp, IPTi and IPTc 
programmes. 
The SNP at codon 540 on the dhps gene is responsible for increased resistance to SP. A cut-
off of 50% prevalence for dhps K540E mutation has been recommended by the WHO above 
which SP-IPTi should not be implemented in any country (Naidoo and Roper, 2010). In East 
Africa, the use of SP has been greatly affected due to the high prevalence of this mutation 
in many countries such as Uganda (Staedke et al., 2004), Kenya (Zhong et al., 2008, 
Bonizzoni et al., 2009), Ethiopia (Alifrangis et al., 2009), and Rwanda (Karema et al., 2010) 
contrary to the situation in West Africa where there is low resistance to SP as result of low 
incidence of the K540E (Naidoo and Roper, 2010).  
There is paucity of data on the prevalence of dhps K540E and dhfr I164L in Nigeria, however 
a 23.8% prevalence of dhps K540E was reported in western Nigeria among children less 
than 5 years (Happi et al., 2005). Based on this we decided to assess the prevalence of 
K540E and the presence if any of dhfr 164L and dhps 581G in Port Harcourt, in the Niger 
Delta region. IPTp was adopted in Nigeria in 2005 as part of the national guidelines.  Since 
then, there has been little or no information about its use or the monitoring of the K540E 
with regards to its effect on IPTp programme in Nigeria. Moreover WHO (2009) advocates 
the monitoring of the prevalence of mutations associated with SP resistance and the 
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determination of the predictive value of mutation at dhps 540 or the quintuple mutation 
haplotype in different settings and populations. 
Studies (Shah et al, 2006, Whitworth et al, 2000, French et al, 2001) have shown that HIV 
subjects have increased incidence of clinical malaria and antimalarial treatment failure. 
Therefore they are more likely to carry more resistant parasites because of increased drug 
pressure. Although the presence of these markers may not affect AL efficacy, it may 
however affect the transmissibility of the resistant strains of the parasite thereby reducing 
the efficacy of SP prophylaxis in areas where it is used in combination with artesunate. 
Furthermore, if the newly emerging mutations in Africa dhfr164L and dhps 581G are found 
in conjunction with the dhfr triple and dhps double mutants there will be reduced 
sensitivity to SP thereby endangering the use of SP for both IPTi and IPTp (Naidoo and 
Roper, 2011). 
This chapter deals with the investigations of the presence of dhps I431V in the HIV-positive 
group as well as establish any relationship between its prevalence and TS use in addition to 
their HIV status. Additionally, the prevalence of dhps K540E and dhfr I164L and any other 
mutations of interest in both genes were investigated in the two groups. 
6.3 Results 
Out of 391 filter papers obtained from the participants on day 0, amplification of the dhps 
gene using PCR yielded 67 positive results; however, some of the sequence was not 
complete for all the codons of interest. Molecular analysis of the sequences showed a 
predominance of the mutant A437G (94%). The mutation on codon 431 Isoleucine change 
to Valine (I431V) previously detected only in Nigerian isolates (Sutherland et al., 2009) was 
found in 19 samples (28.79%) and 2 of these were in mixed form with the wild type 
Isoleucine (I+V). The prevalences of all the alleles are shown in Table 6.1. 
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Table 6.1 Distribution of dhps polymorphisms 
Allele Prevalence 
I431V 19/66 (28.8%) 
S436A/F 26/66 (39.4%) 
A437G 62/66 (94%) 
K540E 0/67 (0%) 
A581G 14/65 (21.5%) 
A613S 15/65 (23.1%) 
 
 
 
Figure 6.1 Polymorphisms on the dhps gene 
Analysis of the sequences revealed the absence of K540E. All the samples retained the 
K540 wild type.  
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6.3.1 Association of the alleles on the dhps gene 
The newly described mutation I431V was observed in 19 samples (28.8%) and 2 of these 
were mixed with Isoleucine (I+V). The overall prevalence of I431V was 28.8% (n=19/66) 
while that of A437G was 94%. The 431V was found to have a strong association with the 
613S. Analysis of the different alleles of the dhps gene showed pair-wise associations 
between the alleles as shown below:  
431V and 613S    OR: 7.6; 95% CI: 1.716- 35.303;         P=0.0012 (N=61)   
581G and 613S                  95% CI:  15.669-8352;            P=0.0000 (N=64) 
436A and 581G   OR: 23.57; 95% CI: 2.732-1052.709;   P=0.0002 (N=58) 
436A and 613S    OR:  37.92; 95% CI: 4.501-1655.282   P=0.000 (N=61)    
There was no special association of the 437G mutations with HIV status. Our earlier 
hypothesis is that HIV-positive patients are infected with parasites that are selected by the 
drug they take and therefore their response to the drug will differ from that of the HIV-
negative patients. We expected a difference in the outcome of the mutations. Our results 
show that there was no association between the HIV status and the 431V mutation. Using 
chi square test, we compared the frequency of mutations at position 431 on both arms and 
we found no difference (P=0.876). Out of all the polymorphisms in the 613, there was no 
581G that did not present in combination with 613S. We could not calculate the OR 
however the P value =0.000. 
6.3.2 Haplotypes of the dhps gene   
Our results show a variety of different antifolate resistance-associated haplotypes on the 
dhps genes. The prevalences of the various haplotypes are presented in the Table 6.2 
below. The most common pfdhps haplotype is the ISGKAA with 50.8% followed by the 
VAGKGS. 
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Table 6.2 Dhps haplotypes 
Haplotype Frequency Percentage 
VAGKGS 8 12.3 
ISGKAA 33 50.8 
VAGKAA 7 10.8 
VAGKAS 1 1.5 
IAGKAA 4 6.2 
VSGKAA 1 1.5 
ISAKAA 4 6.2 
IAGKAS 2 3.1 
VSGKAA 1 1.5 
ISAKGA 1 1.5 
IFAKAS 1 1.5 
ISGKGS 1 1.5 
IAGKGS 1 1.5 
Total 65 100 
*mixed genotypes were included in both categories; therefore total frequency is greater than the total 
number (59). 
 
Nucleotide sequences of the dhps gene showed mixed infections in some samples and 
these were more prevalent in the HIV-positive samples. Fig 6.2 and 6.3 show two HIV-
positive samples with mixed infections (at positions 436 and 437). We did not observe any 
difference in the prevalence of mutant alleles of the dhps gene between the HIV-positive 
individuals and the HIV-negative control group.  
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Figure 6.2 Diagram showing the chromatogram of mixed infection at position 436 in a HIV-positive 
patient 
 
Figure 6.3 Diagram showing the chromatogram of mixed infection at positions 436 and 437 in a 
HIV-positive patient 
6.3.3 New mutations 
In addition to the known polymorphisms on the dhps gene, we observed two novel 
synonymus polymorphisms. A change at nucleotide 1732 from thymine to cytosine 
(T1732C) did not result to any change in the amino acid which remained leucine (L), and at 
position 1878 from adenine to guanine (A1878G) while retaining the same amino acid 
Glutamine (G). These polymorphisms occurred as mixed infection in a single HIV-negative 
patient.  
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Figure 6.4 Chromatogram from Geneious of sample 425 showing two synonymus mutations with mixed infection at two different positions in the same 
sample
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6.3.4 Dhfr polymorphisms 
On the dhfr gene we were able to amplify only 48 full gene fragments encompassing the 
loci of interest. Table 6.3 shows the various haplotypes obtained on the different genes. 
Molecular analysis of the sequences showed a predominance of the triple mutant (N51I, 
C59R, S108N) with a 95.83% prevalence. No single isolate carried the pure wild type 
haplotype NCSI instead there was a haplotype consisting of a mixture of wild type and 
mutant alleles (NCNI) and a single case of both the mutant haplotype and haplotype 
mixture of wild type and mutant allele.  
The predominant haplotype was IRNI (codons 51, 59, 108 and 164). All the samples showed 
only wild type on codon 164, so there was no quadruple mutant. There were a total of 
three different combinations of the dhfr mutations in all the sequenced samples. The 
S108N allele had the highest prevalence (97.9%).   
 
Table 6.3 Dhfr haplotype 
Type Frequency Percentage 
ICNI/IRNI 1 2.08 
IRNI 46 95.83 
NCNI 1 2.08 
Total 48 100 
*N=48 
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Figure 6.5 Distribution of the polymorphisms on the dhfr gene showing the allele S108N with the 
highest prevalence. 
 
6.4 Trimethoprim/Sulphamethoxazole (TS) assay 
Towards the completion of our studies, Dr. Harparkash Kaur who did the lumefantrine 
assay developed a protocol for detecting trimethoprim and sulphalmethoxazole (TS) in the 
laboratory. Day 7 samples collected for estimation of lumefantrine on filter papers pre-
treated with 0.75M tartaric acid were used. Participants identified as positive for either 
component of TS are presented in Table 6.4 (N = 18). The remaining 158 participants tested 
were negative for both drugs. 
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Table 6.4 TS assay result 
Sample ID Trimethoprim conc SMX conc HIV status Reported TS use 
86 3.19 59.28 0 ND 
104 0.00 24.30 0 ND 
46 0.00 20.96 1 N 
150 0.00 19.06 1  ND 
51 3.08 12.81 1 N 
48 0.00 10.45 1 N 
41 0.91 8.00 1 N 
49 0.00 7.13 1 N 
164 0.00 6.35 1 N 
103 0.00 2.63 0 ND 
101 0.00 2.29 0 ND 
121 0.00 2.09 0 ND 
153 0.00 2.01 1 N 
152 0.00 1.77 0 ND 
192 0.00 1.06 0  ND 
165 0.00 0.81 1 N 
167 0.00 0.53 1 N 
169 0.00 0.03 1 Y 
*Legend: HIV status: 0=Negative; 1=Positive; Reported TS use: N=no; Y=yes; ND=no data 
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Observation of our results shows that detection of the TS did not match with the 
questionnaire answers obtained from participants. Out of the 176 samples analysed, only 
18 samples were identified to have presence of either trimethoprim or sulphamethoxazole 
and only 3 of these 18 had the presence of trimethoprim detected. Analysis of the different 
alleles of the dhps gene based on our initial hypothesis that the TS being taken by HIV-
positive people may be placing sulphonamide selective pressure for alleles at the dhps loci 
showed pair-wise associations between the dhps 437 and TS presence. 
 
Table 6.5 Pair-wise association between TS positivity and dhps 437 
*N=35 
Pair-wise relationship between TS and dhps437A shows that participants with detectable 
TS on day 7 suggesting recent use were more likely to carry the allele form of Alanine (dhps 
437A) rather than the glycine 437G. (P=0.077, OR=10.0 and CI= 0.096-809).   
Using same analysis for the 431 allele, we observed that there was no relationship 
established as shown in Table 6.6 
Table 6.6 Pair-wise relationship between TS and dhps431   
TSpos 431I 431 I+V 431V Total 
0 26 2 5 33 
1 2 0 0 2 
Total 28 2 5 35 
  
TSpos 437A 437G Total 
0 3 30 33 
1 1 1 2 
Total 4 31 35 
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6.5 Discussions 
Contrary to our hypothesis that there will probably be an increased number of the 431V 
mutations among HIV-positive people because of the use of TS for prophylaxis, the result of 
the study showed no difference in the prevalence of this mutation. This could be attributed 
to the fact that very few of the HIV-positive people were actually taking TS regularly. Our 
observation from the field work in this study is that self-reported TS use among these 
subjects in the Niger Delta region, Nigeria is very low. Out of the 128 microscopy positive 
people recruited, only 27.7% (28/101) of the 128 reported regular use of TS. Analysis of the 
TS assay revealed no relationship between the dhps431 and TS use thereby disproving our 
hypothesis of any relationship of this allele to TS use. 
Some of the HIV subjects were placed on TS at the initiation of ARV therapy but 
discontinued the use thereafter. Analysis of the results from the assay for detection of TS, 
showed that that detection of the TS did not match with the questionnaire answers as 
mentioned earlier. Therefore TS was not routinely used by our HIV participants. This was 
similar to the observation made in the study (Walker et al., 2010) among HIV-infected 
adults in Uganda and Zimbabwe studies where TS use was not strictly adhered to in some 
centres. 
The insignificant relationship between TS and dhps437A (P=0.077) from our study is 
potentially of interest with a need for larger studies with development of better protocol 
for measuring TS. This is our first attempt to measure this drug so there is need for 
optimising the method for collection of TS. It may be more appropriate to collect the 
samples on the pre-treatment day so as to avoid any possible interaction with any drug 
during treatment. 
The high prevalence of the single mutant A437G observed in the study did not confer 
higher degree of resistance since it only occurred in the absence of K540E required for high 
level resistance to SP (Brooks et al., 1994). Despite the high prevalence of HIV in the region 
and the indiscriminate use of SP as observed from the questionnaire data, there was no 
evidence of K540E observed in the samples even in the HIV cohort; all the samples retained 
the 540K wild type. However, we cannot rule out the possibility of its presence in a larger 
sample size. 
The absence of K540E is in contrast to the 23% reported in children in Ibadan Western 
Nigeria by Happi et al, (2005). This implies that the use of SP for prophylaxis is not under 
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threat in Nigeria since the cut-off threshold for the use of SP is 50% prevalence of K540E. 
Therefore this authenticates/supports the continued use of SP for prophylaxis in IPTp, IPTi, 
IPTc. However, there is need for close monitoring of this polymorphism since its presence 
has been reported by Sutherland et al., (2009) in Ghana a neighbouring country to Nigeria. 
The absence of 540E shows that the dhfr has been more selected than dhps because of the 
long period of use of pyrimethamine as monotherapy for prophylaxis in Nigeria and 
subsequent loss of its efficacy (Nahlen et al., 1989) before it was used in combination with 
sulfadoxine.  
To the best of our records and search, a single presence of 436F found among the HIV 
cohort is the first of this reported case in Nigeria since this has not been previously 
described. This may indicate an early sign of new mutations in the dhps gene being 
introduced into Nigeria as result of co-infection in the HIV patient. It is noteworthy that this 
same patient harboured a mixed infection in the 86 and 184 codons of the mdr1 gene.  
Out of the 48 dhfr sequences of our samples, none had the quintuple mutant (dhfr 
N51I/C59R/S108N and dhps A437G/K540E) which is considered a molecular marker for SP 
resistance and treatment failure (Bwijo et al, 2003; Kublin et al, 2002). However 20.8% 
(10/48) had the dhfr mutants N51I/C59R/S108N and dhps A437G with the absence of 
K540E. The low prevalence of these mutants in our samples could possibly be the reason 
why SP resistance is not very high in our study site, hence its continued effective use for 
IPTp in Nigeria. 
The absence of dhfrI164L is in agreement with the report that dhfrI164L is very rare in sub-
Saharan Africa, as all the report are from East Africa and Madagascar (Alker et al., 2005, 
Lynch et al., 2008, Hamel et al., 2008, Andriantsoanirina et al., 2011). This mutation found 
mostly in South East Asia and South America has been associated with proguanil as well as 
in conjunction with pyrimethamine (Ochong et al., 2008). The two drugs are no longer in 
use in Nigeria even though pyrimethamine monotherapy had long been in use for 
prophylaxis but has lost its prophylactic effect against maternal malaria (Nahlen et al., 
1989, Falade et al., 2007). The  abundance of the triple mutant is an indication of 
pyrimethamine resistance (Ahmed et al., 2006). 
In our study only one of the dhps haplotypes (ISGKGS) had a combination of S436A, A581G 
and A613S in association with A437G. These four mutations are associated with increased 
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levels of in vitro resistance to SP (Triglia et al., 1997, Wang et al., 1997).  With these four 
being very few in our samples, it shows that SP resistance is still not very high.  
There was a very high prevalence of 437G (94%, 61/66) in the entire samples amplified as 
usually obtained in areas of high use of sulphonamides.   
The presence of 581G allele in our study is probably an indication of sustained presence in 
Nigeria since it was first reported among isolates of Nigerian origin imported to the UK  
(Sutherland et al., 2009). This observation calls for a closer monitoring of the use of SP in 
Nigeria so as to ensure the continued use of SP for prophylaxis in Nigeria. 
The triple mutant (N51I/C59R/S108N) of the dhfr gene was the most prevalent with a 
percentage of 95.83% frequency as shown in table 6.3 above. The absence of the 
quadruple mutation as a result of no presence of I164L, probably explains why the 
antifolates are still useful in Nigeria because the quadruple mutations show the highest 
level of antifolate resistance (Peterson et al., 1988, Wang et al., 1997). 
In conclusion, the results from our small sample sized study showed no difference in the 
prevalence of 431V mutant between the HIV-positive and HIV-negative control group. 
However, this does not rule out the possibility of any difference in a larger sample size. Our 
result is similar to the report in study among HIV-infected and HIV-uninfected women on SP 
(Newman et al., 2009) in Uganda. There is need for larger studies involving the assessment 
of pfdhps and pfdhfr mutations in both symptomatic and asymptomatic-malaria HIV-
positive individuals, pregnant women and children leaving in the study area particularly the 
surveillance of dhps K540E in order to ensure the continued use of SP for IPT in the 
environment especially with the report of its presence in the nearby country Ghana. 
Although the significance of the 431V mutation with regards to antifolate resistance has 
not been established, there is need for population studies of this mutation so as to 
ascertain its prevalence and possibly any relationship or association with the use of 
antifolate drugs in the area. 
6.6 Limitations to the study 
The inability to measure the levels of TS in the samples is a major limitation because we are 
not able to assess if there was any interaction with AL. Being the first attempt to measure 
the level, there is need for optimising the method of collecting samples with TS as well as 
assaying or detecting the presence of trimethoprim and sulphamethoxazole.   
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7.1 General discussions  
Malaria still remains major public health challenge in endemic regions especially in sub-
Saharan Africa where it has a geographical overlap with HIV. Recent efforts to control 
malaria have contributed to reducing the prevalence of disease through various control 
measures. WHO (2011) reports a 17% decline in number of malaria cases and a 26% 
reduction in malaria-specific child mortality between 2000 and 2011. According to Dr. 
Margaret Chan, Director–General of World Health Organisation, an estimated 1.1 million 
malaria deaths were averted as a result of a scale-up of malaria interventions (WHO, 
2012b).  Despite the progress made, the war against malaria is yet to be won. Malaria still 
takes the life of an African child every minute (WHO, 2012b). The situation is made worse 
in HIV-infected persons because of immunosuppression. HIV affects the prognosis of 
malaria and vice versa (Whitworth et al., 2000., French et al., 2001, Kublin et al, 2005, 
Mermin et al, 2006).  
The impact of malaria on public health and the overwhelming financial burden especially in 
sub-Saharan Africa cannot be overemphasized. The effort to reach targets for malaria 
elimination and eradication should be intensified in endemic regions. To achieve this, high 
burden countries with large populations like Nigeria and Democratic Republic of Congo 
should be encouraged or empowered to deal with the issues and challenges limiting the 
achievement of this goal. With a population of 162 million and being the eighth most 
populous country in the world and the highest in Africa, the problem of malaria in Nigeria is 
a global problem especially with the high level of migration by Nigerians to the western 
world.  
Resistance to antimalarial drugs by Plasmodium parasites has become a major health 
problem since the first resistance to chloroquine was recorded in Thailand and Cambodia in 
the late 1950s (WHO, 2006). The current antimalarial policy of artemisinin combination 
therapy for the treatment of malaria, as advocated by the WHO, has contributed to 
reductions in morbidity and mortality caused by malaria. However various studies (Noedl 
et, al 2008, Dondorp et al, 2009) indicate that resistance to artemisinin or its derivative 
artemether (Jambou et al, 2005, Dokomajilar et al, 2006) has posed a great threat to the 
continued advancement of malaria control. This calls for active monitoring of the efficacy 
of the ACTs in order to prolong their life and sustain their use. Monitoring of drug efficacy is 
multifaceted and involves both in vivo and in vitro methods. In vivo methods have been 
accepted as gold standard but this is time consuming and very expensive. The employment 
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of molecular markers have proved very effective as tools of surveillance (Djimde et al, 
2001a)  in measuring parasite drug sensitivity as well as drug susceptibility (Laufer et al, 
2006) and in informing policy (Mugittu et al., 2004). The report of the reemergence of 
chloroquine-senstive parasites in areas where it had been withdrawn (Kublin et al., 2003) is 
another proof of the importance of monitoring of molecular markers of resistance. The 
information obtained from such surveillance will be beneficial to informing policy when and 
where there may be need for a change in treatment policy. 
7.2 Malaria/HIV co-infection in Nigeria. 
Malaria is holoendemic in Nigeria and has a geographical overlap with HIV. There is paucity 
of malaria prevalence data in Rivers State. However a cross sectional study among 
pregnant women attending antenatal clinics reports a 26% prevalence of P. falciparum in 
Rivers State. (Wogu et al, 2013). The results of our study show a positive predictive value of 
the microscopy results with 80% of parasitaemia. This was found to be much higher than 
the PCR result. There is urgent need to undertake a cross-sectional study of asymptomatic-
malaria and HIV-co-infected adults in order to measure the prevalence of malaria in these 
subjects considering the fact that prevalence of HIV in the area (6.0%) is higher than the 
national prevalence of 4.6% (NACA, 2011). 
Management of co-infection of malaria and HIV is of great challenge to public health 
especially with regards to drug-drug interactions. The first line treatment of HIV-positive 
patients in Nigeria is a combination of 1 non-nucleoside reverse transcriptase (nevirapine) 
and 2 nucleoside reverse transcriptase inhibitors (lamivudine and zidovudine).  Artemether-
lumefantrine is the first line treatment for uncomplicated malaria. There are no published 
data on the possible drug-drug interactions of these commonly used antiretroviral drugs 
and the antimalarial regimens in use in our study area. 
 
The study was designed to investigate any associations at enrolment between drug 
resistant P. falciparum and the use of medication for either HIV treatment or prevention of 
opportunistic infections with particular reference to the use of TS prophylaxis. Additionally, 
the study was to evaluate the use of AL in the environment of Port Harcourt, Niger Delta 
among HIV co-infected individuals, assess the possible drug-drug interactions between the 
ARVs and antimalarials as well as survey the possible differences in the molecular markers 
of resistance between the two groups. 
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7.3 Summary of results 
7.3.1 Demographic and field results 
Data collected from the questionnaires described socio-economic and socio-cultural factors 
such as age, sex, occupation, marital status and education that affect the spread and 
prevalence of HIV. In consonance with previous studies, the present study observed the 
relationship between sex, marital status, age and education and HIV status. Analysis of the 
questionnaire data revealed that our HIV-subjects consisted mainly of females, married 
people, traders, those with secondary education and people in the age range of 30-39. 
The study is the first from our study area to assess CD4 cell count among HIV-positive 
participants treated for malaria. We were able to demonstrate that treatment of 
asymptomatic-P. falciparum malaria infection improved the CD4 cell count in 38/56 HIV-
positive participants who had paired peripheral CD4 cell counts for days 0 and 28. There is 
need for further detailed study of the impact of treatment of confirmed asymptomatic-P. 
falciparum malaria infection on CD4, since our study over-diagnosed malaria infection by a 
significant amount. 
Three different diagnostic methods for identifying parasitaemia positive samples were 
employed. Results show that microscopy and RDT methods were very poor for correct 
diagnosis in our study site, and the most reliable was post hoc PCR. Hence our statistical 
analysis was based on PCR results, but was hampered by inappropriate recruitment of 
volunteers lacking detectable P. falciparum infection, leading to loss of statistical power in 
the analysis. Correct malaria diagnosis is critical for proper recruitment and enrolment of 
study participants, and future studies need to overcome this obstacle.  
7.3.2 Pharmacokinetic studies 
Results of our pharmacokinetic study show elevated plasma levels of day7 lumefantrine 
concentration in nevirapine–treated HIV-positive patients and corroborates the finding of 
Kredo et al, (2011) in a study among HIV-positive volunteers in South Africa who were 
administered AL. This suggests a possible drug-drug interaction between lumefantrine and 
nevirapine. Although our HIV-positive patients had higher lumefantrine levels, we found no 
evidence of a parasitological benefit of higher plasma levels of lumefantrine. In fact, we 
provided weak evidence that HIV-positive patients are slower to clear sub-patent infections 
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after AL treatment. This indicates a possible perturbation of the immune system of the 
patients.  
Another factor that has been reported to influence variability in individual drug response 
and drug disposition is genetic polymorphism of the host (Owen, 2006; Owen et al, 2006). 
Other studies (Stohr et al, 2008; Mahungu et al, 2009b) report that plasma concentrations 
of nevirapine were influenced by ethnicity in addition to weight, gender and underlying 
hepatic diseases. These factors are closely related to the immune system of the host. Our 
study participants were all of African ethnicity, but specific tribal groupings and individual 
weights were not taken into consideration in the analysis. It is possible that these factors 
may have affected the disposition and response of nevirapine such that an unexpected 
elevation of lumefantrine occurred. In a study of drug-drug interactions in selected ARV 
combinations on the pharmacokinetics of maraviroc, Pozniak et al, (2008) reported a 1.5 
fold increase of maraviroc in the nevirapine containing regimen. This report is contrary to 
the expected inducing action of nevirapine.  
Another possible reason for the failure to clear the parasites despite the apparent 
increased lumefantrine concentration could be due to a possible reduced exposure of 
artemether and DHA as established in a recent Ugandan study (Byakika-Kibwika et al., 
2012). Artemether and DHA exert their pharmacological properties in the first 48hours of 
treatment to clear the parasite biomass leaving behind the residual parasites to the longer 
acting partner drug lumefantrine (Ezzet et al., 1998, Djimdé and Lefèvre, 2009). The study 
did not include the measurement of artemether and dihydroartemisinin levels. The 
knowledge of these values may provide more information on parasite clearance. We 
therefore advocate further studies that will include more detailed pharmacokinetic study 
that will incorporate the measurements of artemether and DHA.  
The inability of the elevated lumefantrine concentration to provide additional 
parasitological benefit could also mean that a possible plateau of the lumefantrine 
concentration has been reached beyond which there would be no increase in effecting 
parasite clearance. However, the study also revealed persistence of sub-patent parasites 
even among treated volunteers in the HIV-negative control group. This is similar to the 
report by Dinko et al, (2013) on Ghanaian children who retained sub-patent parasites after 
treatment of asymptomatic-malaria infection with the ACT dihydroartemisinin - 
piperaquine implying that in chronic low grade malaria infection the immune system may 
be compromised.  
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The proportion of volunteers displaying complete PCR-detectable parasite clearance at day 
28 based on PCR positives at day 0 was 74% (104/144). This is in contrast to previous 
reports of 93.9% successful clearance by microscopy (Falade et al., 2005). However it must 
be noted that Falade’s study was carried out among children with symptomatic P. 
falciparum malaria infection and at the early period of adoption of AL as first-line 
treatment in Nigeria, at which time parasite susceptibility will have been very high. The 
current thesis describes a preliminary study involving AL use and parasite clearance in HIV-
positive persons and there were many confounding factors to the result especially with 
regards to poor microscopy, and missing data on follow-up days.  
Asymptomatic malaria parasitaemia carriage is prevalent in sub-Saharan Africa (Bottius et 
al., 1996, Smith et al., 1994) and carriers remain infective longer than the treated 
symptomatic patients, and thus serve as good reservoirs for further transmission of malaria 
parasites (Alves et al., 2005, Zoghi et al., 2012). There is an urgent need for studies 
involving asymptomatic-P. falciparum infection carriers, who may represent an obstacle to 
proper malaria control. We also propose that future studies should extend follow-up to 42 
days, since studies have reported recrudescence of recurrent parasitaemia after 42days 
(Yeka et al., 2008).  
We therefore advocate a detailed kinetic study with a larger sample size involving both 
symptomatic and asymptomatic malaria infected persons in addition to measuring parasite 
clearance time so that adequate comparisons can be made. There is also need to measure 
the level of the metabolite desbutyl-lumefantrine which has been shown to possess a 
higher antimalarial activity than the parent compound in vitro (Wong et al, 2011). This is 
the first such study of ARV antimalarial interactions in malaria–infected individuals.  
Although we were not able to ascertain by our PCR method whether the remaining 
parasites not cleared by AL were asexual stage parasites or gametocytes, the presence of 
either is important in malaria control since asexual parasites are responsible for the clinical 
symptoms while the gametocytes are involved in transmission. Also we were not able to 
distinguish between new infections and recrudescence. Further expanded studies in the 
area will involve this aspect of research. 
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7.3.3 Molecular markers of genes associated with Artemether-lumefantrine 
An important observation from the result of our study is the strong selection of the 
mdr86N allele among our study samples which was also evident in the HIV-positive arm 
alone. This allele has been suggested as a first step to lumefantrine tolerance and its 
selection as a strong indicator of AL treatment failure or slow clearance (Sisowath et al., 
2005, Humphreys et al., 2007, Mwai et al., 2009). This therefore calls for a close monitoring 
of this allele in order to monitor the efficacy of AL in the area. The accompanying haplotype 
NFD equally associated with slow clearance to AL was found to have a slight selection at 
day 28 and was more prevalent in HIV-positive patients however the haplotype NYD had a 
higher prevalence in the overall population. There is need for close monitoring of AL use 
especially following the report of the NFD haplotype in South-Western Nigeria among 
children (Happi et al, 2009). 
 
The crt76T mutant allele implicated in chloroquine resistance was found to be in very high 
prevalence in our study area despite the official withdrawal of chloroquine indicating that 
its use may still be common in the environment. This was also seen from the field 
observations in the self-reported use of antimalarial drug among participants. This allele 
seems to exhibit an inverse relationship with AL efficacy because it is usually found in areas 
of AL efficacy (Sutherland et al., 2011, Raman et al., 2011) while the wild type allele crt76K 
has been implicated in recurrent infections following AL treatment (Sisowath et al., 2009). 
Future studies of ARV-antimalarial interactions in this area should also measure the 
prevalence of detectable chloroquine in peripheral blood samples taken at enrolment. 
         
 The recent study in Tanzania (Malmberg et al., 2013b) established an inverse relationship 
between day 7 lumefantrine concentration and the NFD haplotype, stating that samples 
with the NFD haplotype had lower levels of lumefantrine concentrations and were able to 
withstand estimated lumefantrine concentration 15-fold higher than those with YYY 
haplotype. We were not able to associate the 86N polymorphism nor the NFD haplotype 
with lumefantrine concentration because parasite genotyping was not carried out at the 
time of drug measurement (day 7), however we advocate that further studies should 
incorporate the evaluation of this relationship. Since pfmdr1 and pfcrt genes are both 
involved in modulation of resistance in P. falciparum malaria, routine and close monitoring 
of these molecular markers is critical in order to preserve and sustain the efficacy of ACTs. 
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Three new polymorphisms which have not been previously reported were detected in 
three of our study samples in addition to the rare mdr86F reported in Swaziland (Dlamini et 
al., 2010). It is of interest that these new mutations were all found among HIV-negative 
participants. The implications of these mutations are not clear but may indicate 
polymorphic drug pressure on this gene by the various drugs being taken in the 
environment. Data from our questionnaire show that AL is the third most commonly used 
drug by the participants, albeit without prescription. This calls for urgent actions to be 
taken with regards to enforcing the policies of antimalarial drug use in the country, 
including appropriate diagnosis. 
 
7.3.4 Relationship of polymorphisms with antifolate markers. 
 
The results of our study showed no difference in the prevalence of molecular markers 
related to antifolate drugs between the HIV-positive and HIV-negative control group. This 
does not support our former hypothesis that HIV-positive people may harbour parasites 
different from their HIV-negative counterparts because of the drugs they take, in particular 
TS. This observation is similar to the results observed from the study among HIV-infected 
and HIV-uninfected women taking SP for IPTp in Uganda and Zimbabwe and HIV-infected 
women taking TS for prophylaxis (Newman et al., 2009).  
Analysis of our trimethoprim-sulphamethoxazole (TS) showed weak evidence of a 
relationship between dhps437A and TS use. This result is of interest and requires further 
studies employing larger sample size, in addition to optimisation of the sampling protocol 
and method for the recovery of trimethoprim and sulphamethoxazole from field samples. 
This study is a first attempt of this assay, which was not available at the time we designed 
the study protocol, and the data are thus preliminary. The presence of a single case of the 
rare dhps436F from a HIV-positive participant is of interest since to our knowledge there 
has been no previous report of this mutation in Nigeria.  
A result of importance from our results is the absence of dhps K540E in the small sample 
sized-population studied.  The K540E is very relevant in the decision of continuous use of 
SP for intermittent treatment of malaria. The study data thus suggest that SP use is not 
under threat yet in the study area, however there should be a close monitoring of the use 
since there has been a previous report of this mutation among children in western Nigeria 
(Happi et al, 2005) and in nearby Ghana (Sutherland et al, 2009). Another important 
discovery from our study is the absence of dhfr I164L mutation in our samples. This 
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mutation has been associated with resistance to proguanil and is also implicated in SP 
resistance because of the pyrimethamine content in SP (Ochong et al., 2008, 
Andriantsoanirina et al., 2011). Its absence in conjunction with the absence of dhps K540E 
gives credibility to the continued use of SP for IPT in our environment, with the caveat that 
larger surveys are needed to confirm the absence of these two alleles. 
The findings of this study therefore will serve as additional information to the limited data 
available on the use of AL in Nigerian adults and provides a template for sample size 
calculation for future larger studies. More studies involving children and pregnant women 
in multiple sites are needed in order to confirm the findings from the study especially since 
there is no published report of AL use, molecular markers associated with it and drug-drug 
interactions between antimalarials and ARVs in the Niger Delta region. There is also need 
for in vitro sensitivity assays of antimalarial drugs in use for prophylaxis and treatment 
especially the ACTs. 
7.4 Summary of findings 
This is a preliminary study and first of its kind to investigate drug-drug interactions between 
ARVs and the antimalarial drug AL in HIV-positive patients co-infected with P. falciparum. 
We were able to also provide a limited analysis in relation to parasite clearance. We 
present the first attempt to assay the presence of trimethoprim and sulphamethoxazole 
from blood spots on filter papers collected from individuals treated for malaria. The results 
of the study could be summarised as follows: 
 Day 7 peripheral blood levels of lumefantine were significantly higher in nevirapine-
treated people. 
 There was no evidence of a parasitological benefit of the higher blood levels of 
lumefantrine  
 Overall parasite clearance on day 28 after administration of AL was 74.3% (107/144). 
HIV-positive persons had a lower parasite clearance (OR:2.86: P=0.007) 
 Strong selection of mdr86N at day3 after treatment with AL 
 Weak evidence of selection of NFD haplotype at day 28 
 Absence of mutation at codons 1034 and 1042 on the mdr gene 
 High prevalence of crt76T in the study area, especially in the HIV-group 
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 Absence of dhps 540E and dhfr 164L 
 A single isolate with the dhps 436F allele. 
 No difference in the prevalence of antifolate markers between the HIV-positive and 
HIV-negative group. 
 Presence of new mutations on the mdr1 gene and the dhps gene. 
 Artemether-lumefantrine treatment improved CD4+ counts in HIV-positive people with 
and without PCR-positive parasitaemia. 
7.5 Limitations to the study 
As previously mentioned in chapter 3, the major weakness of our study was the poor 
quality of enrolment microscopic diagnosis, such that the study was under-powered 
because of a very small sample size. Prior to the study, there was unavailability of data to 
be used as a framework for sample size calculation. Other factors include many industrial 
strikes  by hospital staff during sample collection, frequent power outages leading to poor 
storage and even loss of some collected samples, frequent breakdown of machines and 
equipment used for sample analysis and transportation difficulties for both study 
participants and our team of workers thereby impinging on our follow-up studies.  
Notwithstanding the limitations, the work has provided a template for future larger studies 
of AL use and the malaria/HIV interactions in the environment.  
 
7.6 Conclusions and Recommendations 
 
According to the summary proceedings from the 3rd Annual malaria control programme 
review of Ethiopia and Nigeria (2012), the major challenges to malaria control in Nigeria 
include insufficient baseline on malaria prevalence, weak national surveillance system, 
limited availability of ACTs and RDTs, microscopy for malaria diagnosis and high rates of 
treatment seeking in the private sector (pharmacies, drug vendors, shops). In order to win 
the war of malaria control in Nigeria, these key factors must be addressed. The limitations 
to our study with regards to poor microscopy, and thus incompleteness of data, have 
emphasised this need. The strong selection of the mdr86N on day 3 after treatment with AL 
and the slight selection of NFD haplotype both of which have been implicated in AL 
treatment failure and slow clearance have shown that there is obvious threat on the 
efficacy of AL in the study area. There is therefore urgent need for active surveillance 
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studies to be carried out especially for molecular markers of ACTs and other drugs of 
relevance in the control of malaria in Nigeria, particularly in the Niger Delta where there is 
paucity of published data on malaria studies. 
Observation from field work has revealed that malaria treatment in Nigeria is mostly done 
without confirmatory laboratory diagnosis and there are also high rates of treatment 
seeking in the private sector as mentioned previously. This contributes to the misuse and 
poor administration of antimalarial drug thereby increasing the possibility of increased 
drug resistance and drug-drug interactions. There was no co-ordinated effort between the 
health workers with regards to research into antimalarial drug resistance and surveillance 
of molecular markers related to the drugs. The present study can provide a good platform 
for the initiating of a properly organised research team with particular reference to active 
monitoring and surveillance of molecular markers especially to the ACTs and SP so as to 
sustain or prolong their use in the area and advise policy where need may arise for change 
in policy. The platform should also incorporate the malaria/HIV interaction studies with 
special emphasis on the potential drug-drug interactions considering the very high 
prevalence of HIV in the environment.  
 
There is need to invest in machineries that will encourage proper diagnosis such as the 
Loop-mediated Amplification kit (LAMP) which have been proven to show greater accuracy 
over microscopy and requires minimal training in addition to requiring less time compared 
to PCR and is equally cheaper (Polley et al., 2013) or where not applicable proper training 
and external quality assurance for microscopy and use of RDT before treatment. There is 
also need for community health education for improved and efficient health services.  
 
Review of the literature has revealed that many studies on antimalarial drug resistance in 
Nigeria were carried out in the western part of the country, close to the major urban 
centres. This may not represent a true picture of the situation in the entire country. The 
high level of migration in the Niger Delta as a result of the large deposit of the natural 
resource of oil and gas in the area and the strategic position of Nigeria in the global map of 
both HIV and malaria therefore calls for investment on increased and expanded study in 
multiple sites in order to achieve the millennial development goal of malaria elimination. 
Every effort to improve malaria control in this area will be beneficial globally.  
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Annexe 4. Information sheet 
A study of the efficacy of 
Coartem in the clearance of 
malaria infections in HIV-
positive and HIV-negative 
Nigerian adults
This study is  in collaboration with
The London School of Hygiene and 
Tropical Medicine, London.
Pharm(Mrs). Ify Chijioke-Nwauche
0802 323 5061
Dr. C. A . Nwauche
0802 314 8155
If you agree to take part in the study, you will be 
asked to give a small blood sample from your arm 
today, 3rd day and 4 weeks after today to monitor 
your progress. We will also take few drops of 
blood from your finger today, tomorrow and 2 
days after today to ensure that the drug is 
clearing the parasite.  The diagnosis will be made 
by a quick dipstick method and confirmed by 
microscopical examination. Some of the blood 
will be put on a special type of paper to find out if 
the parasites show signs of resistance. We will tell 
you the result of the test. If tested positive, you 
will be treated with Coartem. 
Do I have to take part?
No.  You do not have to take part and you can 
withdraw  anytime if you do not want to take the drug.
Will the study bring me any discomfort?
You will have some discomfort for a short time when 
blood will be collected but it will not last long.  
We will also test for HIV using a standard HIV kit.
How will I benefit from the study?
You will get free treatment of the malaria now or any 
other episode within the study period of 2-3 months. 
Your participation will also help us  to find out  if 
parasites in Port Harcourt are resistant in future to 
Coartem.
Malaria is an important illness caused by 
Plasmodium transmitted through the bite 
of female anopheles mosquito.
Patients with malaria in our country are 
treated first with the antimalarial drug 
“Coartem”.
However if the malaria parasite becomes 
resistant to the drug, there is a chance the 
treatment may not work well. 
Therefore it is important to know when 
this may start happening so we can give 
you a different treatment.
The possibility of resistance may be 
investigated using certain techniques and 
requires small amount of blood.
What will be done during the study?
Malaria is an important illness caused 
by Plasmodium transmitted through 
the bite of female anopheles mosquito.
Patients with malaria in our country 
are treated first with the antimalarial
drug “Coartem”.
However if the malaria parasite 
becomes resistant to the drug, there is 
a chance the treatment may not work 
well. 
Therefore it is important to know when 
this may start happening so we can give 
you a different treatment.
The possibility of resistance may be 
investigated using certain techniques 
and requires small amount of blood.
Introduction:
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Annexe 5. Consent form 
MALARIA CHEMOTHERAPY  STUDY                                                   CONSENT FORM 
 
Efficacy of Artemether-Lumefantrine (AL) In the Clearance of Malaria infections in HIV-
positive and HIV-negative Nigerian adults. 
 
 
Name: --------------------------------Study ID: ----------------
Phone Num: ------------------   
                                                                                          
House Address: -------------------------------------------------  
 
“I have understood the verbal explanation concerning this study and I understand what will be 
required of me and what will happen to me if I take part in it” 
 
“My questions concerning the study have been answered. 
 
“I understand that at any time I may withdraw from this study anytime I want without affecting 
my normal care” 
 
“I agree to take part in this study” 
 
----------------------------------------------------------------------------------------------------------------- 
Name/signature of Patient                   Date    
  
 
 
---------------------------------------------------------------------------------------------------------------------
Witness’s signature         Date 
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Annexe 6. Questionnaire for HIV-positive participants 
Malaria Chemotherapy: HIV-positive group questionnaire 
The Efficacy of Artemether-Lumefantrine (AL) In the Clearance of Malaria 
infections in HIV-positive and HIV-negative Nigerian adults. 
 
Study ID:      _______________                                                                                                               
Wt:                 _______________   
 
Ht:                   _______________    
 
Date of Birth: ______________                                     
 
Please enter the appropriate number in the boxes 
  
 Gender:  Male (1); Female (2)                                                                                                    
 
 Religion: Christianity (1); Muslim (2); Traditional religion (3); others (4)                          
 
Marital status: married/single/ divorced /widowed                                                            
Level of education: Primary (1); secondary (2); tertiary (3)                                                 
 
Occupation: Snr. Civil servant (1); Jnr civil servant (2); Trader (3); Business                          
man/woman (4); Teacher  (5); Housewife (6); Oil worker (7); Student (8); Others (9). 
Spouse’ occupation: Snr. Civil servant (1); Jnr civil servant (2); Trader (3); Business 
man/woman (4); Teacher (5) Housewife (6); Oil worker (7); Student (8); Others (9). 
When did you fall ill?  
< 3 months (1); 3-6 months (2); 6 months-1 yr (3); > 1 year (4)                                          
 
When did you seek medical help?  
< 3 months (1); 3-6 months (2); 6 months-1 yr (3); > 1 year (4)                                          
When did you register in the HIV clinic?  
< 3 months (1); 3-6 months (2); 6 months-1 yr (3); > 1 year (4)                                                                              
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How many family members are aware of your condition?  
All (1); father (2); mother (3); spouse (4) children (5); siblings (6); None (7)                                                                                                                                                                 
How long have you taken the ARV drugs? 
> 6mths (1); 6mths-1yr (2); 1yr-2yrs (3); > 2yrs (4)                                                                  
                                                              
What medicines have you taken in the last 3 months? 
Medicine Name Start Date Still taking 
CQ   
Camoquine   
Fansidar   
Metakelfin   
Maloxine   
Artesunate   
Coartem   
Lonart   
Paracetamol   
Septrin   
Zidovudine   
Lamivudine   
Stavudine   
Nevirapine   
Efavirenz   
 
Please write any other medication and the reason for taking it  
____________________________________________________________________ 
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Please enter the appropriate number in the boxes:  1=yes; 2=no 
Have you been taking your Septrin regularly?                                                                        
How often do you have malaria?                                                                                             
 Monthly (1); once in 3 months (2); once in 6 months (3); once a year (4); rarely (5)     
 Do you have any symptoms now?                                                                                                                                      
Do you use 
Insecticide                                                                                                                                           
Insecticide treated net                                                                                                                    
Mosquito repellent                                                                                                                        
 Mosquito coil                                                                                                                       
Window netting in your house                                                                                                         
Is there any child in the house that has malaria now?                                                             
 
Thank you for answering the questions 
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Annexe 7. Questionnaire for HIV-Negative participants (Control group) 
Malaria Chemotherapy: HIV-negative group questionnaire 
The Efficacy of Artemether-Lumefantrine (AL) In the Clearance of Malaria 
infections in HIV-positive and HIV-negative Nigerian adults.  
 
Study ID:              __________________                                                                                                               
Wt:                          _________________   
Ht:                            _________________   
Date of Birth:         _________________                                     
Please enter the appropriate number in the boxes 
  Gender:  Male (1); Female (2)                                                                                                   
 Religion: Christianity (1); Muslim (2); Traditional religion (3); others (4)                                
Marital status: married/single/ divorced /widowed                                                                  
Level of education: Primary (1); secondary (2); tertiary (3)                                                         
Occupation: Snr. Civil servant (1); Jnr civil servant (2); Trader (3); Business 
man/woman (4); Teacher  (5); Housewife (6); Oil worker (7); Student (8); Others (9). 
Spouse’ occupation: Snr. Civil servant (1); Jnr civil servant (2); Trader (3); Business 
man/woman (4); Teacher (5) Housewife (6); Oil worker (7); Student (8); Others (9). 
How often do you have malaria? 
 Monthly (1); once in 3 months (2); once in 6 months (3); once a year (4)                           
Please enter the appropriate number in the boxes:  1=yes; 2=no 
Do you have symptoms now?                                                                                                         
Do you useInsecticide                                                                                                                         
Insecticide treated net                                                                                                                  
Mosquito repellent                                                                                                                       
 Mosquito coil                                                                                                                             
Window netting in your house                                                                                                         
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Is there any child in the house that has malaria now?  
What medicines have you taken in the last 3 months? 
Medicine Name Start Date Still taking 
CQ   
Camoquine   
Fansidar   
Metakelfin   
Maloxine   
Artesunate   
Coartem   
Lonart   
Paracetamol   
Septrin   
 
Please write any other medication and the reason for taking it  
____________________________________________________________________ 
 
Thank you for answering the questions 
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Annexe 8. Published paper  
Ifeyinwa Chijioke-Nwauche, Albert van Wyk, Chijioke Nwauche, Khalid B. Beshir, 
Harparkash Kaur, Colin J. Sutherland 
HIV-Positive Nigerian Adults Harbor Significantly Higher Serum Lumefantrine Levels than 
HIV-Negative Individuals Seven Days after Treatment for Plasmodium falciparum Infection 
Antimicrobial Agents and Chemotherapy p. 4146–4150 
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HIV-Positive Nigerian Adults Harbor Significantly Higher Serum
Lumefantrine Levels than HIV-Negative Individuals Seven Days after
Treatment for Plasmodium falciparum Infection
Ifeyinwa Chijioke-Nwauche,a,b Albert van Wyk,e Chijioke Nwauche,c,d Khalid B. Beshir,b Harparkash Kaur,e Colin J. Sutherlandb
Department of Clinical Pharmacy and Management, Faculty of Pharmaceutical Sciences, University of Port Harcourt, Rivers State, Nigeriaa; Department of Immunology
and Infection, Faculty of Infectious and Tropical Diseases, LSHTM, London, United Kingdomb; Department of Haematology, Blood Transfusion and Immunology, College
of Health Sciences, University of Port Harcourt, Rivers State, Nigeriac; Centre for Malaria Research & Phytomedicine, University of Port Harcourt, Rivers State, Nigeriad;
Department of Disease Control, Faculty of Infectious and Tropical Diseases, LSHTM, London, United Kingdome
Management of coinfection with malaria and HIV is a major challenge to public health in developing countries, and yet potential
drug-drug interactions between antimalarial and antiviral regimens have not been adequately investigated in people with both
infections. Each of the constituent components of artemether-lumefantrine, the first-line regimen for malaria treatment in Nige-
ria, and nevirapine, a major component of highly active antiretroviral therapy, are drugs metabolized by the cytochrome P450
3A4 isoenzyme system, which is also known to be induced by nevirapine. We examined potential interactions between lumefan-
trine and nevirapine in 68 HIV-positive adults, all of whom were diagnosed with asymptomatic Plasmodium falciparum infec-
tions by microscopy. Post hoc PCR analysis confirmed the presence of P. falciparum in only a minority of participants. Day 7
capillary blood levels of lumefantrine were significantly higher in HIV-positive participants than in 99 HIV-negative controls
(P 0.0011). Associations between day 7 levels of lumefantrine and risk of persistent parasitemia could not be evaluated due to
inadequate power. Further investigations of the impact of nevirapine on in vivomalaria treatment outcomes in HIV-infected
patients are thus needed.
Malaria and HIV are two of the most important health prob-lems facing developing countries and are among the most
common infections in sub-Saharan Africa. HIV coinfection is
thought to contribute to 3million additionalmalaria cases, higher
malaria parasite densities in immunosuppressed children, and a
5% greater mortality rate (1, 2). HIV also increases the risk of
Plasmodium falciparum infection progressing to clinical malaria
in adults, especially in those with advanced immunosuppression,
by eroding the efficacy of acquired immunity (3). The choice of
antimalarial drug for the treatment of HIV patients therefore is of
utmost importance considering the dangers of comorbidity, but
sufficient pharmacokinetic and parasitological evidence to make
this choice is currently lacking.
Combination therapies in current use for malaria in Africa
comprise a derivative of the artemisinin family of drugs com-
bined with at least one nonartemisinin partner drug. The most
widely used such combination is artemether plus lumefantrine
(coartemether; AL). Artemether is metabolized in the liver by
the isoenzyme CYP3A4, to its active metabolite dihydroartemis-
inin (DHA), with peak plasma concentration being reached
around 2 to 3 h after oral administration (4); elimination half-life
is estimated at approximately 1 h. There is thus only limited op-
portunity for DHA to participate in drug-drug interactions. Lu-
mefantrine is partiallymetabolized to desbutyl-lumefantrine, pre-
dominantly through CYP3A4, reaching peak plasma levels
approximately 10 h after oral administration, and is then cleared
slowly, showing a terminal half-life of 4 to 6 days in P. falciparum
malaria cases (5–9).Oral bioavailability of lumefantrine is variable
and highly dependent on administration with fatty foods (5, 9,
10).
The antiretroviral drug nevirapine (NVP) is a nonnucleoside
reverse transcriptase inhibitor that is well absorbed after oral ad-
ministration with90% bioavailability, generally achieved about
4 h after oral dosing, and has a long half-life (11). NVP is exten-
sively metabolized by the same CYP3A4 isoform as artemether
and lumefantrine and is also known to upregulate the isoenzyme
(12, 13). Thus, NVP autoinduces its own metabolism and poten-
tially that of any other drugs metabolized through this route. This
raises the possibility of significant drug-drug interactions of NVP
with lumefantrine and other antimalarials (1). Kredo and col-
leagues (6) initiated a pharmacokinetic study in 18 South African
volunteers that were HIV infected and receiving NVP therapy,
compared to 18 naive controls, each of whom took a full adult
course of AL; none of the study subjects were infected with Plas-
modium sp. This study found differences between NVP recipients
and controls in several pharmacokinetic parameters for lumefan-
trine, themost important of which was a significantly higher day 7
lumefantrine concentration in the NVP group. These authors
concluded that further studies of drug-drug interactions between
NVP and lumefantrine were urgently needed in malaria-infected
subjects.
Artemether-lumefantrine, which is currently the recom-
mended therapy for malaria treatment, was introduced in Nigeria
in 2005 as the first-line regimen for uncomplicatedmalaria. Rivers
State, in the Niger Delta area of southern Nigeria, has a high prev-
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Copyright © 2013, American Society for Microbiology. All Rights Reserved.
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alence of HIV infection (7.4% of the population), and malaria
transmission is hyperendemic. The study was designed to address
the lack of data regarding the pharmacokinetics of AL among
HIV-positive subjects in this setting, where asymptomatic parasite
carriage is common. We hypothesized that following treatment
with AL for concomitant P. falciparum infections, day 7 blood
concentrations of lumefantrine in HIV-positive individuals on
NVP therapy would differ from those in HIV-negative individu-
als. Any such difference may also have a measurable impact on
parasite clearance in treated asymptomatic individuals, as day 7
lumefantrine concentration is known to be an important determi-
nant of antimalarial efficacy in individuals with symptomatic ma-
laria (4).
MATERIALS AND METHODS
Study area. The study was carried out at the University of Port Harcourt
Teaching Hospital and the Braithwaite Memorial Specialist Hospital Port
Harcourt, Nigeria, from September 2010 to May 2011. Port Harcourt is
the capital of Rivers State in the Niger Delta, rich in the nation’s oil re-
sources. The region is dotted with oil and gas activities which attract an
international workforce, and commercial sex workers follow the camp
(14). These socioeconomic conditions contribute to a high estimated
population prevalence of HIV infection of 7.4% (15). Malaria is holoen-
demic in Nigeria, with transmission all year round, but malaria cases are
most common during the rainy season, from April to September, with
peaks of rain and intense transmission between May and July. Annual
rainfall averages more than 3,550 mm in the region.
Patients and samples. This paper describes an exploratory pharma-
cokinetic study with a simple unmatched case-control design, ancillary to
a study designed to track molecular markers of drug resistance in HIV-
infected individuals, using active detection of P. falciparum infection fol-
lowed by treatment with AL, which is the regimen recommended by the
University of Port Harcourt Teaching Hospital guidelines for uncompli-
catedmalaria in adults. The work was conducted from September 2010 to
May 2011. The main endpoints of the current analysis were day 7 periph-
eral blood lumefantrine levels and parasite carriage at day 3 and day 28
posttreatment. The primary endpoint for which the study was designed
and powered was carriage of parasite genetic markers of antimalarial re-
sistance. This analysis is ongoing and will be reported elsewhere.
Participants were recruited if theymet the following eligibility criteria:
16 to 65 years of age, willingness to have HIV status confirmed from
clinical records or by a point-of-care test, P. falciparum positive bymicro-
scopic examination of a blood film, and provision of a signed informed
consent form. HIV-positive patients were recruited from the HIV adult
clinic of both hospitals. HIV-negative participants were recruited from
the hospital communities, including staff and students. HIV-negative pa-
tients were screened and confirmed virus negative with the use of the HIV
Determine point-of-care test (Alere Medical Co., Ltd., Matshuhidai-shi,
Chiba, Japan). Each was then screened for malaria by standard micros-
copy. Permission for the study was obtained from the Research Ethics
Committees of the University of Port Harcourt Teaching Hospital, the
Braithwaite Memorial Specialist Hospital, and the London School of Hy-
giene and Tropical Medicine, London, United Kingdom.
Enrolled patients were treated with AL (Coartem; Novartis Pharma,
Nigeria) according to the manufacturer’s dosing regimen: 4 tablets twice
daily for 3 days for persons with a weight of35 kg. Patients were advised
to eat before taking the tablets. Most of the patients took their first dose at
the site, having been preinformed to eat before coming. Patients were
followed up till day 28. On day 7, capillary blood samples were taken from
a finger prick.
For drugmeasurements, 100l of blood wasmeasured using a pipette
and dropped on a filter paper (glass microfiber paper; Fisherbrand
FB59431) pretreated with 0.75 M tartaric acid (Fisher Scientific). The
papers were allowed to air dry and were then stored in individual pouches
with a silica desiccant to absorb moisture. The preserved papers were
transferred to the London School of Hygiene and Tropical Medicine. Fil-
ter paper-adsorbed blood samples were analyzed for lumefantrine using
liquid chromatography mass spectrometry (LCMS; Thermo Finnigan
LCQ instrument) by following a modified protocol based on previously
published methods (16). Briefly, bloodspots were extracted in methanol-
water (4:1; 350 l), and the extracts were filtered through a cotton wool
plug. Each sample (20 l) was separated on a Dionex Acclaim 120 3-m
C18 column (4.6 by 150 mm, with 120-Å pore size, fitted with a guard
column) and eluted with ammonium formate (20 mM, pH 2.7) and
methanol (vol/vol; 85:15) isocratically at a flow rate of 500 l/min. The
column temperature wasmaintained at 35°C. The electrospray ionization
(ESI) sourcewas operated in positivemodewith the capillary temperature
set to 350°C and sheath and auxiliary gas (nitrogen) flow rates of 60 and 20
arbitrary units, respectively. Peak identity was confirmed by using blood
spiked with lumefantrine standards (0 to 30 g/ml), adsorbed onto filter
paper, and extracted in the same manner as the patient samples. Quanti-
tation was performed using selective ion monitoring for the transition of
m/z 530 to 512. The lower limit of detection was determined to be 0.1
g/ml, the lower limit of quantification was 1.0 g/ml, and the upper
limit of quantification was 20.0 g/ml.
Plasmodium falciparumDNAwas prepared from dried spots (10 to 20
l) onWhatman paper as previously described (17), and codons 24 to 201
of the pfmdr1 locus were amplified by nested PCR (18). Relative quanti-
fication of parasite DNA was performed by an established quantitative
PCR (qPCR) method, as previously described (19).
Data were entered into spreadsheets and analyzed in STATA 11 (Stata
Corp., Madison WI). Continuous data were compared between groups
using Wilcoxon’s rank sum test, while categorical comparisons in 2-by-2
format were performed using the 2 distribution.
RESULTS
Out of 80 attendees at the two HIV clinics who agreed to have a
malaria film read, 68 were identified as positive for P. falciparum
and returned for day 7 follow-up (85%).None of these individuals
reported concurrent symptoms suggestive of clinical malaria. A
total of 126 individuals agreed to have a rapidHIV test performed,
of which 99were found to be negative forHIV-specific antibodies,
were identified as infectedwithP. falciparum, and attended for day
7 follow-up (79%); none of these individuals were symptomatic.
These 167 participants were treated with a full adult course of AL
and followed up on days 3, 7, and 28 for repeat blood sampling.
To confirmmicroscopic diagnosis of P. falciparum parasitemia
at enrollment, nested PCR amplification of the amino-terminal
fragment of the pfmdr1 gene was carried out on DNA extracted
from the first blood sample taken from each participant. Nested
PCRwas also performed onDNA extracted from all day 3 and day
28 filter paper blood samples. Unexpectedly, a high proportion of
enrollees (78.1%) were found to be aparasitemic by nested PCR,
suggesting poor specificity of the original microscopic diagnosis
(Table 1). There was a strong association between PCR positivity
at day 0 and day 3 (odds ratio [OR], 5.56; 95% confidence interval
[CI], 1.76 to 17.32; P 0.0004), suggesting good reproducibility
of parasite detection for the PCR method, in contrast to results
obtained with microscopy.
Using the PCR data as a more reliable test for parasite carriage,
we found weak evidence that HIV-positive people were more
likely to be parasitemic at day 0 (OR, 2.05; 95% CI, 0.917 to 4.60;
P 0.054), which may reflect slightly higher parasite densities in
this group and thus a greater likelihoodof parasites being correctly
identified by the screening microscopists. HIV-positive subjects
were not significantly more likely to be PCR positive for P. falcip-
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arum at day 3 and/or day 28 after AL treatment than were HIV-
negative individuals (OR, 1.75; 95% CI, 0.776 to 3.95; P 0.141).
Both HIV status and lumefantrine concentration at day 7 were
recorded for all 167 individuals. We examined the distribution of
lumefantrine concentration at day 7 in all study participants and
found highly significant departure from normality (z score 
7.581, P  0.0001), which remained after (natural) logarithmic
transformation (z 5.372,P 0.0001). In an exploratory analysis
following the methods of Kredo et al. (6), we removed as outliers
5 samples with extremely low measured lumefantrine concentra-
tions (0, 0, 0.01, 0.08, 0.08M, all in theHIV-negative group) and
log transformed as described above. Departure from the normal
distribution was then marginally nonsignificant (z  1.594, P 
0.054). After consideration of these findings, we decided to take
the conservative approach of using only nonparametric methods
for testing statistical significance of comparisons and retained all
data in the analysis.
HIV status, and thus nevirapine use, was found to have a sig-
nificant effect on the concentration of lumefantrine 7 days after
treatment (Wilcoxon rank sum test z3.270, P 0.0011), with
a median concentration in the HIV-negative group of 2.75 M
(interquartile range [IQR], 1.03 to 4.31) and in the HIV-positive
group of 3.55 M (IQR, 2.07 to 5.37) (Fig. 1). However, the 5
individuals with extremely low lumefantrine readings (identified
in the previous paragraph) were all in the HIV-negative group, so
to test for possible bias caused by this group, we performed the
comparison with these 5 measurements removed. In this explor-
atory analysis, a significant association remained between HIV
status and lumefantrine concentration at 7 days after AL treat-
ment (z2.830, P 0.0046).
As many of our subjects were shown to be parasite negative by
PCR, we tested for any effect of parasitemia on lumefantrine con-
centrations at day 7.Overall, in all 166 evaluable individuals, PCR-
positive parasitemia at day 0 was not associated with any differ-
ence in day 7 lumefantrine concentration in our sample set (37
positive versus 129 negative individuals). There was a weak asso-
ciation between day 3 PCR-detected parasitemia and higher lume-
fantrine concentrations (z2.305, P 0.021), suggesting that
greater lumefantrine bioavailability among NVP recipients was
not improving AL treatment outcomes. This effect was not strong
enough to confer a statistically significant deficit in parasite clear-
ance for HIV-positive individuals as a group; considering only
those participants with follow-up data from both day 3 and day 28
(n 140), 33.9%ofHIV-positive individuals had PCR-detectable
parasitemia on either or both day 3 and day 28, compared to
22.7% of HIV-negative individuals (OR, 1.75; 95% CI, 0.776 to
3.95; P 0.141). Assessment of day 0 parasitemia using qPCRwas
performed for 8 individuals (including 5 who were HIV positive)
who were subsequently PCR positive on day 3, and 15 who had
cleared parasites by day 3 (including 9 who were HIV positive).
This exploratory analysis did not provide any evidence that higher
starting parasitemia increased the likelihood of an individual re-
maining PCR positive for P. falciparum on day 3 (Wilcoxon rank
sum test z0.904, P 0.37).
DISCUSSION
The coformulated combination of artemether, a sesquiterpene
lactone derived from the natural compound artemisinin, with the
aryl amino-alcohol lumefantrine, as a systemic racemic fluorene
mixture, has become the most widely distributed and available
antiretroviral chemotherapy throughout Africa. As antiretroviral
chemotherapies have also becomemore widely available for treat-
ment of HIV patients in health systems in Africa, detailed under-
standing of any interactions between these two chemotherapies is
urgently needed. In this study, we show that HIV-positive adults
taking regular NVP who were treated with AL for microscopically
apparent P. falciparum infection had significantly higher day 7
plasma concentrations of lumefantrine than treated adults who
were HIV test negative and not receiving NVP. However, we
found no evidence that submicroscopic parasite persistence at day
3 after AL treatment was prevented in individuals with higher day
7 plasma levels of lumefantrine; in fact, HIV-positive individuals
were slightly more likely to have PCR-detectable parasitemia on
day 3 or day 28 thanwereHIV-negative participants, although this
was not significant.
Our findings are consistent with those of Kredo et al. (6) and
confirm that drug-drug interactions between AL and NVP are
potentially important. However, NVP stimulation of the CYP3A4
isoenzyme would be expected, a priori, to lower peripheral lume-
fantrine levels, due to an increase in the amount of lumefantrine
metabolized to desbutyl-lumefantrine, a potent derivative that is
normally found at a concentration between 0.5% and 5% of that
of the parent compound at day 7 in the few studies available (8,
20). Food intake also alters lumefantrinemetabolism; wewere not
TABLE 1 Parasite carriage by microscopy and PCR in 68 HIV-positive
and 99 HIV-negative individualsa
HIV status
No. of individuals (%) PCR positive for
P. falciparum on day:
0 3 28
Positive (n 68b) 17 (29.9) 8 12
Negative (n 99) 20 (17.2) 12 12
a All 167 individuals were reported as positive for P. falciparum parasites on
microscopic examination of thick blood films.
b Sixty-seven of these individuals were receiving daily nevirapine antiretroviral therapy,
and one received efavirenz. All HIV-positive patients also received the nucleoside
reverse transcriptase inhibitors lamivudine and zidovudine.
FIG 1 Day 7 lumefantrine concentration in AL-treated participants. Midline
of each box plot is the median, with the edges of the box representing the
interquartile interval. Whiskers delineate the 5th and 95th percentiles. Lume-
fantrine concentration was below the normal limits of detection in five indi-
viduals, all in the HIV-negative group (see the text).
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able to supervise the food intake of our participants while they
were taking AL, but all were informed of the need to accompany
their medication with fatty food. The apparently increased bio-
availability of lumefantrine in NVP recipients produced no mea-
surable parasitological benefit in our patients; on the contrary,
one-third of HIV-positive (and thus NVP-receiving) participants
were found to have persisting PCR-detectable P. falciparum para-
sitemia at day 3 and/or day 28, compared to less than a quarter of
the control group. This difference, which suggests that perturba-
tion of the immune system in HIV infection may have some im-
pact on antimalarial effectiveness in these dual-treated patients,
was not statistically significant. The case-control design used here
may be prone to selection bias, and this could affect parasitological
outcomes. However, univariate analysis of posttreatment para-
sitemia versus age, weight, gender, and educational attainment
found no evidence of confounding by any of these parameters
(data not shown). The recent observation that coadministration
of NVP with AL leads to reduced maximal concentration of both
artemether and DHA (21) suggests an alternate explanation for
reduced parasite clearance at day 3 in patients receiving both reg-
imens. Nevertheless, further studies of the parasitological impact
of antiretroviral-antimalarial drug-drug interactions in ade-
quately powered studies are urgently needed, not least because of
the important role of the host immune system in clearing drug-
treated malaria parasites (3, 22). In our study, all HIV-infected
participants were identified through attendance at a weekly clinic
in which all receivedNVP (except for a single patient on efavirenz;
when this patient was excluded from the analysis, the relationship
between NVP use and lumefantrine concentration at day 7 re-
mained significant). Compliance with antiretroviral treatment
was not evaluated directly. Future studies with HIV patients not
receiving NVPmay permit discrimination between drug-drug in-
teractions and the impact of retroviral disease per se on lumefan-
trine bioavailability.
A major weakness of our study was the poor quality of enroll-
mentmicroscopic diagnosis, such that themajority of participants
had in fact failed a major inclusion criterion. This had two main
impacts. First, the studywas greatly underpowered to evaluate any
parasitological outcomes, as so many participants were actually
uninfected (with P. falciparum). Second, we were not able to ana-
lyze parasite densities with any confidence and thus were left with
the binary variable of PCR positivity as the remaining reliable
measure of malaria infection. Further, by this method, we cannot
rule out the possibility that some of our positive PCRs on post-
treatment blood samples were detecting gametocytes of P. falcip-
arum only. These sexual-stage parasite forms are infective to
Anopheles sp.mosquitoes but do not contribute to clinicalmalaria
symptoms and cannot divide. Gametocytes are well known to sur-
vive in a minority of AL-treated patients after clearance of the
actively dividing asexual parasite stages (23, 24). Nevertheless, we
have recently described persistence of asexual parasites in asymp-
tomatic Ghanaian school children treated with artemisinin com-
bination therapy, suggesting that subclinical parasitemia may be
more difficult to clear than previously thought (25).
In conclusion, this is the second study to find evidence that
NVP-recipient HIV patients harbor a significantly higher periph-
eral blood concentration of lumefantrine than do HIV-negative
controls, 7 days after receiving a full treatment course of AL. Our
findings corroborate the findings of Kredo et al. (6) in a larger
group of AL-treated individuals, some of whom were infected
with P. falciparum. Insufficient parasitological data were available
to determine whether this difference in lumefantrine concentra-
tion provides any parasitological benefit to NVP-treated HIV pa-
tients with malaria infections.
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